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Abstract
At least 20% of women of reproductive age in parts of sub Saharan Africa are HIV-infected 
and transmission of HIV from mother-to-child through breastfeeding up to 2 years 
postpartum may account for half of the vertical transmission observed. However, little is 
known about factors within the breast that may influence milk viral load and/or 
transmission of HIV to the infant. The aim of this study was to explore the inflammatory 
processes that may affect the risk of mother-to-child transmission.
This thesis was based on work from 4 different field studies: Rural Tanzania (n=85), urban 
South Africa (n=144), an urban hospital in Zambia (n=22) and an urban community in 
Zambia (n=112). Two of these studies were fully undertaken by the author (Zambian 
community and Zambian hospital studies) and two of the studies involved retrospective 
laboratory and statistical analysis by the author (Tanzanian study and South Africa study). 
The studies were designed to investigate the influence of social, biological and 
breastfeeding indicators on HIV status and severity of HIV infection in breastfeeding 
women. In addition, to determine if breast milk C-reactive protein (CRP) was a suitable 
surrogate measure for systemic inflammation and risk of mother-to-child transmission 
measured by non-invasive breast milk sampling.
HIV infection in breastfeeding Zambian women was independently associated with raised 
breast milk CRP with an odds ratio (OR) of 3.91 (95% Cl: 1.50, 10.17, p=0.005), giving 
birth to a male infant (OR=2.53; 95% Cl: 1.38, 4.64; p<0.01) and greater maternal wealth 
(OR=1.12; 95% Cl: 1.05, 1.22; p=0.001). Severity of HIV infection (women with a CD4
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count at delivery of <500 cells/mm ) was independently associated with raised breast milk 
CRP (OR=2.49; 95% Cl: 1.61, 3.87; p<0.001) and breast milk RNA (OR=1.28; 95% Cl: 
1.00, 1.63; p=0.05). Breast milk CRP was found to correlate with plasma CRP (rs>0.60; 
p<0.05) and breast milk IL-8 (rs>0.42; p<0.05); to be associated with poor infant feeding 
technique, poor feeding practice, maternal breast inflammation and reduced infant weight 
gain (p<0.05). Breast milk CRP was shown to positively correlate with breast milk RNA 
and inversely correlate with maternal CD4 count in South African women (p<0.05).
Breast milk CRP has been shown to be associated with maternal HIV status and increased 
HIV severity in breastfeeding sub Saharan African women. Further work is needed to 
assess if CRP could be used as a surrogate risk factor for mother to child transmission of 
HIV.
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Foreword
i L
I first arrived in Lusaka, Zambia on 25 October 1999. It was Zambian Independence Day 
and the rainy season had just started. This was the first time I had ever set foot in Africa. I 
had no idea what to expect and after reading the Lonely Planet Guide to Lusaka I was more 
than a little nervous. What I discovered was a country that I fell deeply in love with, the 
smell of the rains, the beauty of the flame trees in full bloom, the deep orange colouring of 
the earth and how I was made to feel so welcome by the Zambian people. I was bom lucky; 
I was bom into a country that has the ability to provide free education and health care for 
all. Most of the Zambians I met had never and would never have this opportunity, not only 
that but Zambia was facing a deadly HIV epidemic which was affecting the most vulnerable 
members of its society; the poor, the women and the children. Zambia has taught me so 
much, more than I could ever give in return but I hope that this research may in someway be 
a small gesture of my thanks.
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Chapter 1 
Background and aims of the study
Collaborative links between the Centre for International Child Health, Institute of Child 
Health, University College London and the University of Zambia Medical School (based in 
Lusaka) and the Lusaka Central Board of Health have existed since 1998. As a result of 
this a number of research projects have been jointly designed and undertaken. These links 
have also provided training in research methods, data analysis and laboratory skills to 
personnel in Zambia and visits to both sites by researchers to develop research ideas and 
collaborations.
1.1 Zambia
Zambia is a landlocked country in sub-Saharan Africa surrounded by eight neighbouring 
countries: Democratic Republic of the Congo, Tanzania, Malawi, Mozambique, Zimbabwe, 
Botswana, Namibia and Angola (see figure 1.1). It has a landmass of 752,612 km and is 
divided into nine provinces. Zambia, under the name of Northern Rhodesia, was 
administered by the South Africa Company from 1891 until its take over by Great Britain in 
1923. During the 1920s and 1930s advances in mining spurred on development and 
immigration and brought relative prosperity to the region but unfortunately the decline in 
copper prices from the late 1970s onwards severely affected the Zambian economy. 
Zambia gained its independence in 1964 Under the leadership of Kenneth Kaunda and 
elections in 1991 brought an end to one-party rule (CIA, 2002).
17
Zambia has a tropical climate, modified by altitude as it sits on a high plateau, with the 
rainy season running from October to April. The country’s natural resources include 
copper, cobalt, zinc, lead, coal, emeralds, gold, silver, uranium and hydropower. The 
country faces potential environmental disaster with air pollution and resulting acid rain in 
the mineral extraction and refining region; chemical runoff into watersheds; poaching 
seriously threatens rhinoceros, elephant, antelope and large cat populations; deforestation; 
soil erosion; desertification and lack of adequate water treatment (CIA, 2002).
Figure 1.1: Map o f Zambia
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Zambia’s population is estimated at 10.4 million (Research and dissemination branch.,
1999) with a population growth rate of an estimated 2.9% (World Bank Group., 2002), see 
table 1.1 for a list of developmental indicators. Major ethnic groups are African, 
comprising seven major tribal groups: Bemba, Kaonda, Lozi, Lunda, Luvale, Nyanja and 
Tonga (98.7%); European (1.1%); other (0.2%). Major practicing religions are Christian 
(50-75%, dependent on region); Muslim and Hindu (24-49%, dependent on region); 
although there are widespread practices of indigenous beliefs (CIA., 2002). The official 
language of Zambia is English although there are over 72 tribal languages spoken 
throughout Zambia including Nyanja, Bemba, Lozi and Tonga. Literacy levels throughout 
the country are 78.2% (85.6% among males and 71.3% among females). Zambia is one of 
the most urbanised countries in Africa with approximately 40% of all Zambians living in 
urban areas (Research and dissemination branch., 1999). Urbanisation varies considerably 
between provinces with about 85% of the populations of Lusaka province and 90% of the 
Copperbelt province living in urban areas.
Despite progress in privatisation and budgetary reform, Zambia’s economy is still weak. 
Zambia has a debt of US$6.5 billion with an inflation rate of 27.3%, and the Zambian local 
currency (the Kwatcha) is still very unstable. The countrywide unemployment rate is 50% 
and 86% of the population are living below the poverty line (CLA., 2002). The gross 
national product (GNP) per capita is only $330 giving an average wage of less than $1 per 
day (World Bank Group., 2002).
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Housing and environmental conditions are generally poor with only 42% of the population 
living in dwellings with durable roofs and 33% of the population living in dwellings with 
durable walls. Only 17.3% of the population have access to electricity and 88% of the 
population still use wood, coal or charcoal as cooking fuel; 28% of the population have 
access to piped water with 20% of the population still accessing their water supply from a 
river or stream (Research and dissemination branch., 1999).
Lusaka is the capital city of Zambia and is located in the south-eastern part of the country.
It has a population of just over 1 million and its main economic activities centre around 
manufacturing and construction. Lusaka is divided into 18 residential districts with many 
illegal townships built on the edges of the city. The city itself faces many serious 
environmental issues including insufficient water resources and water pollution, ineffective 
solid waste management, undeveloped waterborne sanitation systems, deforestation and 
toxic and problems with disposal of hazardous waste.
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Table 1.1: Developmental indicators
1996 1999 2000
PEOPLE
Population, total 9.2million 9.9million 10.1 million
Population growth (annual %) 2.6 2.2 2.1
Life expectancy at birth (years) 38.5 38.0
Fertility rate, total (births per woman) 5.3
Mortality rate, infant (per 1,000 live births) 114.5
Mortality rate, under 5 (per 1,000 live births) 186.5
Births attended by skilled health staff (% of total) 47.0
Urban population (% of total) 43.3 44.2 44.5
Prevalence o f HIV (females, % aged 15-24) 17.8
Illiteracy rate, adult male (% males 15+) 17.3 15.4 14.8
Illiteracy rate, adult female (% females 15+) 33.6 29.7 28.5
ENVIRONMENT
Surface area (sq. km) 752,600 752,600 752,600
Forest area (sq. km) 312,500
Annual deforestation (% change) 2.4
Freshwater per capita (cubic meters) 11,497.7
C 02 emissions (metric tons per capita) 0.3
Improved water source (% o f population with access) 64.0
Improved sanitation facilities, urban (% of urban ' 
populations with access)
99.0
Energy use per capita (kg o f oil equivalent) 636.8 626.4
Electricity use per capita (kwh) 560.0 540.0
ECONOMY
GNI, Atlas method (current USS) 3.4 billion 3.2 billion 3.0 billion
GNI per capita, Atlas method (current USS) 360.0 320.0 300.0
GDP (current USS) 3.3 billion 3.1 billion 2.9 billion
GDP growth (% annual) 6.6 2.0 3.5
Inflation, GDP deflator (annual %) 23.6 20.5 18.1
Agriculture, value added (% of GDP) 17.6 24.1 27.3
Industry, value added (% of GDP) 34.8 25.3 24.1
Services, etc., value added (%GDP) 47.7 50.6 48.6
Export o f goods and services (% o f GDP) 31.3 22.6 30.6
GNI: Gross national income 
GDP: Gross domestic product
Adapted from world development indicators database (World Bank Group., 2002)
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1.2 Health of the Population
Zambia is one of the poorest countries in the world and this is reflected in its lack of access 
to health care facilities. In rural areas, only 50% of the population have access to a health 
centre or clinic within 5km of their home and 17% have to travel 16km or more to a health 
care facility. In urban areas, 99% of the population have access to a health centre or clinic 
within 5km of their home (Research and dissemination branch., 1999).
There are 84 hospitals throughout Zambia that provide a total of 1.9 hospital beds per 1,000 
population. There are a further 1,082 health centres/clinics bringing the total beds to 2.9 
per 1,000 population. In 1995 there were 655 doctors in Zambia, making a total of 7.0 
doctors per 100,000 population; there were also 10,378 nurses, giving a total of 1.2 health 
workers per 1,000 population (Research and dissemination branch., 1999). However, due 
to the poor economic condition of Zambia, many health workers have left the country to 
work elsewhere, and the HIV/AIDS (human immunodeficiency virus/ acquired immune 
deficiency syndrome) epidemic has further reduced this already overstretched workforce.
The crude birth rate (per 1,000 population) has fluctuated over time, rising from 47.7 in 
1969 to and estimated 55.2 in 1999 (Research and dissemination branch., 1999), but 
dropping quite dramatically to an estimated 41.5 in 2001 (CIA., 2002). Likewise the 
percentage population growth rate has dramatically declined from 3.1% in 1990 (Research 
and dissemination branch., 1999) to 1.9% in 2001 (CIA., 2002). The crude death rate per 
1,000 population has risen from 16.7 in 1980 (Research and dissemination branch., 1999),
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to an estimated 22.0 in 2001 (CIA., 2002). Maternal mortality ranges from more than 800 
per 100,000 births in rural areas to 500 per 100,000 in urban areas (Research and 
dissemination branch., 1999). National infant mortality is estimated at 90.9 per 1,000 
(CLA., 2002) with life expectancy at birth declining from 54 years in 1980 to 37 years in 
2001 (CLA., 2002). The dramatic changes in these population health indicators result from 
the effects of excess mortality due to AIDS. This has resulted in lower life expectancy, 
higher infant mortality and death rates, lower populations and growth rates, and changes in 
the distribution of the population by age and sex than would otherwise be expected.
Lusaka is the largest city in Zambia with some of the highest HIV-infection rates in the 
country. For most of the HIV pregnant mothers in Lusaka, infant feeding options are 
limited due to financial and social constraints, with a week’s formula feed costing more 
than half a family’s weekly income. In addition exclusive formula feeding may be seen as a 
disclosure of HIV status. Given these conditions, Lusaka serves as an ideal location to 
investigate factors associated with mother to child transmission among HIV infected 
mothers who chose to breastfeed.
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1.3 Study hypothesis and research aims
1.3.1 Hypothesis
Inflammatory markers of HIV infected women present in the plasma and breast milk may 
differ from those of HIV uninfected women and may also be dependent on the severity of 
the HIV infection. These inflammatory processes may affect the risk of mother to child 
transmission.
1.3.2 Aims
The principal aims of the study were to:
I Determine the social, biological and breastfeeding indicators associated with HIV
status.
II Determine the social, biological and breastfeeding indicators associated with
severity of HIV.
III Determine if milk C-reactive protein, measured by non-invasive breast milk
sampling, could be a suitable surrogate measure for systemic inflammation and a 
potential indicator of increased risk of mother to child transmission of HIV.
24
The remainder of this thesis will provide:
Chapter 2: An overview of current available literature on HIV and mother to child 
transmission.
Chapter 3: A description of the data collection methods, sample analysis, data analysis 
and project limitations.
Chapter 4: The results of the study in relation to the 3 research aims.
Chapter 5: A discussion of the results and their possible implications.
Chapter 6: Conclusions and ideas for future research.
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Chapter 2 
Literature review of HIV
This literature review consists of five parts (2.1-2.5). The first (2.1) will provide an 
overview of the HIV epidemic, the second (2.2) will present more detailed literature on the 
processes of mother to child transmission of HIV, the third (2.3) will review mother to child 
transmission through breastfeeding, the fourth (2.4) will summarise the above information 
and the final section (2.5) outlines the conceptual framework of my study.
2.1 Epidemic of the human immunodeficiency virus
The human immunodeficiency virus (HIV) is the virus that causes the acquired immune 
deficiency syndrome (AIDS). Two distinct types of HIV have been identified thus far. 
HIV-1, which has several subtypes, is responsible for the worldwide epidemic. HIV-2, the 
less virulent of the two viruses, is confined mostly to West Africa, but has recently begun to 
spread to some countries in Asia. HIV-1 and HIV-2 are thought to have a common ancestor 
and the evidence suggests that the viruses diverged sometime before the 1940s (Zhu et al., 
1998). In this thesis HIV is used throughout for HIV-1. HIV/AIDS was first recognised in 
1981 and has since become a major pandemic. By leading to the destruction and/or 
impairing of cells in the immune system, HIV progressively destroys the body’s ability to 
fight infections and certain cancers. Transmission mechanisms accounting for HIV 
infection include: unprotected (i.e. without a condom) vaginal and anal intercourse, 
unprotected oral sex, needles (IV drugs, tattooing and needle stick injuries), blood 
transfusions and vertical transmission from mother-to-child.
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In developing countries the emergence of the HTV epidemic has dramatically changed 
patterns of disease in affected communities. As in developed countries, previously rare 
opportunistic diseases such as Pneumocystis carinii and certain forms of meningitis have 
become more commonplace (Cochi et al., 1986). In addition, as HIV seroprevalence rates 
have risen, there have been significant increases in the burden of endemic conditions such 
as tuberculosis (TB) (Cochi et al., 1986). For example, as HIV seroprevalence increased 
sharply in Blantyre, Malawi from 2% in antenatal mothers in 1986 to 24% in 1997 (R 
Chimzizi, 2004), TB admissions at the city’s main hospital rose more than 400%, from 657 
in 1986 to 2,734 in 1995, with the largest increase in cases among young adults aged 
between 15 and 44 years (Harries et al., 1997). In the rural Hlabisa district of South Africa, 
admissions to TB wards increased 460% from 303 patients in 1992 to 1393 patients in 
1998, concomitant with a steep rise in HIV seroprevalence, from 4% in antenatal women in 
1992 to 29% in 1998 (Floyd et al., 1999). High rates of mortality due to endemic 
conditions such as TB, diarrhoeal diseases and wasting syndromes, formerly confined to the 
elderly and malnourished, are now common among HIV-infected young and middle aged 
people in many developing countries (NIAID, 2002; UNAIDS., 2002; Harries et al., 1997; 
Floyd et al., 1999).
In studies conducted in both developed and developing countries, death rates are markedly 
higher among HIV infected individuals than among HIV uninfected individuals. For 
example in Uganda, 19,983 adults in the rural Rakai District were followed for 10 to 30 
months between 1994 and 1997 and those with HIV were 20 times more likely to die than 
HIV-uninfected individuals during 31,432 person-years of observation (Sewankambo et al.,
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2000). In Malawi, mortality of children up to 3 years of age who survived the first year of 
life was 9.5 times higher among HIV- infected children, in a study of children recruited 
from 12 -36 months of age (Taha et al., 1999). Similarly in South Africa, the death rates for 
children hospitalised with severe lower respiratory tract infections was 6.5 times higher for 
HIV-infected than uninfected infants (Madhi et al., 2000). In a 39 country study to assess 
the annual HIV-attributable under 5 mortality rate, HIV infection was found to cause 7.7% 
of the deaths in 1999, a rise from 2% in 1990 (Walker et al., 2002). Zambia was found to 
be one of the worst affected countries with HIV-attributable under 5 mortality of 30 per 
1000 (Walker etal., 2002).
HIV prevalence varies greatly in different settings, ranging from 0.006% in the UK to 
35.4% in Botswana (UNAIDS 2002). This is particularly true in sub-Saharan Africa where 
HIV spreads heterosexually in adults, and where HIV prevalence in some cities has 
stabilised at around 30% of the adult population (UNAIDS 2003). This shows little or no 
sign of decline despite the impact of AIDS-related mortality depleting the most vulnerable 
segment of the population (Carael and Holmes, 2001). There are signs that the HIV 
epidemic has levelled off in Zambia, where national HIV prevalence has remained stable 
since the mid-1990s, at over 20% (UNAIDS 2003). Two factors are causing the apparent 
stabilisation of prevalence rates: AIDS mortality rates and HIV incidence; overall
prevalence might appear stable but it hides a persistently high number of annual, new HIV 
infections and an equally high number of AIDS deaths (UNAIDS 2003).
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Differences in HIV prevalence between different regions in Africa cannot always be 
explained by differences in time since the introduction of the virus into the population 
(Buve et al., 1995). For example there was evidence that HIV was circulating in Kinshasa, 
the capital of the Democratic Republic of the Congo, well before 1980 (Clumeck et al., 
1983), but between the first survey among pregnant women in 1985 and a later survey in 
1999 the prevalence of HIV infection in pregnant women remained relatively stable at 
around 5% (International census, 2002). However, in South Africa the HIV prevalence 
among pregnant women increased from 1% in 1991 to 25% in 2000-2002 (International 
census, 2002; UNAIDS 2003).
The suggestion that some HIV-1 clades have greater infectivity than others still remains 
unsubstantiated, indicating that variations in vulnerability leading to increased sexual 
exposure, and greater efficiency of transmission may account not only for the different 
prevalence rates between other continents and Africa, but also differences between sub- 
Saharan Africa and the rest of the continent (Janssens et al., 1997). Three groups of HIV-1 
clades designated M (major), N (normal), and O (outlier) have been identified (Peeters et 
al., 1997). Groups M viruses have been further divided into subtypes A, B, C, D, F, G, H, J 
and K (McCutchan, 2000). Almost all subtypes are prevalent in sub-Saharan Africa. The 
most prevalent subtypes are A and its recombinants in West Africa, A and D in Eastern 
Africa, and C in the Horn and Southern Africa (Peeters et al., 1997; McCutchan, 2000; 
Janssens et al., 1997). Most of the HIV-1 subtypes reported in Zambia have been type C 
(Louwagie et al., 1995; Betts et al., 1997; Heyndrickx et al., 2000). However, due to the 
constant human traffic into Zambia from neighbouring countries (see figure 1.1), HIV-1
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subtypes other than C have been reported (Peeters et al., 1997; McCutchan, 2000; Janssens 
et al., 1997). Studies have identified an A/C recombinant (Salminen et al., 1997) and group 
O (Peeters et al., 1997) and another study has identified new HIV-1 D-like and G-like 
subtype sequences in the Zambian population (Handema et al., 2001).
Zambia is one of the five countries most severely affected by HIV/AIDS in sub-Saharan 
Africa and as a result health indicators have been deteriorating; 20% of all Zambia adults 
are estimated to be HIV-infected (CIA, 2002). In Lusaka, the level of infection in pregnant 
women is estimated to have increased from 8% in 1985 to 32% in 1999 (Research and 
dissemination branch, 1999). In some rural locales, infection levels among pregnant 
women were estimated to be almost identical to that in urban centres. For example in 
Minga, an area in Zambia’s Eastern Province, HIV infection rates were estimated to be 
18%. However, in general, rural areas had lower prevalence rates than urban areas, ranging 
from 8 to 13% in 1998 (International census, 2002). In 1997-1998 the HIV-infection rate of 
commercial sex workers in Ndola, Zambia’s second largest city, was found to be as high as 
68% (International census, 2002). Within all of Zambia’s major towns and cities there is a 
great disparity in infection rates between women and men in the same age groups. For 
example among 20-24 year olds 28% of females tested were HIV positive versus 8% of 
males (International census, 2002).
In Zambia the main reported mode of transmission is through heterosexual sex, and 
biologically there is a higher rate of transmission from male to female than from female to 
male (UNAIDS 2003). Women are especially vulnerable to risk of HIV infection through
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both economical and social reasons (World Bank, 2004; Gomez and Marin, 1996). 
Economically, financial or material dependence on men means that women cannot control 
when, with whom and in what circumstances they have sex. Many women also have to 
exchange sex for material favours and for daily survival, an exchange which is in many 
cases the only way a woman can provide for herself and her children (World Bank, 2004; 
Sobo, 1995).
In many countries (including Zambia), socially and culturally women are not expected to 
discuss or make decisions about sexuality (World Bank, 2004; Gomez and Marin, 1995). 
Often they are unable to request the use of a condom or any form of protection and by 
refusing sex or requesting condom use, they often risk abuse as there is a suspicion of 
infidelity (World Bank, 2004). In Zambia multiple partners (including sex workers) are 
culturally accepted for married and unmarried men, and women are expected to have 
relations with or marry older men, who are more experienced, and therefore are more likely 
to be infected (World Bank, 2004).
In a study in Uganda to establish the extent to which socio-economic status affects the 
acquisition of HIV, data was collected in 1992 from 1,784 respondents with results for HIV 
serology and information on demographic, socio-economic and some behavioural variables. 
Higher levels of education and better quality urban dwellings were significantly related to 
HTV status, as was household wealth (Kirunga and Ntozi, 1997). In areas where poverty 
was endemic the wealthier and more educated the person the higher the risk of HIV 
infection (Gisselquist et al., 2003).
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Girls and women (aged 1 4 - 4 4  years) in Africa are particularly vulnerable to infection due 
to their lower socio-economic and political status (UNAIDS 2003). With a combination of 
women having less access to safe sex information and with older men more likely to be 
HIV infected, more women are infected with HIV than men (UNAIDS 2003).
HIV is a progressive disease accompanied by destruction of the immune system largely 
through a depletion of CD4+ T-lymphocytes. A variety of haematological abnormalities 
have also been associated with HIV including lower haemoglobin concentrations (Semba et 
al., 2000; Lundgren and Mocroft, 2003; Sullivan et al., 1998) and depletion of other cell 
lines such as neutrophils, thrombocytes and red blood cells (van den Broek et al., 1998a; 
Evans and Scadden, 2000; Kulkosky et al., 1999).
Severity of HIV infection is commonly monitored using a combination of CD4 count and 
HIV RNA plasma viral load (Centre for Disease Control, 2004). However, in sub-Saharan 
Africa both the scale of the epidemic and the expensive and complex laboratory equipment 
required to carry out these analyses makes monitoring the progression of the disease in most 
people currently impossible. Acute phase reactants, non-specific indices of infection and 
inflammation, may also be affected during disease progression (Fauci, 1988), and may be 
useful markers in predicting prognosis and effectiveness of intervention. C-Reactive 
protein (CRP) is one such acute phase reactant. It can be measured relatively easily and at 
low cost and, although it is not recognised by recent WHO guidelines for HIV treatment 
(WHO, 2004b) and limited research has been completed in this area, it may have a role in 
monitoring HIV-infected patients in regions were antiretroviral therapies are becoming
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available but where frequent monitoring of viral loads and CD4 counts is still cost 
prohibitive (Feldman et al., 2003a). One of the aims of this project was to examine this 
concept in more depth by measuring CRP non-invasively in the breast milk of HIV infected 
women.
In summary sub-Saharan Africa is the worst affected region in the world with 26.6 million 
people currently living with HIV/AIDS, including approximately 3.2 million people newly 
infected in 2003 (UNAIDS 2003). Zambia is one of the worst affected countries and 
despite indications of a stabilisation of prevalence rates they are not declining. Significant 
increases in endemic conditions such as TB are putting huge pressure on an already over­
stretched medical service exacerbating already high poverty levels and affecting the most 
vulnerable members of Zambian society: the poor, the women and the children.
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2.2 Mother-to-Child transmission
At the end of the twentieth century it was estimated that there nearly 1.5 million HIV- 
infected children were living in the world and that approximately 70,000 infants were 
acquiring infection each year from their mothers (Miotti et al., 1999). In sub Saharan 
Africa, women now account for over half of the annual incidence of infections in adults 
(Miotti et al., 1999). Most of these women are in their childbearing years and transmit the 
infections to their offspring at a rate of approximately 2,000 cases per day (Miotti et al.,
1999). An estimated 5 million people were newly infected with HIV in 2003, about 10% of 
whom were children (UNAIDS 2003). Africa accounts for only 10% of the world 
population and yet 90% of all HIV-infected infants live in Africa (Joint United Nations 
Programme on HIV/AIDS, 2002). In developed countries the impact of interventions to 
reduce vertical transmission is already apparent and there has been a marked reduction in 
the number of children bom with HIV infection (Connor et al., 1994; Andiman, 2002; The 
International Perinatal HIV Group, 2002; The European Collaborative Study, 1994). Sadly 
in developing countries, where the epidemic is at its highest, this is not the case (Andiman, 
2002; UNAIDS, 2003).
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2.2.1 Timing and rates o f transmission
The overwhelming majority of paediatric HIV infections are as a result of mother to child 
transmission (MTCT) of the virus, either during pregnancy (Newell, 1998; Courgnaud et 
al., 1991; Simonon et al., 1994), delivery (Newell, 1998; Simonon et al., 1994) or the 
postnatal period (Newell, 1998; Van de Perre et al., 1991). In developing countries the risk 
of a baby acquiring the virus from an infected mother, in the absence of preventative 
measures, ranges from 25% to 48% (Dabis et al., 1995; Wiktor et al., 1997; De Cock et al.,
2000). In Zambia, it is estimated that about 40% of infants bom to women infected with 
HTV become infected themselves, with approximately 4,000 children in Lusaka alone 
becoming infected every year (Stringer et al., 2003). The relative importance of in utero, 
intrapartum and postnatal transmission can only be estimated, but there is a consensus that a 
substantial proportion of transmission occurs in late pregnancy or during delivery 
(Mofenson et al., 1999; Rouzioux et al., 1997; Newell, 1998; De Cock et al., 2000) with 
MTCT also being associated with breastfeeding (John-Stewart et al., 2004).
In industrialised countries, transmission rates in untreated non-breastfeeding populations 
range from 14%-32% which increases to 25% to 48% among breastfeeding populations in 
developing countries (Wiktor et al., 1997; De Cock et al., 2000; Leroy et al., 1998). The 
reasons for the higher rates in developing countries are multiple, but near-universal 
breastfeeding is possibly the most important (Wiktor et al., 1997).
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2.2.2 Risk Factors for Transmission
Pregnancy and breastfeeding constitute major challenges to the maternal immune system. 
Local factors at the maternal-foetal interface are required to maintain tolerance and used to 
ensure foetal survival (Salmon JE et al. 2004). Viruses and foetuses face similar 
immunological challenges. The virus must avoid host recognition of intracellular infection; 
the foetus allogenic recognition (Huddleston H and Schust DJ 2004). Some possible 
modulators of immune responses at the maternal-foetal interface include alterations in the 
TH1/TH2 cytokine response (Hill J et al., 1995, Piccinne M et al., 1998), changes in 
secreted leukocyte protease inhibitors (SLPIs) (Fahey J and Wira C, 2002) and immune 
modulatory effects of reproductive hormones (Thellin O et al., 2000; Schulst D et al.,
2002). This complex maternal response to pregnancy and delivery may not only influence 
foetal survival but also HIV viral transmission.
The possible maternal immunological risk factors for transmission of HIV to an infant 
include genetic determinants of immune response (MacDonald et al., 1998), high maternal 
viral load (Shaffer et al., 1999; Mofenson et al., 1999; Garcia et al., 1999), advanced 
maternal HIV clinical disease, low CD4 counts and a low CD4:CD8 ratio (Lepage et al., 
1993; St Louis et al., 1993) and prolonged rupture of membranes (Landesman et al., 1996). 
Other risk factors include co-infection with sexually transmitted diseases, chorioamnioitis 
(Goldenberg et al., 1998) and placental inflammation (St Louis et al., 1993; Shearer et al., 
1997; Tovo et al., 1997) which may increase the viral load through the cervical tract. These
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risk factors are included in table 2.1 and are weighted according to the strength of the 
available published data.
Markers of inflammation include acute phase proteins such as AGP and CRP. Markedly 
increased AGP concentrations are observed in a number of conditions such as acute 
myocardial infarction, trauma, pregnancy and surgery (Hochepied et al., 2003). The 
concentration of CRP increases rapidly following both infection and tissue injury caused by 
a variety of inflammatory diseases (Macintyre et al., 1982). With acute phase proteins 
being raised during inflammation and placental inflammation being associated with 
peripartum transmission (Mwanyumba et al., 2002), it could be hypothesised that acute 
phase proteins may be associated with peripartum MTCT.
There is some evidence that breast milk can confer immunity to HIV, with breast milk of 
women with established infection having HIV-specific IgG and IgA antibodies (Lawrence 
RA, 1999) and HIV-specific IgM (Van de Perre et al., 1993).
Secretory leukocyte protease inhibitor (SLPI) is also considered to be protective against 
mucosal transmission of HIV including in the breast milk (Hocini et al., 2000). However, 
as well as being a risk factor for transmission in the antenatal and perinatal period, low 
maternal CD4 counts have long been associated with an increased risk of MTCT in the 
breastfeeding period and as with placental inflammation there is limited evidence linking 
breast inflammation with MTCT. Knowledge of the risk factors for transmission and the 
timing of transmission of MTCT are important since they may have a direct impact on the
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design of preventative strategies. These risk factors are discussed in greater detail within 
this section.
Table 2.1 Risk factors associated with increased overall risk of MTCT
Strong evidence Limited evidence
Maternal 
High viral load 
Advanced disease
Immune deficiency (measured by CD4 
counts and CD4:CD8)
Maternal
Anaemia
Sexually transmitted disease
Chorioamnionitis
Placental inflammation
Frequent unprotected sexual intercourse*
Multiple sex partners*
HIV infection acquired during pregnancy or
breastfeeding period
Several o f  these factors interact and are
confounding
Obstetric
Vaginal delivery (when compared with 
elective caesarean before labour and before 
rupture of membranes)
Duration of rupture of membranes
Obstetric
Invasive procedures 
Episiotomy
Infant
Prematurity
Breastfeeding
Infant
Lesions of skin and/ or mucous membranes 
(oral thrush)
May be confounding factors
* Probably due to acquisition of further virus or minor trauma 
Adapted from (UNICEF et al., 1998)
2.2.2.1 Maternal HIV viral load
HIV viral load has been well studied in a number of different populations of women 
(Blanche et al., 1997; Coll et al., 1997; Contopoulos-Ioannidis and Ioannidis, 1998; O'Shea 
et al., 1998; Garcia et al., 1999). Detailed information is now known on the increased risk 
of MTCT in women with high plasma HIV viral load. In a study in West Africa to 
investigate the relationship between maternal plasma RNA viral load and MTCT in
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children, Leroy et al., (2001) found that high maternal viral load was a strong predictor of 
transmission. In another study high maternal viral load at 18-28 weeks antenatally was 
independently associated with a significantly increased risk of MTCT up to 6 weeks 
postpartum (Semba et al., 1999a). Elevated maternal viral load has also been shown to be a 
significant predictor of infant disease progression in HIV infected infants at 18 months of 
age. In another study women with detectable HIV RNA viral load were shown to be almost 
six times as likely to transmit HIV as women with undetectable viral load (Thea et al., 
1997). Mofenson et al. 1999 reported that among 480 women who all received zidovudine 
(an antiretroviral drug) before or from early pregnancy, the only independent risk factor for 
transmission was maternal baseline (third trimester) HIV RNA levels, with an increase in 
odds ratio per log increase HIV RNA viral load. None of the 84 women with undetectable 
levels of HIV RNA at baseline or the 107 with undetectable RNA at delivery transmitted to 
their infant. Even when a reduced course of zidovudine therapy was used, maternal viral 
load at delivery was highly predictive of transmission. This was also seen in a trial of short 
course oral zidovudine monotherapy in Thailand, where therapy was initiated at 36 weeks 
and 80% of the vertical transmission rate could be explained by maternal viral load at 
delivery in women who did not breastfeed (Shaffer et al., 1999).
Antiretrovirals have been shown to be an effective way to reduce MTCT. Even among 
women who breastfeed, a short course of antiretroviral therapy has been shown to be 
effective in reducing mother to child transmission, with a 38% reduction in multicentre 
trials in West Africa at 6 months and 30% at 15 months (Dabis et al., 2001). Comparable 
results have also been seen in Cote d’Ivoire in a randomised control trial of 280 HIV
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infected pregnant women, 140 women received a short course of zidovudine and efficacy 
was found to be 44% at age 4 weeks and 37% at 3 months (Wiktor et al., 1999). Nevirapine 
has also been found to lower the risk of HIV-1 transmission during the first 14-16 weeks of 
life by nearly 50% in a breastfeeding population of Ugandan women. This simple and 
inexpensive regimen could decrease mother-to-child HIV-1 transmission in less-developed 
countries even in breastfeeding populations (Guay et al., 1999).
2.2.2.2 Maternal CD4
As with maternal viral load the level of maternal HIV-induced immunodeficiency has been 
extensively investigated and shown to be an important risk factor in MTCT. Women with 
low CD4 cell count (<200 cells mm ) near the time of delivery and those who have been 
diagnosed with severe clinical disease were found to be 3 times as likely to transmit than 
those less severely affected by HIV infection (Leroy et al., 2001; The European 
Collaborative Study, 2001). Therefore, low maternal immune status (low CD4 cell counts) 
significantly reduces the ability of short course antiretrovirals to prevent MTCT. In a study 
to assess the 24 month efficacy of a maternal short-course zidovudine regimen in West 
Africa, the cumulative risk of MTCT among children bom to women with CD4 cell counts 
< 500 per mm at study enrolment were similar, even in women receiving anti retroviral 
prophylaxis when compared to those in the placebo group (Leroy et al., 2002).
In a prospective follow up study of 172 HIV-infected women in Uganda, MTCT rates in 
women with CD4 counts of <600 cells per mm were significantly higher than the rates 
among women with no evidence of immune suppression (Wabwire-Mangen et al., 1999).
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Even more concerning is that a maternal CD4 lymphocyte count < 200/mm resulted in an 
increased mortality risk to all children, irrespective of their HIV status, bom to HIV- 
infected mothers (Dabis et al., 2001).
2.2.2.3 Acute phase proteins
Less information is known about the influence of the acute phase response on MTCT. 
Despite acute phase proteins being measured in a number of MTCT trials their influence on 
the risk of transmission has not been fully studied. The acute phase response is an innate 
body defence seen during acute illnesses and involves the increased production of certain 
blood proteins termed acute phase proteins. Acute phase proteins are a group of proteins, 
such as C-reactive protein (CRP) and alpha (l)-acid glycoprotein (AGP), produced by cells 
in the liver in response to inflammation and tissue damage, which also promote 
inflammation, activate the complement cascade, and stimulate chemotaxis of phagocytes 
(Hochepied et al., 2003; Macintyre et al., 1982; Fauci, 1988).
Markedly increased AGP concentrations are observed in a number of conditions such as 
acute myocardial infarction, trauma, pregnancy and surgery (Hochepied et al., 2003). The 
concentration of CRP increases rapidly following both infection and tissue injury caused by 
a variety of inflammatory diseases (Macintyre et al., 1982). CRP binds to membrane 
phospholipids in microbial membranes and it functions as an opsonin, sticking the 
microorganism to phagocytes (Macintyre et al., 1982). It activates the classical complement 
pathway causing ‘leaky’ epithelium and thereby allowing the passage of immune cells into 
the general circulation (Macintyre et al., 1982).
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Evidence of chronic stimulation of the acute phase reaction seem to indicate a worsening 
prognosis in a variety of chronic disease settings (Gabay and Kushner, 1999; Munford,
2001). Both AGP and CRP have been shown to be independently associated with an 
increased HIV-1 plasma viral load and lower CD4 count in HIV infected Kenyan women 
(Baeten et al., 2002). With acute phase proteins being raised during inflammation and 
placental inflammation being associated with peripartum transmission (Mwanyumba et al.,
2002), it could be hypothesised that acute phase proteins may be associated with peripartum 
MTCT. In a longitudinal study of 209 HIV infected American women, plasma CRP 
concentration was found to be a powerful predictor of mortality (p<0.01) after adjusting for 
age,-body mass index, serum albumin, CD4 cells and HIV-1 plasma RNA (Feldman et al., 
2003a).
2.2.2.4 Intrapartum risk factors
It is estimated that over two-thirds of perinatal MTCT in a non-breastfeeding population 
occurs during delivery (Rouzioux et al., 1997; Kuhn et al., 1997; Newell, 1998). 
Prematurity and events around labour and delivery that result in an increased exposure of 
the infant to the mother's infected blood or vaginal secretions have also been shown to 
increase vertical transmission (Kumar and Shahul, 1998;Landesman et al., 1996). Studies 
of twins have indicated that exposure of virus in the cervical secretions during delivery is an 
important risk factor, as first bom twins are more likely to be infected, especially after 
vaginal delivery (Goedert, 1997;Goedert et al., 1991). Although this was a comprehensive 
epidemiological study in nine different country settings, data from only 66 sets of twins 
were evaluated. The contribution of these factors to MTCT in Africa has been less well
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studied, although recent results from Malawi in a cohort of 315 twin pairs bom between 
1994-1998, found that in contrast to the authors of earlier studies, birth order was not an 
important risk factor for infection in twins (Biggar et al., 2003).
A significant proportion of perinatal HIV transmission occurs during the intrapartum period 
(Newell, 1998) with intrapartum events such as an extended time between rupture of 
membranes and delivery (Mandelbrot et al., 1998; Landesman et al., 1996), and acute 
chorioamnionitis in Kenyan women (Mwanyumba et al., 2002), being associated with 
increased risk of MTCT. Vaginal lavage before membrane rupture, as a method of reducing 
the exposure of the infant to the vims in the cervical secretions, may be associated with 
reduced MTCT (Gaillard et al., 2001).
Delivery by elective caesarean section has long been proposed as a means of reducing foetal 
exposure to HIV laden maternal secretions or blood. In large scale comprehensive studies, 
it has been well documented that delivery by elective caesarean section before the onset of 
labour and rupture of the membranes reduced transmission by more than 50% (The 
European mode of delivery collaboration group, 1999; The International Perinatal HIV 
Group, 2002; Blanche et al., 1997). Reports from a meta analysis of 15 prospective cohorts 
indicate that the risk of transmission is reduced by 87% if elective caesarean section is 
carried out in women who also receive antiretroviral therapy during pregnancy (The 
International Perinatal HIV Group, 2002).
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2.2.2.5 Gender
There is a steadily increasing volume of information regarding gender differences in MTCT 
in the antenatal period. Differences in virological and immunological markers of disease 
progression between the sexes have been described in a number of studies (European 
collaborative study, 2003; European collaborative study, 2002; Sterling et al., 2001). Girls 
have been shown to have consistently lower CD4 counts than boys, with earlier and higher 
viral loads before 4 years of age (European collaborative study, 2003). This suggests 
differences in reaction to primary HIV infection and possible differences in timing of 
MTCT. Limited data on mother-child pairs have shown that girls may be at higher risk of 
acquiring HIV infection than boys (Gabiano et al., 1992; Temmerman et al., 1995). In a 
recently published multivariate analysis of 3,231 mother-child pairs enrolled in the 
European collaborative study, girls had a 1.5 times greater risk of infection compared with 
boys after allowing for antenatal antiretroviral therapy, elective caesarean section and 
maternal CD4 counts, (European collaborative study, 2004). The authors concluded that 
transmission before 36-38 weeks antenatally may occur more commonly in girls than boys. 
However, the risk of MTCT did not differ by sex for infants with intrapartum exposure 
(European collaborative study, 2004).
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2.3 Transmission through breastfeeding
The importance of mother to child transmission through breastfeeding has been briefly 
mentioned in the previous section. As the main objectives of the thesis relate to 
breastfeeding in HIV infected women, a more detailed review of MTCT through 
breastfeeding is presented here.
The first reports indicating the possibility of HIV-1 transmission through breastfeeding 
were in breastfed infants of women who were infected postnatally through blood 
transfusion or through heterosexual exposure (Van de Perre P. et al., 1991; Palasanthiran et 
al., 1993; Stiehm and Vink, 1991; Hira et al., 1990; Colebunders et al., 1988; Lepage et al., 
1987; Ziegler et al., 1985). A meta analysis of data taken from published literature of 2,375 
HIV-1 infected women and their infants, 499 of whom were breast fed, estimated the risk of 
breast milk HIV-1 transmission as 16% (John et al., 2001). Breast milk transmission risk 
was 21% in cohorts with mean/median duration of breastfeeding of 3 months or more 
whereas in cohorts with median duration of breastfeeding for less than 2 months 
transmission risk was significantly lower at 13% (John et al., 2001). In a separate analysis 
of 702 infants with prolonged duration of breastfeeding, the risk of late postnatal 
transmission (infection occurring later than three to six months of age) was 4% (John et al., 
2001).
There is in vitro evidence that mammary epithelial cells (MEC) can be infected by the virus 
and that hormones normally associated with lactation (including p-estradiol and prolactin)
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may stimulate virus replication (Toniolo et al., 1995). MEC-derived HIV might have 
selective advantages for the infection of mucosal epithelial cells and be trophic for infant 
oral or gastrointestinal epithelial cells (Toniolo et al., 1995). It is possible to infect neonatal 
rhesus monkeys with simian immunodeficiency virus (Baba et al., 1994), and kittens with 
feline immunodeficiency virus (Sellon et al., 1994) by applying cell free virus on intestinal 
mucosa. This suggests that cell-free HIV in breast milk could infect cells of the intestinal 
mucosa in breastfed infants.
Even in HIV-infected populations which practice breastfeeding the majority of children 
bom to HIV-infected mothers will not be infected (Van de Perre et al., 1993). 
Consequently, although both cell free (RNA) and cell associated (DNA) HIV has been 
detected in the breast milk (Van de Perre et al., 1999a; Ruff, 1994; Van de Perre et al., 
1993), mechanisms of breast milk transmission are not yet fully understood.
2.3.1 Timing of HIV transmission
Transmission of HIV through breast milk can take place at any time during lactation. The 
persistence of maternal antibodies and the presence of a 'window period' during which 
infection is undetectable using current available technology makes it impossible to 
determine whether an infant has been infected during delivery (intrapartum) or through 
breastfeeding in the immediate period following birth (UNICEF et al., 1998). Therefore, 
when HIV infected women breastfeed their infants, it is not possible to differentiate
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between HIV transmission attributable to delivery and that resulting from breastfeeding 
until approximately 4-6 weeks postpartum (Newell, 1998; Bobat et al., 1997; Mandelbrot et 
al., 1996; Bertolli et al., 1996; Simonon et al., 1994; Datta et al., 1994).
In the earlier years of research into MTCT, the RNA polymerase chain reaction (PCR) as a 
method to determine HIV status was not widely used and was not as reliable as it is today. 
Results must, therefore, be viewed with caution and difficulties determining the exact 
timing of transmission should be taken into account (Dabis et al., 1995). A handful of 
studies have attempted to estimate the rate of MTCT through breastfeeding in mothers 
known to be HIV uninfected at delivery. In a systematic literature review of 4 studies with 
a limited number of mother-child pairs, it was estimated that 29% of infants become HIV 
infected if the mother first becomes infected in the postpartum period (Dunn et al., 1992). 
These high vertical transmission rates vary, 16% in a study of 1,954 HIV uninfected women 
recruited in Zambia, sixteen of these women (out of the 634 that returned for their yearly 
follow-up) became HIV positive and 3 of their 19 children acquired HIV (Hira et al., 1990). 
In an Australian study 27% of infants breastfed by mothers who were infected with HIV-1 
through postpartum blood transfusions or intravenous drug use became infected, although 
the numbers of this study were very small with only 10 mothers recruited (Palasanthiran et 
al., 1993). Of a prospective cohort of 212 Rwandan women known to be HIV uninfected at 
delivery 16 women became HIV infected and nine of their infants subsequently acquired the 
infection (Van de Perre et al.,*1991).
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Rates of transmission through breastfeeding in HIV-infected mothers seroconverting in the 
postpartum period may not be an accurate portrayal of the majority of women who are HIV- 
1 infected before pregnancy. Variations in HIV-1 virulence during seroconversion, 
concurrent infections and breastfeeding rates may all contribute to differences in 
transmission. However, with recent progress in reducing transmission in the peripartum 
period the importance of transmission through breastfeeding increases (Guay et al., 1999; 
Connor et al., 1994; Andiman, 2002; The International Perinatal HIV Group, 2002; The 
European Collaborative Study, 1994). Infants bom to mothers who acquired HIV infection 
before delivery may be exposed to lower milk viral load, presence of antibodies to HIV-1 in 
breast milk and transplacental exposure to neutralising antibodies (Willumsen et al., 2001), 
thereby reducing the risk of transmission through breastfeeding.
Using data from four studies with a limited duration of breastfeeding it has been suggested 
that the highest risk period for transmission may be within the first few weeks of life (Dunn 
et al., 1998). Nearly 63% of all transmission through breastfeeding in a study in Kenya was 
found to have occurred by 6 weeks postnatally (Nduati et al., 2000). There is strong 
evidence for a gradual and continued increase in transmission risk as long as the child is 
breastfed (Taha et al., 1998; Leroy et al., 1998; Nduati et al., 2000; Miotti et al., 1999).
In a randomised controlled trial in Nairobi, Kenya 425 pregnant women were assigned to 
either a breastfed or formula fed group. Investigators measured MTCT rates, HIV-free 
survival and mortality at 24 months of age. Data analysis was based on 401 live-bom 
infants (197 were in the breastfeeding group, 204 in the formula group). In the
49
breastfeeding group there was 96% compliance with 'any breastfeeding', but in the formula 
fed group there was only 70% compliance with 30% of women giving their child breast 
milk in addition to formula. By 24 months of age the cumulative probability of HIV- 
transmission in the breastfeeding group was 36.7% (95% Cl: 29.4 - 44.0%) compared to 
20.5% in the formula arm (95% Cl: 14.0 - 27.0%). Although overall mortality was not 
significantly different among the formula fed (20.0%) and the breastfed infants (24.4%) at 
24 months, HIV-free survival was significantly greater in the formula fed group (70% vs. 
58%). Interestingly the risk of postnatal transmission was not linear, with 63% of postnatal 
infections occurring at 6 weeks, 75% by 6 months and 87% by 12 months of age (Nduati et 
al., 2000).
Later postnatal transmission through breastfeeding can be determined using currently 
available diagnostic tools. Studies of infants found to be negative by PCR testing at 2-6 
months but who subsequently have shown evidence of infection have provided estimates of 
the risk of late postnatal transmission ranging from 4% in a study by Bertiolli et al., 1996 to 
16% in a study by Nduati et al., 2000 (see table 2.2 for details).
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Table 2.2 Studies of the risk of late postnatal transmission
Studies Number of 
infants in 
study
Time of 
negative PCR
Median length 
of breastfeeding 
(months)
Risk of HIV 
infection 
through late 
postnatal 
breastfeeding
Leroy et al., 
2003 (3-site 
study)*
334 1.5-12 months 8.1 (study site 1) 
15.2 (study site 2) 
19.4 (study site 3)
9.1%
Nduati et al., 
2000
401 1.5-24 months 17 16.2%
Leroy et al., 
1998 (meta 
analysis)
429 2.5-15.7 months 15 9.2%
Taha et al., 
1998
621 7 weeks not available 9.6%
Ekipini et al., 
1997
45 3-6 months 20 12%
Bertolli et al., 
1996
189 3-5 months 12 4%
Simonon et 
al., 1994
180 3 months 19 4.9%
♦Placebo group only
Adapted from UNICEF/UN AIDS/WHO HIV and Infant feeding brochure, 1998.
There is an ever-increasing quantification of risk factors associated with the likelihood of 
transmission through breastfeeding. Many factors involved in the overall risk of MTCT are 
likely to play a role in the risk of transmission through breastfeeding alone as well as factors 
specific to the breast and to the infant, and the possibility of breast milk also containing 
anti-infective properties should not be forgotten. These risk factors and possible benefits 
will now be considered.
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2.3.2 Breast milk risk factors
A number of factors have now been identified which appear to increase the risk of 
transmission through breastfeeding (see table 2.3). These include maternal viral load and 
virus type and other viral characteristics, maternal immune status, maternal malnutrition, 
duration of breastfeeding, the type of breastfeeding practiced (exclusive or mixed feeding) 
and the presence of breast abscesses, mastitis, cracked nipples and oral lesions in the infant 
(UNICEF et al., 1998). The risk factors will now be discussed in more detail.
2.3.2.1 RNA viral load
Breast milk viral load has not been as extensively studied as maternal viral load, however, 
there is an increasing volume of research in this area showing high breast milk viral load is 
strongly associated with increased risk of MTCT through breastfeeding. Breast milk HIV-1 
RNA levels have been shown to partially correlate with systemic viral load (Lewis et al., 
1998; Semba et al., 1999a), and are likely to be associated with the risk of transmission 
through breastfeeding (Semba et al., 1999a). In a study in South Africa, RNA viral load 
was found to be highly variable between breasts over time (Willumsen et al., 2000). 
Detectable HIV RNA in breast milk at any time during the first 6 months postpartum was 
shown to be a risk factor for transmission in another study in South Africa (Pillay et al.,
2000). This result concurred with a previous study in Malawi showing a 5-fold risk in 
transmission if RNA viral load had been detected in breast milk samples taken at 6 weeks 
postpartum (Semba et al., 1999a). Caution should however be used in interpreting this data 
as viral load at 6 weeks was found to be associated with infant HIV status. More recently a
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study in West Africa showed a 2.6 fold increase in transmission through breastfeeding for 
every logio increase in plasma viral load measured in late pregnancy (Leroy et al., 2003). If 
some of the virus present in the breast milk is there as a result of an opening in the 
paracellular pathway between the tight junctions of the mammary epithelial cells, 
permitting plasma-derived components to enter the milk, other plasma indicators [e.g. CRP] 
may also be present in the breast milk (Willumsen, 2001).
Table 2.3 Risk of transmission through breastfeeding
Risk Factor Strength of evidence
High maternal HIV viral load
• Seroconversion during pregnancy, 
delivery or postpartum
• Advanced disease
Strong
Advanced disease
• Clinical symptoms
Strong
Immune deficiency
• Low CD4 cell counts
Strong
Maternal Malnutrition Limited
Duration of breastfeeding Strong
Non-exclusive breastfeeding in the first 3-6 months Limited but increasing
Breastfeeding whilst experiencing breast infections
• Mastitis
• Abscesses
Limited
Breastfeeding whilst experiencing nipple fissures Limited
Breastfeeding an infant with mouth sores Minimal and confounding
Adapted from (UNICEF et al., 1998)
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2. S. 2.2 Maternal CD4 count
As well as being a risk factor for transmission in the antenatal and perinatal period, low 
maternal CD4 counts have long been associated with an increased risk of MTCT in the 
breastfeeding period. Although strongly correlating with plasma HIV RNA viral load, 
maternal CD4 counts are an independent factor for breastfeeding transmission risk. Low 
CD4 counts in plasma have been associated with detection of HIV DNA in breast milk 
(Nduati et al., 1995; Rousseau et al., 2003; Willumsen et al., 2003). In a recent analysis on 
pooled data from two West African studies (Leroy et al., 2003), a maternal CD4 count <500 
cells per mm in plasma close to the time of delivery was associated with a three-fold 
increase in risk of late postnatal transmission through breastfeeding after 4-6 months of age, 
compared to women with CD4 cell counts > 500 cells per mm3. A meta-analysis of data 
from nine trials in sub-Saharan Africa on 4,000 children showed the risk of postnatal 
transmission after 4 weeks of age to be strongly associated with maternal CD4 cell count, 
with a 3.4 fold risk where CD4 cell counts were between 200 and 500 cells per mm , 
compared to the reference group greater than 500 cells per mm (Read, 2003).
2.3.2.3 Breast inflammation
Breast inflammation covers a variety of factors, including inflammation due to poor feeding 
technique and/or external inflammations of the breast (e.g. nipple lesions). Currently there 
is limited evidence linking breast inflammation with MTCT. Many of the symptoms of 
breast inflammation are transient and short lived; consequently their specific risk to MTCT 
through breastfeeding may be low and difficult to measure. However, as one of the aims of
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this research was to measure inflammatory factors in the breast milk, a detailed examination 
of the published literature is presented.
Mastitis is a local inflammation of the breast during which the paracellular pathways 
between mammary epithelial cells open up. It causes tenderness, redness and heat and is 
characterised by an increase in breast milk sodium concentrations and inflammatory cells 
(Lawrence RA, 1999; Morton, 1994). The response is localised, usually occurs only in one 
breast and in severe cases systemic ‘flu-like’ symptoms may be seen in the mother. 
Mastitis affects up to one third of women during the first 2 months after delivery and it has 
recently emerged as a possible risk factor for HIV transmission through breastfeeding 
(Willumsen et al., 2003). However, as the symptoms only last for a few days and may be 
present in one breast only, the overall risk of transmission is thought to be low.
In a cohort study in Nairobi (Embree et al., 2000), HIV transmission was independently 
associated with the presence of maternal nipple lesions, maternal CD4 count below 400
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cells per mm , infant oral thrush below the age of 3 months and prolonged duration of 
breastfeeding (>6 months postpartum).
In a study in Blantyre, Malawi (Semba et al., 1999b), 334 HIV-positive and 96 HIV- 
negative women were followed from pregnancy to 12 weeks post delivery. Using stored 
breast milk samples collected at 6 weeks postpartum, Semba et al. 1999b, found that 
elevated sodium levels in the milk (> 12mmol/L), indicative of sub clinical mastitis, were 
present in 28.4% of mothers of 88 HIV-infected infants but in only 12.5% of mothers of
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uninfected infants (n=240) at 6 weeks of age. The researchers found that HIV infection 
itself was not a risk factor for mastitis (as measured by elevated breast milk sodium levels) 
as 16.4% of HIV-infected women and 15.6% of uninfected women had elevated breast milk 
sodium concentrations. Breast milk viral load was determined on a sub sample of 134 
women; median breast milk viral load was 700 copies/mL in mothers of infected, versus 
undetectable in mothers of uninfected infants, and 920 copies/mL in women with raised 
milk sodium, versus undetectable in those with normal sodium levels (Semba et al., 1999b).
Interleukin-8 (IL-8) is the cytokine involved in mastitis for which there is the most 
information in humans (Filteau et al., 1999b). mRNA for IL-8 has been found in both 
breast milk cells and mammary gland epithelial cells (Palkowetz et al., 1994; Floyd et al., 
1999; Srivastava et al., 1996) and also in breast milk itself (Filteau et al., 1999a). Breast 
milk IL-8 has been found to correlate with breast milk Na/K (Filteau et al., 1999a; Filteau et 
al., 1999b; Willumsen et al., 2000), but little information is known about normal levels of 
IL-8 within milk as wide variations are seen between studies (Srivastava et al., 1996; 
Filteau et al., 1999b). Levels within the breast seem to vary over time; in Tanzanian 
women IL-8 concentration ranged from 35pg/mL to approximately 90pg/mL during the first 
3 months of lactation (Filteau et al., 1999b). IL-8 in breast milk has also been found to 
correlate with breast milk viral load at 1 week, 6 weeks and 3 months postpartum 
(Willumsen et al., 2000), suggesting that IL-8 may be an indicator of increased risk of 
vertical transmission through breastfeeding.
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Serum IL-8 concentrations are significantly increased in HIV-infected individuals 
(Matsumoto et al., 1993) and may contribute to some of the clinical manifestations that 
occur during AIDS. Studies indicate that HIV-positive individuals infected with 
Pneumocystis carinii express higher levels of IL-8 compared to HIV-negative individuals 
with the same infection (Benfield et al., 1997). In vitro, IL-8 is induced early after 
monocytic infection, followed by continued increased expression. A close correlation has 
been seen between extra cellular IL-8 levels and the concentration of HIV p24 antigen 
(Esser et al., 1996). However, further in vitro work has produced conflicting results 
showing that cytokine induced IL-8 production is depressed in chronic HIV infection of 
promonocytic cells (Tiemessen and Martin, 2000). Latently HIV-1 infected cells (i.e. those 
not actively reproducing the HIV virus) have been shown to have a marked reduction of IL- 
8 secretion, as opposed to IL-8 released from productive HIV-1 infected cells and non-HIV 
infected cells (Ohashi et al., 1994). Raised IL-8 in the breast milk may therefore be an 
indicator of productive HIV-1 infected cells and may account for the correlation between 
breast milk IL-8 and breast milk RNA viral load.
HIV-infected mothers with raised breast milk sodium levels also had lower CD4 counts, 
higher plasma and breast milk viral load, and breast milk lactoferrin concentrations (Semba 
et al., 1999b). Breast milk sodium, lactoferrin at 6 weeks and plasma viral load during 
pregnancy were all associated with increased risk of MTCT at 6 weeks (45.4%) and 12 
months of age (50.9%) (Semba et al., 1999b). After adjusting for maternal viral load and 
breast milk HIV, women with mastitis at 6 weeks were 2.3 times more likely to have HIV- 
infected infants at 12 months. However, the risk of MTCT at 12 months was not assessed
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for infants uninfected at 6 weeks, therefore, it is difficult to draw a conclusion regarding the 
increased risk of transmission during that period for uninfected infants exposed to high 
levels of breast milk sodium. Both breast milk sodium (Neville et al., 1984), and viral load 
vary throughout lactation in each individual woman (Van de Perre P. et al., 1993; Ruff et 
al., 1994). It may, therefore, be difficult to attribute breast milk transmission of HIV to a 
single episode of sub clinical mastitis or high viral load, especially when other factors 
known to influence the rate of transmission, such as maternal CD4 are also associated with 
the observed outcome (Willumsen et al., 2000).
A study of women in Durban, South Africa aimed to investigate sub clinical mastitis in a 
breastfeeding population where HTV was endemic. Of 269 women with infants < 20 weeks 
of age, 71 (26%) had a Na/K ratio of greater than 0.6 (indicative of sub clinical mastitis) in 
milk from one breast and 77 (29%) had raised Na/K in both breasts. After controlling for 
infant age, exclusive breastfeeding was associated with a significantly lower Na/K ratio 
(0.58, 95% Cl: 0.53-0.62, n=160) than mixed feeding within the previous 24 hours (1.05, 
95% Cl: 0.82-1.35, n=52, P0.0001). The authors concluded that mixed feeding may result 
in milk stasis which could increase milk sodium concentrations (Willumsen et al., 2000). 
They then went on to investigate sub clinical mastitis among a group of women known to 
be HIV-infected. The increased mammary epithelial permeability which resulted in raised 
milk sodium (Peaker, 1975), could also permit non specific leakage of the virus into the 
milk. The elevations in inflammatory cytokines such as IL-8 then recruit leukocytes, 
possibly carrying cell associated virus, into the milk (Willumsen et al., 2000). Willumsen 
et al. 2000 found, that moderately (0.6-1.0) or greatly raised Na/K (>1.0) was common and
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often unilateral. Considering both breasts together, normal, moderately raised or greatly 
raised Na/K was found in 51%, 28%, 21% respectively of milk samples at one week 
(n=190); 69%, 20%, 11% at 6 weeks (n=167); and 72%, 16% and 12% at 14 weeks 
(n=122). IL-8 concentrations correlated significantly with both Na/K and viral load at all 
time points. Na/K correlated with viral load at 1 and 14 weeks. They also found that at one 
week, exclusive breastfeeding was associated with lower milk viral load than mixed 
feeding. They concluded that sub clinical mastitis among HIV-infected women increased 
the risk of vertical transmission through breastfeeding by increasing breast milk viral load 
and that the causes of sub clinical mastitis, which may include local or systemic infection, 
micronutrient deficiencies or poor lactation practice, needed to be further investigated 
(Willumsen et al., 2000).
2.3.2.4 Integrity o f  mucosal membranes
During breastfeeding the infant oral, tonsillar and intestinal mucosa come in close contact 
with the virus. HIV may enter through breaches in the mucosal barrier, or through infection 
of mucosal associated lymphoid tissue (Ekpini et al., 1997; Embree et al., 2000). Factors 
resulting in disruption of the integrity of the infants’ mucous membranes, such as oral 
thrush may be associated with the risk of transmission through breastfeeding, although the 
direction of causality may be difficult to establish since early HIV infection may be 
associated with thrush (Ekpini et al., 1997; Embree et al., 2000). If cell-free or cell- 
associated virus is able to infect lymphocytes in the sub mucosa by passing through 
breaches in the intestinal mucosa, conditions that result in intestinal epithelial damage may 
increase the risk of transmission (Willumsen et al., 2000). Feeding with cow’s milk,
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allergic reactions to complementary foods and infectious illness can all result in intestinal 
damage. It has been hypothesised that infants who are exclusively breastfed may have a 
less permeable and therefore healthier lining of the gut than those receiving breast milk and 
complementary feeds (Willumsen et al., 2000). However, a study in South Africa showed 
no difference in infant intestinal permeability between these two groups of infants 
(Willumsen et al., 2000), although infants who had been diagnosed with HIV infection at 
14 weeks had higher permeability at 6 and 14 weeks postpartum (Rollins et al., 2001). 
These results could be explained if mothers of infants who were infected with HTV in the 
late postpartum period had higher breast milk concentrations of certain inflammatory 
factors known to cause increased epithelium permeability, such as CRP.
2.3.2.5 Colostrum vs. mature milk
Limited and conflicting information has been published comparing the infectivity of 
colostrum or mature breast milk. Cell free and cell-associated HIV-1 have been detected in 
both colostrum and mature breast milk of women with established HIV infection. HIV 
DNA (cell-associated virus) was detected in 70% of 47 colostrum samples and 
approximately 50% of breast milk samples obtained at 6 (n=30) and 12 (n=15) months 
(Ruff, 1994). However, in contrast, in a Kenyan study (Nduati et al., 1995), a higher 
proportion of breast milk samples collected between 7 days and 6 months had HIV DNA 
(65% of 108 samples) than did (51% of 77 samples); p=0.05.
Due to the inability to distinguish between HIV infection acquired during late pregnancy, 
delivery or through early breastfeeding, it is not easy to study the exact role of colostrum in
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breastfeeding-related HIV transmission. What is known is that colostrum and mature milk 
contain different types of cells and different levels of immune modulating components (e.g. 
vitamin A, immunoglobulins and lactoferrin) (UNICEF et al., 1998). In addition the 
increased number of inflammatory cells contained in colostrum could possibly lead to an 
increased viral load. However, the total volume of colostrum ingested by the infant is much 
smaller than that of mature milk, and the higher concentrations of IgA and IgM antibodies 
as well as other anti-infective cells in colostrum may offer protection against infection (Van 
de Perre P., 1999b). In a study by Tess et al., (1998) vertical transmission was not 
associated with a history of colostrum intake in 148 breastfed infants.
2.3.2.6 Mode o f infant breastfeeding
Limited data has shown that exclusive breastfeeding reduces the risk of MTCT though 
breastfeeding when compared to mixed feeding. Exclusive breastfeeding is the term used 
to describe breastfeeding without supplementary feeds such as water, other liquids or semi­
solid foods (Piwoz and Preble, 2000; WHO, 2002a). In general exclusive breastfeeding is 
recommended for the first six months of life (WHO, 2002a). Exclusive breastfeeding 
reduces the risk of infant mortality from diarrhoea and respiratory infections (Victora et al., 
1989 and Victora et al., 1997), and it also protects against other diseases such as neonatal 
sepsis, acute otitis media, and necrotising enterocolitis (Piwoz and Preble, 2000).
In a prospective study of 549 mother-infant pairs in Durban, South Africa, Coutsoudis et al. 
1999 reported that at 3 months, 18.8% (95% Cl: 12.6-24.9) of 156 never-breastfed children 
were estimated to be HIV-1 infected compared with 21.3% (17.2-25.5) of 393 breastfed
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children (p=0.05). However, the estimated proportion of HIV-infected infants by 3 months 
was significantly lower for those exclusively breastfed to 3 months than in those who 
received mixed feeding before 3 months (14.6% [7.7-21.4] vs. 24.1% [19.0-29.2], p=0.03). 
After controlling for confounding variables, this represented a 48% reduction in 
transmission risk for exclusively breastfed infants when compared to mixed fed infants. At 
15 months, 24.7% of the babies who had been exclusively breastfed for at least 3 months 
were HIV-positive, compared to 35.9% of the mixed fed babies (Coutsoudis et al., 2001). 
Infant mortality was also greater among the mixed fed babies (15 deaths) than both the 
formula fed babies (7 deaths) and the exclusively breastfed group, where no deaths occurred 
during the follow up period (Coutsoudis et al., 2001).
Since the publication of this research large scale trials in Zambia and Zimbabwe have been 
undertaken to examine mode of breastfeeding in more detail. However, no transmission 
data has yet been published.
2.3.2.7 Gender
As in the antenatal period, differences in gender are increasingly being linked to risk of 
MTCT in the postpartum period through breastfeeding. In a recent meta-analysis of late 
postnatal transmission (Read, 2003), the child’s gender was significantly associated with 
late postnatal transmission, with girls being 40% less likely to become infected after 4 
weeks of age than boys. This is the opposite to what is seen in the antenatal period 
(European Collaborative Study, 2004). The risk of late postnatal transmission through 
breastfeeding was highest for boys breastfed by mothers with CD4 counts below 200
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cells/mm , followed by boys breastfed by mothers with CD4 counts between 200 and 499 
and then girls breastfed by mothers with CD4 counts below 200. Duration of breastfeeding 
was similar between both boys and girls and no detail was available as to the introduction 
of complementary foods. It may be that boys were introduced to complementary food 
earlier, with mixed feeding associated with a higher risk of transmission (Read, 2003).
2.3.3 Benefits of breastfeeding in children bom to HIV infected mothers
So far the potentially harmful effects of breastfeeding has been discussed, but there may 
also be some benefits. Many innate immunological mechanisms may exist to protect the 
host from infections and harmful foreign antigens and these may contribute to the 
prevention of HIV transmission from the mother to the child. However, there is a relative 
paucity of information regarding the ability of the breast milk from HIV infected mothers to 
protect the infant both from HIV transmission and from common childhood illnesses. Due 
to the nature of the disease it may be expected that HIV-infected women have some degree 
of immune dysfunction affecting both antibody and cell mediated immune responses. 
Infants breastfed by HIV-infected women may, therefore, have lower levels of protection 
from common childhood illnesses such as respiratory infections and diarrhoeal diseases.
Published research of morbidity and mortality in breastfed babies by HIV infected mothers 
has produced conflicting results. In a randomised controlled trial in Kenya to evaluate the 
mode of infant feeding in the risk of mother to child transmission (Nduati et al., 1995), the 
two year mortality rate between those infants who were breastfed and those who were
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formula fed was not significantly different. The incidence of diarrhoea and pneumonia was 
also similar (Mbori-Ngacha et al., 2001). However, after adjusting for HIV status, infants 
in the breastfeeding arm had significantly better nutritional status than those in the formula 
arm over the two-year period. Coutsoudis et al., 2003, found that HIV-infected infants who 
were never breastfed had a poorer outcome that the breastfed infected children. During the 
first 2 months of life, infants who were never breastfed, regardless of their HIV status, were 
nearly twice as likely to have an illness episode than breastfed infants.
In a South African study partially breastfed and exclusively formula fed HIV-infected 
infants had similar frequencies of failure to thrive, diarrhoea and pneumonia as uninfected 
infants bom to HIV-infected mothers (Bobat et al., 1997). With improved nutritional status 
in HIV-infected breastfed infants when compared to their formula fed counterparts (Mbori- 
Ngacha et al., 2001), this may indicate that the nutritional properties of milk between HIV- 
infected and HIV-uninfected women do not differ but that the immune protection conferred 
by the breast milk does (Bobat et al., 1997).
Limited work on breast milk of HIV-infected mothers has shown some conferred immunity 
to HIV, with breast milk of women with established infection having HIV-specific IgG and 
IgA antibodies (although these are limited to only a few viral proteins) (Lawrence RA, 
1999). HIV-specific IgM has also been found, with lack of persistent IgM in breast milk 
collected at 18 months being associated with a high risk of transmission of HIV, suggesting 
that it performs a protective role against HIV transmission to the infant (Van de Perre et al., 
1993).
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Secretory leukocyte protease inhibitor (SLPI) is considered to be protective against mucosal 
transmission of HTV including in the breast milk (Hocini et al., 2000). It is thought to act 
on target cells rather than the virus and in vitro has been shown to inhibit internalisation of 
HIV-1 (Hocini et al., 2000). However, SLPI in breast milk was not associated with 
decreased transmission in a study from Cameroon (Becquart et al., 2000). CD8 cytotoxic T 
lymphocytes, which recognise a range of HIV-1 antigens, have been found in breast milk of 
US and Zambian women (Sabbaj et al., 2002), but, their exact role, if any, in prevention of 
transmission is not yet known.
Immune components in breast milk are notoriously difficult to analyses due to the complex 
matrix of breast milk. In addition in vitro studies, although a vital part of understanding the 
function of the immune factors, do not always reflect what is occurring in vivo. Increased 
research in this area may prove vital in gaining a greater understanding of the process of 
MTCT through breastfeeding.
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Summary
Sub-Saharan Africa remains the region worst affected by the AIDS epidemic. 
Between 25 and 28 million people are living with HIV/AIDS in the region.
HIV is affecting the most vulnerable sections of society: the poor, women and 
children.
The global spread of HIV through heterosexual contact has led to a high prevalence 
of infection among sexually active women of reproductive age.
Effective monitoring and treatment of the disease is currently impossible in most 
African settings.
The overwhelming majority of paediatric infections are as a result of mother to child 
transmission:
o In utero risk factors 
High maternal viral load 
Poor maternal immune status 
Placental inflammation and co-infections 
o Intrapartum risk factors
High maternal viral load and poor maternal immune status
Prematurity
Mode of Delivery
Prolonged rupture of membranes during vaginal delivery
o Postpartum risk factors
High maternal viral load and poor maternal immune status
Breast milk viral load and non-specific antibody levels
Breast health
Duration of breastfeeding
Feeding mode
Infant intestinal integrity
• Available interventions can significantly reduce transmission to the infant during 
pregnancy and delivery but do not yet address the breastfeeding period.
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2.5 Conceptual framework
The project described in this thesis was designed to investigate a number of issues 
surrounding breastfeeding and maternal HIV status. It was designed to look at both HIV 
infected and uninfected women and examines data obtained from three sub Saharan African 
countries and four different populations of women. Two of these studies were fully 
undertaken by the author (Zambian community based study and Zambian pilot study) and 
two of the studies involved retrospective laboratory analysis by the author (Tanzanian study 
and South African study). In the Tanzanian study (n=85) and the Zambian pilot study 
(n=22) maternal HIV status was unknown, in the Zambian community based study (n=l 12) 
and the South African study (n=144), HIV status was known.
Figure 2.1 presents the conceptual framework that was developed for this study. Although 
the data was analysed to look at broad issues regarding HIV, including social and 
breastfeeding indicators (chapter 1, section 1.3 for detailed aims and objectives), one of the 
main outcomes was to examine whether breast milk CRP had a potential role in measuring 
the risk of mother to child transmission. The conceptual framework hypothesises why CRP 
could be used as a surrogate indicator of MTCT.
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Figure 2.1 Conceptual Framework
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Chapter 3 
Materials and Methods
3.1 Context of the study
Due to the very nature of HIV it would be expected that the immune responses in HIV- 
infected women would differ from those of HIV-uninfected women. In some cases HIV- 
uninfected children bom to HIV-infected women have greater incidences of morbidity and 
mortality when compared to children bom to HIV-uninfected women (Mbori-Ngacha et al., 
2001). However, there is a great paucity of information available to compare the immune 
responses of normal, healthy HIV-uninfected women with those infected with HTV, or 
indeed healthy HIV infected mothers with those with immunosuppression (CD4 counts 
<500 cells mm3). MTCT of HIV is a complex and multi factored event. Maternal CD4 
counts and viral loads are well documented to be high risk factors for transmission 
(UNICEF 1998), but to use these to monitor pregnant women would require complex and 
expensive laboratory equipment and skilled personnel, making their use in most developing 
countries almost impossible.
This research project focuses on inflammatory factors in HIV infected and HIV uninfected 
women in sub Saharan Africa. The overall aim of this research was to determine the nature 
and extent of inflammatory markers in breast milk and plasma in order to assess possible 
risk factors for MTCT through breastfeeding (see chapter 1, section 1.3). These aims 
involved comparing a number of factors, including social, biological and breastfeeding 
indicators, in HIV infected and HIV uninfected women. This project was based on research 
from 4 different field studies: Rural Tanzania, urban South Africa, an urban hospital in 
Zambia and an urban community in Zambia.
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3.2 The Studies
3.2.1 Zambia hospital based pilot study 
Project aims:
•  To determine if breast milk CRP was a suitable surrogate measure for systemic 
inflammation and a potential indicator of increased risk of MTCT.
Research undertaken by the author:
A pilot study was conducted at the University Teaching Hospital; Lusaka, Zambia designed 
to investigate breast milk inflammatory factors in women with systemic inflammation. The 
study received ethical approval from the Institute of Child Health, University College 
London and the Department of Medicine, University of Zambia, and the participants gave 
written informed consent. 22 women with systemic infection in the postpartum period, as 
defined by clinical diagnosis were recruited over a 4-month period and gave breast milk 
samples from each breast daily until discharge. The samples were hand expressed into a 
plastic container, immediately frozen at -70°C, transported to London on dry ice and stored 
at -70°C prior to analysis. See table 3.1 for characteristics of the subjects. I was involved 
in the design of the study and the questionnaires used, and also the recruitment and training 
of project midwives. I was also responsible for obtaining ethical permission for this study 
both in the UK and Zambia, for sample collection, processing and data entry.
Sample analysis:
Breast milk samples were analysed for CRP, Na/K and IL-8 concentrations, and the 
questionnaire data was entered by the author. Limited data analysis was undertaken for this
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study because of the small sample size. Details of the laboratory and statistical analyses are 
given later in this chapter (sections 3.3.5 and 3.4 respectively).
3.2.2 Tanzanian study 
Project aims:
• To determine if breast milk CRP was a suitable surrogate measure for systemic 
inflammation and a potential indicator of increased risk of MTCT.
Research undertaken by others:
Details of this study have been reported previously (Filteau et al., 1999b). Briefly, 85 
women were recruited when visibly pregnant in a study designed to look at oil 
supplementation on sub clinical breast inflammation, from sites in rural Tanzania. At their 
third trimester, women were allocated to one of three treatment groups: controls given a 
small amount of rice; a red palm oil supplementation group given 2mg provitamin A 
carotenoids and lmg a-tocopherol per day; and a sunflower oil supplementation group 
given 5.7 mg a-tocopherol per day. Venous blood samples were collected at recruitment 
and at 1 and 3 months postpartum, and spot milk samples were collected from each breast 
(and subsequently mixed) at 1 and 3 months postpartum. Blood samples were separated 
and the plasma was aliquotted into lmL containers. The plasma and breast milk samples 
were then frozen and transported to London on dry ice and stored at -70°C prior to analysis. 
The blood samples were analysed for vitamins A and E and inflammatory markers in the 
plasma (CRP and AGP) and the milk was analysed for IL-8. See table 3.1 for 
characteristics of the subjects.
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Research undertaken by the author:
Breast milk was analysed for milk CRP concentrations.
Sample analysis:
Breast milk CRP was compared against previously obtained plasma CRP data, 
data or samples analysis from this study was used for this thesis. Details of the 
analysis can be found later in this chapter (section 33.5).
3.2.3 South African study 
Project aims:
• To determine indicators associated with severity of HIV.
• To determine if breast milk CRP was a suitable surrogate measure for systemic 
inflammation and a potential indicator of increased risk of MTCT.
Research undertaken by others:
Details of this study have been reported previously (Willumsen et al., 2000). Briefly, HIV- 
infected pregnant women were recruited from the antenatal clinic at McCord’s Hospital, 
Durban, South Africa as part of a trial to study the effect of vitamin A supplementation on 
MTCT of HIV. Breastfeeding women were recruited and asked to return to the clinic when 
their infants were 1, 6 and 14 weeks old for clinical examination. They completed a 
questionnaire about infant feeding and breast health, and gave a donation of spot milk 
samples from each breast on each of the 3 visits. Samples were frozen and then transported 
to London on dry ice and stored at -70°C prior to analysis. See table 3.1 for characteristics 
of the subjects.
no further 
laboratory
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Research undertaken by the author:
Breast milk was analysed for milk CRP concentrations.
Sample Analysis:
Breast milk CRP concentrations were compared against a number of biological and social 
indicators previously obtained by the author. Details of the laboratory and statistical 
analyses can be found later in this chapter (sections 3.3.5 and 3.4 respectively).
3.2.4 Zambian community study 
Project aims:
• To determine indicators associated with HIV status
• To determine if breast milk CRP was a suitable surrogate measure for systemic 
inflammation and a potential indicator of increased risk of MTCT.
Research undertaken by the author:
This was a longitudinal study of HIV-infected and uninfected women in the community in 
Lusaka designed to look at a broad spectrum of health indicators, including nutrition, 
morbidity and breastfeeding technique over 16 weeks postpartum. The study received 
ethical approval from the Institute of Child Health, University College London and the 
Department of Medicine, University of Zambia, and participants gave informed written 
consent. 500 women were seen by a midwife antenatally, at delivery and regularly during 
the first 16 weeks postpartum, for a total of 12 visits. Morbidity was monitored according 
to standardised protocols at each visit and blood samples were taken at 2 time points and 
milk samples were collected at 11 time points. Women with and without sub clinical 
mastitis at each time point were compared in terms of HIV infection, complications during
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pregnancy and delivery, symptoms of postpartum infection, vitamin A, C, E status, milk 
cytokine concentrations, milk CRP concentrations, milk bacteriology, milk HIV viral load, 
and growth of their infants. It was agreed by the project steering committee that data from 
the first 120 subjects enrolled in the study would be available for use in this thesis. Of the 
first 120 women there were 8 drop outs (2 due to infant death and 6 who moved from the 
study area), leaving a total of 112 women and infants. For my project, questionnaire data, 
plasma acute phase proteins, milk Na/K, milk IL-8 and milk CRP concentrations were used 
from the first 112 women recruited into the study. See table 3.1 for characteristics of the 
subjects. I was involved in the study and questionnaire design, the recruitment and training 
of staff and obtaining ethical permission in Zambia. All of the breast milk analyses for 
CRP and IL-8 were undertaken by myself. The other laboratory analyses were undertaken 
by myself and other laboratory staff under my supervision. Data entry was undertaken by 
myself and other project staff. All of the laboratory databases (with the exception of the 
Na/K database) were entered and cleaned by the author.
Sample analysis:
Breast milk samples were analysed for CRP, IL-8 and Na/K, blood samples were analysed 
for acute phase proteins and haemoglobin. These results were then compared with a 
number of biological and social indicators. Details of the laboratory and statistical analysis 
can be found later in this chapter (sections 3.3.5 and 3.4 respectively).
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Table 3.1: Subject characteristics in each population
Variable Zambia pilot study
n = 22
Tanzania
n=158
South Africa
n = 144
Zambia community study 
n = 112
Study design Longitudinal Cross sectional Cross sectional Longitudinal
Study population Women systemic 
inflammation in the 
postpartum period
Healthy pregnant women in rural 
community
Healthy pregnant HIV infected 
women in urban community
Healthy pregnant HIV infected 
and uninfected women in urban 
community
Samples taken Breast milk Breast milk and plasma Breast milk and plasma Breast milk and plasma
Project aim* III III II and III I and III
Infant sex
M
F
U
11
Data not 
available
62
82
52
60
Birthweight (kg)
Median± 25th/75,hpercentile 
Range
3.10 ± 2 .4 ,3 .3  
(1 .6 5 -4 .2 0 )
Data not 
available
3.20 ±2.9 , 3.4 
(2.04 -  4.40)
2.92 ± 2 .7 ,3 .3  
(1 .6 0 -4 .0 7 )
Maternal age (yrs) 
Mean± SD 
Range
26.50 ± 22 .0 ,30 .0  
(1 5 -4 0 )
27.89 ±21.1,34.7  
(1 8 -4 5 )
24.00 ± 22.0,28.0  
(1 4 -3 7 )
23.00 ± 20 .0 ,27 .0  
(1 4 -3 8 )
No. Live births 
Meant SD 
Range
2.50 ± 1 .0 ,3 .0  
( 1 - 7 )
3.84 ±2.28  
( 1 - 9 )
2.0 ±(1.0, 3.0) 
( 1 - 4 )
2.0 ±1 .0 ,3 .0  
( 1 - 6 )
*See Chapter 1, section 1.3 for details of researc i aims
D esign o f  Zambian pilot study
Design o f  Zambian com munity based study
Collection o f  breast milk samples and 
questionnaire details
Collection o f  plasma and breast milk 
samples and questionnaire details
Analysis o f  breast milk samples from HIV 
infected South African women for CRP 
Data entry and analysis
Recruitm ent o f 22 women (HIV status 
unknown) adm itted to hospital in 
the postpartum  period w ith systemic 
. . . . inflam m ation.......................
Analysis o f  matched plasma and breast 
milk samples from Tanzanian women (HIV 
status unknown) for CRP 
Data entry and analysis
Questionnaire data entering and analysis 
Breast milk analysis for N a K. IL-8 and 
CRP
Sample data entry and analysis
Recruitm ent o f  56 HIV uninfected pregnant 
women and 56 HIV infected pregnant. 
Followed women from 36 weeks antenatal 
to 6 weeks postpartum
Questionnaire data entering and analysis 
Breast milk sample analysis for Na/K and 
IL-8
Development o f  breast milk CRP assay 
Analysis o f  breast milk samples for CRP 
Sample data entry and analysis
3.3 Methods
3.3.1 Data collection team
Details of the data collection for the Tanzanian and South African studies have been 
reported previously (Filteau et al., 1999b; Willumsen et al., 2000).
Zambian pilot study:
For the Zambian Urban Hospital study, 2 local midwives were employed to help identify 
participants for the study, collect breast milk samples and undertake the questionnaires 
under my supervision. They worked for the study on a part time basis whilst still being 
employed by the University Teaching Hospital.
Zambian community study:
For the Zambian community study, a large number of staff were involved including 6 
people on a full time basis (study coordinator, myself as laboratory coordinator, midwife 
coordinator, midwife assistant, administrator and a driver) as well as a number of part time 
staff (senior administrator, 3 laboratory technicians and 26 midwives).
3.3.2 Study population
Details of the study population for the Tanzanian and South African studies have been 
reported previously (Filteau et al., 1999b; Willumsen et al., 2000).
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Zambian pilot study
No information on the study population was taken, although all the women recruited lived 
within the Lusaka area.
Zambian community study
Women were recruited from the township of Chilenje situated in Zambia’s capital city, 
Lusaka. Lusaka is comprised of 18 residential areas and 24 townships. Chilenje is the third 
largest township with a population of nearly 85,000 (Lusaka health district management 
team, 2002). It has a population growth rate of 4%, which is a decrease of >2% from the 
1998 census growth rate estimates, with over 4,500 pregnancies per year and 20.1% of its 
population under 5 years of age (Lusaka health district management team, 2002). Child 
health indicators show a 7% prevalence of underweight children and a malnutrition rate in 
children <5 years of age of 29.6cases/1000 population. 62% of children under 1 year of age 
experience some form of immunisation coverage (Lusaka health district management team, 
2002).
The HIV-infection rate is estimated to be approximately 30% (Lusaka health district 
management team, 2002), which is in agreement with our clinic HIV voluntary counselling 
and testing procedure that gave a percentage of approximately 28% in pregnant women 
attending the antenatal clinic.
3.3.3 Recruitment
Details of the recruitment for the Tanzanian and South African studies have been reported 
previously (Filteau et al., 1999b; Willumsen et al., 2000).
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Zambian pilot study:
The subjects were recruited between February 2000 and June 2000. Study midwives 
approached women admitted to hospital within the postpartum period. The midwife would 
explain the purpose of the study, the type of questions that would be asked, that all the 
answers would be confidential and that daily breast milk samples would be taken. Inclusion 
criteria were verbal and/or written consent and ability to provide breast milk samples. 
Questionnaires used as part of the study are included in Appendix 2.2.
Zambian community study:
The subjects in the Zambian community study were recruited between June 2001 and April 
2002. A specially trained midwife approached groups of pregnant mothers waiting for 
antenatal checkups at the Chilenje community clinic. Initially the midwife gave group HIV 
counselling to all the mothers present. If any of the women were interested in being tested 
they were then counselled again individually in a private setting. The midwife would then 
explain the purpose of the study, the type of questions that would be asked, that all the 
answers would be confidential and the samples that would be taken. The inclusion and 
exclusion criteria are listed below. It should be emphasised that women who wished to be 
tested but did not want to be included in the study received the same quality of care, 
including antiretroviral treatment at labour and birth, as those recruited to the study.
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Inclusion criteria: 1. Verbal (and if possible written) informed
consent.
2. 30 weeks pregnant with intent to breastfeed
after birth.
3. Ability to provide breast milk and plasma
samples.
Exclusion criteria: Did not meet the above inclusion criteria.
The questionnaires used as part of the study are included in Appendix 2.1
3.3.4 Collection and processing of breast milk and plasma samples 
Details of the collection and processing of breast milk and plasma samples for the 
Tanzanian and South African studies have been reported previously (Filteau et al., 1999b; 
Willumsen et al., 2000).
Zambian pilot study:
Mothers were asked to manually express 5-10mL of breast milk into a 25mL sterile 
universal container. No cleaning of the breast was required prior to expression nor was 
there any restriction in breastfeeding prior to expression. Samples were taken at any time 
during the day when it was convenient for the mother. The samples were then placed 
directly into a -70°C freezer. Samples were then packed in dry ice and transported to 
London by air where they were immediately stored at -70°C prior to analysis.
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Zambian community study
Mothers were asked to manually express 5-10mL of breast milk into a 25mL sterile 
universal container (polypropylene jars with screw top lids). No cleaning of the breast was 
required prior to expression nor was there any restriction of breastfeeding prior to 
collection. The samples were collected between 9am and 4pm, stored in a cool box 
immediately after collection and transported to the Virology Laboratory at the University 
Teaching Hospital. The milk samples were then gently inverted and returned to an upright 
position on 4 occasions and aliquotted into lmL plastic cryogenic vials. Duplicate lmL 
breast milk samples were initially stored at -70°C in separate freezers in case of freezer 
failure or a power cut. Samples to be analysed for IL-8, CRP, AGP and some for Na/K 
were then packed in dry ice and transported to London by air where they were immediately 
stored at -70°C prior to analysis.
A lOmL sample of venous blood was collected into lOmL ethylenediaminetetraacetic acid 
(EDTA) tubes and gently inverted 4 times. Plasma was separated by centrifugation (3000 
rpm) for 10 minutes. The plasma was aliquotted into 0.5mL samples and stored at -70°C, 
with one duplicate sample in a different freezer. Samples to be analysed for CRP and AGP 
were then packed in dry ice and transported to London by air where they were immediately 
stored at -70°C prior to analysis.
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Photo 3.1: Senior Zambian project staff
Photo 3.2: Recruitment of a study subject: Midwife coordinator and pregnant mother 
fill in the recruitment questionnaire
3.3.5 Biochemical methods and quality control
Unless stated, the biochemical methods and quality control data for the Tanzanian and 
South African studies have been recorded previously (Filteau et al., 1999b; Willumsen et 
al., 2000).
3.3.5.1 Breast milk Sodium/potassium
Breast milk Na/K was measured in both the Zambian community and the Zambian pilot 
studies.
Na/K concentrations in breast milk were measured, in both London and Lusaka, by flame 
photometry using an IL943 digital flame photometer (Instrumental Laboratories, UK). As 
there was no commercially available standardised quality control (QC) for breast milk, we 
set up an in house QC using breast milk kindly donated from a London mother and in 
addition used a standardised urine QC (Instrumental Laboratories, UK). The urine setting 
on the machine, which covered a wider range than plasma, was used throughout. Due to the 
large number of breast milk samples to be analysed for Na/K in the Zambian community 
study the analyses took place both in the UK and in Zambia. Selected samples of duplicates 
were analysed in both countries to allow for the regular random cross checking of results.
In a previous study, the percentage recovery of Na/K in spiked breast milk samples was 
104% ± 1 %  and was not influence by milk fat content (Woodfin and Filteau, personal 
communication). Consequently Na/K concentrations were measured in this study in whole 
milk without any removal of fat. Using the urine QC, the intra assay coefficient of variation
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(CV) was 0.53% (n=10) and the interassay CV was 1.12% (n=73, samples run over a 1 year 
period). For the breast milk QC the interassay CV was 1.12% (n=14, run over 6 months). 
For summaries of data for the means, standard deviations, intra- and interassay CVs for 
each assay and study please see table 3.2.
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Photo 3.3: Some of the Chilenje clinic study midwives
Photo 3.4: Supervision o f  breastfeeding technique: Midwife observes the 
breastfeeding technique of recruited mother
3.3.5.2 Plasma a-acidglycoprotein (AGP)
Plasma AGP concentrations were measured in the Zambian community study.
AGP was measured using two methods. The first was by a sandwich enzyme-linked 
immunosorbant assay (ELISA) using both capture and horse radish peroxidase-conjugated 
antibodies to AGP from Dako (Cambridge, UK) and an AGP standard from Behring 
Diagnostics (Milton Keynes, UK). An ELISA is based on the principle of antibody binding 
(see figure 3.2), where a 96 well microtitre plate is coated with a specific capture antibody 
to the protein to be measured. When the sample or standard is added the specific proteins 
bind to the antibody. An enzyme (horse radish peroxidase) is bound to the second antibody. 
This antibody also binds to the protein of interest and the horse radish peroxidase is reacted 
with a substrate to give a coloured complex, which is read at 450nm by an optical density 
reader. The amount of the protein (AGP) is proportional to the optical density produced 
and concentrations of the AGP can be calculated by comparing the optical density of the 
sample with that of a standard curve (see figure 3.4).
ELISA plates, composed of 96 wells with volumes of 300pL volumes, were coated with 
50p,L the capture antibody diluted 1/1000 in a 0.1 M Na2CO3/NaHC03 diluting buffer (pH 
9.6) and stored overnight at 5°C. The wells were then washed with 300pL of buffer 
containing phosphate buffered saline (PBS) and Tween-20 (pH 7.2) to prevent non-specific 
binding and remove unbound antibodies. Each well was filled with 300pL of washing 
buffer which was then discarded; the process was repeated a further 3 times and the plate 
was dried by draining. The plate was then blocked for 1 hour with a 1% bovine serum
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albumin (Sigma Aldrich, UK) to remove excess antibodies and incubated at 37°C. A series 
of standards were freshly prepared on each occasion ranging from O.OOlmg/L to 
0.055mg/L. They were prepared by diluting 5pL of a l.lOg/L AGP solution in 5mL of the 
diluting buffer (preparation A: l.lmg/L). 1ml of preparation A was then made up to lOmL 
diluting buffer (preparation B: 0.1 lmg/L). Serial dilutions of preparation B were then made 
to give 0.055mg/L (standard 1), 0.01375mg/L (standard 2), 0.006875mg/L (standard 3), 
0.0034375mg/L (standard 4), 0.00171875mg/L (standard 5), 0.000859mg/L (standard 6 ). 
50 pL of the standards and the test plasma samples in duplicate and the plasma quality 
control (kindly donated by Great Ormond Street Hospital) in triplicate all diluted at 
1/10,000 in diluting buffer were added to the 96 well plate as indicated in figure 3.3 and 
incubated for 1 hour at 37°C. After washing the plate 50 pL of peroxidase-conjugated anti 
AGP antibody (the secondary antibody) at a dilution of 1/2000 was added and incubated for 
1 hour at 37°C. After washing the plate for the final time, 50pL per well of substrate 
solution containing 3,3,,5,5’-tetramethylbenzidine (Sigma Aldrich, UK) in a 0.11M sodium 
acetate solution (pH 5.5) was added and incubated in the dark for 10 minutes at room 
temperature to form a colour complex. 25pL per well of 2M sulphuric acid was finally 
added to stop the reaction. The plate was then placed in an ELISA reader where the optical 
density was read at 450nm. A typical standard curve is shown in figure 3.4. The plasma 
QC had an intra assay CV of 9.60% (n=7) and an interassay QC of 15.06% (n=10, samples 
run over a 3 month period). See table 3.2 for details. The interassay CVs were calculated 
taking the mean QC of the first plate run each day.
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Photo 3.5: University teaching hospital study midwives
Photo 3.6: Mother donating a breast milk sample: Hand expression into a universal 
container
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Figure 3.4 Standard curve for AGP by ELISA
AGP std curve
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AGP cone on log scale(mg/L)
Duplicates are shown for each concentration (some overlap can be seen)
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The second method was an immunoassay using capture antibody to AGP from Dako 
(Cambridge, UK) and an AGP standard from Behring Diagnostics (Milton Keynes, UK). 
The turbidity obtained following immuno-precipitation was directly proportional to the 
plasma AGP concentration and was measured using a COBAS Fara analyser. A series of 
standards were prepared ranging from 0.001 g/L to 0.036g/L. They were prepared by 
diluting the l.lOg/L AGP standard 1:30 with a KH2PO4/ K2HPO4-3H2O dilution buffer -pH
7.3 (167pL standard + 4833pL dilution buffer) to give a concentration of 0.036g/L 
(standard 1). This was then serially diluted 5 times to give a total of 6 standards. Plasma 
samples were diluted 1/60 in dilution buffer and the antibody was prepared at a ratio of 1: 
2.75 in diluting buffer. The samples were loaded onto the auto-analyser with lOOmL of 7% 
polyethylene glycol reaction buffer. The quality control plasma (for details see AGP ELISA 
assay) was run at the same time and gave an intra assay CV of 6.12% (n=10) and an 
interassay CV of 12.72% (n=10, samples run over a month (see table 3.2).
For the final analysis of samples (chapter 4), the COBAS results were presented as the data 
was more easily normalised.
3.3.5.3 Plasma C-reactive protein
Plasma CRP was measured in the Zambian community study.
CRP was measured by sandwich ELISA using both capture and horse radish peroxidase- 
conjugated antibodies to CRP from Dako (Cambridge, UK) and a CRP standard from 
Behring Diagnostics (Milton Keynes, UK) as described by Filteau et al., 1999b. The
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principle of this assay is the same as described previously for AGP (see section 3.3.4.2) 
with volumes, buffers, QC and antibody dilutions the same as those used in the AGP 
ELISA assay. A standard curve was prepared ranging from 3.47pg/L to l l lp g  /L using 
Behring diagnostics standard OQ1K (concentration 22.1mg/L). The top standard was 
prepared by adding 5juL to lmL of diluting buffer giving a concentration of 11 lpg/L; this 
was then serially diluted to make the standard curve. The plasma QC gave an intra assay 
CV of 5.27% (n=7) and interassay CV of 9.83% (n=12, over a time period of 18 months), 
see table 3.2 for details.
3.3.5.4 Breast milk CRP
Breast milk CRP was measured in the Zambian community, Zambian pilot, Tanzanian and 
the South Africa studies.
The principle of the milk CRP assay was the same as for plasma CRP. The volumes, 
buffers (except diluting buffer) and antibody dilutions were also the same. In preliminary 
studies 0.05% Tween was added to breast milk samples, but the mean recovery of CRP 
spiked into milk was found to be 128.2%; SD±3.11, n=4 suggesting high levels of non­
specific binding. This was overcome by the addition of 1,1,2 trichlorotrifluoroethane to the 
diluting buffer which has been used in previous immunological assays in breast milk 
(Montagne et al., 2000). This gave a mean recovery of the CRP standard of 100.1%; SD± 
0.04, n=4. A standard curve was prepared ranging from 13.8pg/L to 1.7pg/L in diluting 
buffer (as previously described but with the addition of 0.05% 1,1,2
trichlorotrifluoroethane). The top standard was prepared by adding 5pL of the CRP
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standard to lmL of diluting buffer (preparation A), 125pL of preparation A was then added
to lmL of diluting buffer to give the top standard (13.8pg/L).
Standards 2-6 were then prepared as follows:
500|liL  of standard 1 + 500pL diluting buffer: standard 2 (6.9pg/L)
750pL of standard 2 + 250pL diluting buffer: standard 3 (5.2pg/L)
500pL of standard 2 + 500pL diluting buffer: standard 4 (3.5pg/L)
750pL of standard 4 + 250pL diluting buffer: standard 5 (2.6pg/L)
500pL of standard 4 + 500pL diluting buffer: standard 6 (1.7jig/L)
Using this method and a dilution of 1/25 of breast milk gave an intra assay CV= 5.38% n=4 
and an interassay CV of 12.00% (n=16, over a time period of 18 months). However, due to 
the large range of CRP concentrations in breast milk samples, a spiked milk sample was 
also used as a QC with a final dilution of 1/200 being chosen. This gave an intra assay CV 
of 6.56%, n=4 with an interassay CV of 11.45% (n= 16 over a period of 18 months), see 
table 3.2 for further details.
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3.3.5.5 Breast milk IL-8
Breast milk IL-8 was measured in both the Zambian community and the Zambian pilot 
study.
Breast milk IL-8  was analysed by an enzyme-linked immunosorbant assay (ELISA) using 
the Pelikine Compact™ human IL-8  ELISA kit from CLB Central Laboratory of the 
Netherlands Red Cross Blood Transfusion Service. Adaptation for the use with human 
breast milk has been previously reported (Filteau et al., 1999a). The principle of this assay 
is similar to that described previously (see section 3.3.4.2). The original milk dilutions of 
1/2 needed to be adjusted, as the results tended to fall on the non-linear portion of the 
standard curve. Milk was diluted 1/4 and 1/8 with diluting buffer, with the 1/8 milk 
dilution being chosen for sample analyses. This gave an intra assay CV of 3.95% (n=7).
ELISA plates were coated with the coating antibody diluted 1/100 in coating buffer 
provided in the ELISA kit and incubated overnight at 5°C. The plates were then washed 
and blocked (in blocking buffer provided by the kit) for 1 hour at room temperature. A 
standard curve was prepared ranging from lpg/mL to 240pg/mL. The test milk samples in 
duplicate, and the same milk quality control as used in breast milk CRP in triplicate, were 
added to the plate and stored for 1 hour at room temperature. After washing the plate, the 
secondary biotinylated antibody at a dilution of 1/100  was added to the plate and incubated 
at room temperature for 1 hour. The plate was then washed and horse-radish peroxidase 
conjugated strepavidin was added and incubated for 30 minutes at room temperature. After 
washing the plate the substrate solution was added and after 30 minutes the reaction was
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stopped by the addition of a 2M sulphuric acid solution. The plate was then placed in an 
ELISA reader where the optical density was read at 450nm. Quality control milk had an 
interassay CV of 4.06% (n=6 , over a time period of 1 month) and intra assay CV of 
2.80(n=7), see table 3.2 for details.
3.3.5.6 Haemoglobin
Haemoglobin was measured in the Zambian community study.
Haemoglobin was measured as an indicator of iron deficiency anaemia (cut off below 11.0 
g/L indicative of deficiency) (WHO, 2004c). A portable Hemocue was used (Hemocue, 
Sheffield, UK) that measured haemoglobin by photometry. A pin-prick sample of blood 
was taken and placed onto a cuvette which was placed in the precalibrated portable 
photometer to give an immediate result covering a range from 0 -2 5 .6  g/dl. According to 
the manufacturers, correlation of the Hemocue was 0.99 when compared to a reference 
method with an accuracy of ± 1.5% (Hemocue, 2000). Haemoglobin was assessed at the 
same time as taking blood &/or breast milk samples.
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Table 3.2: Summary o f the quality control data for the biochemical analysis
Substrate No. Assays Mean* SD* Intra assay 
CV(%)
Interassay
CV(%)
Community 
Na/K urine 
QC
73 2.96 0.03 0.53
(10)
1.12
Community 
Na/K milk 
QC
14 1.27 0.02 n/a** 1.12
Community 
milk IL-8
6 197.18 6.63 2.80
(7)
4.06
Community 
milk CRP
16 0.23 0.03 5.38
(4)
12.00
Community 
spiked milk 
CRP
16 2.31 0.26 6.56
(4)
11.45
Community 
plasma CRP
12 0.34 0.03 5.27
(7)
9.83
Community 
plasma AGP 
ELISA
10 0.31 0.05 9.60
(7)
15.06
Community 
plasma AGP 
COBAS
10 0.57 0.07 6.12
(10)
12.72
Hospital
Na/K
13 3.11 0.05 0.53
(5)
1.63
Hospital 
milk IL-8
10 90.20 7.94 3.95
(7)
8.80
Hospital 
milk CRP
9 0.24 0.02 5.38
(4)
8.33
Tanzania 
milk CRP
12 0.24 0.03 5.38
(4)
9.50
South Africa 
milk CRP
10 0.26 0.02 5.38
(4)
9.50
South Africa 
spiked milk 
CRP
10 2.79 0.27 6.56
(4)
9.73
*n= same as first column 
** no intra assay QC run
Quality control data presented above is for samples analysed by the author for this project 
only. Although results of plasma CRP and breast milk IL-8 and Na/K from Tanzania and 
South Africa are presented, their QC data have been previously published (Filteau et al., 
1999b, Willumsen et al., 2000).
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Photo 3.5: University teaching hospital study midwives
\ i
Photo 3.6: Mother donating a breast milk sample: Hand expression into a universal 
container
3.4 Analysis of data
Questionnaire data was entered in to Epi-Info version 6.04, and after double entry and 
cleaning was converted into the Statistical Packages for Social Sciences (SPSS) version 
10.0. Laboratory data was directly entered into SPSS and was double entered and cleaned. 
All analyses were completed using SPSS version 10.0.
3.4.1 Stage 1
The initial analysis consisted of a descriptive data analysis looking at means, ranges, 
confidence intervals, frequencies and the distribution of the various dependent variables. 
This was followed by data normalisation (where possible), and correlations and associations 
between the variables. Due to the large volume of analysis completed on these datasets, not 
all the data analyses are present in the results chapter. All relevant preliminary analysis 
integral to the project, but not necessary for the understanding of the results chapter are 
found in Appendix 3.1. Variables that were non-normally distributed were natural logged 
(socio economic variables, IL-8 , CRP in plasma and breast milk, AGP, haemoglobin and 
CD8 count) or logged base 10 (breast milk viral load) as is consistent with previously 
published data. After normalisation, skewness and kurtosis were checked and all 
parameters were within, or approaching normal range [(-1, +1) for skewness; (-3, +3) for 
kurtosis]. Previously published data for Na/K used a natural log transformation (Filteau et 
al., 1999a; Filteau et al., 1999b; Willumsen et al., 2000; Willumsen et al., 2003). However,
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when the data was reexamined it was found to be non-normally distributed even after this 
transformation. Na/K data was, therefore, analysed non-parametrically and cut off points 
were defined using Receiver Operating Characteristics (ROC) curve analysis to define a 
plot of true positive rate against false positive rate for different cut offs of a diagnostic test 
(see Appendix 3.2). ROC analysis was developed during World War II for the analysis of 
radar images. Radar operators had to decide whether a blip on the screen represented an 
enemy target, a friendly ship, or just noise. The ability of radar receiver operators to make 
these important distinctions was called the Receiver Operating Characteristics. An ROC 
curve demonstrates the tradeoff between sensitivity and specificity (any increase in 
sensitivity will be accompanied by a decrease in specificity) with the area under the curve 
being a measure of accuracy. Cut offs of <0.9 and > 0.9 were used for Na/K in this thesis 
with a sensitivity of 87.5% and a specificity of 100%.
In both the Zambian pilot study and the Zambian community based study a checklist of 
questions was used by the midwives to determine infant breastfeeding technique and 
maternal breast pain (see Appendix 2). In both cases the total score was calculated and the 
25th percentile was used as a cut off point to differentiate between ‘good feeding technique’ 
and ‘poor feeding technique’; ‘high level of breast pain’ and Tow level of breast pain’. 
Exclusive breastfeeding was defined as the infant receiving breast milk only from the 
mother (no other liquids or solids). Mixed feeding was defined as the infant receiving other 
liquids and solids in addition to breast milk. Percentile ranks or percentile scores are 
defined with respect to a norm or reference group. As such, percentile scores provide a 
convenient way to convey each woman’s feeding technique relative to the other women
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thinvolved. The 25 percentile was chosen as it was thought to be less restrictive than lower 
percentile points (e.g. 10%). Questionnaires were designed under the guidance of Dr 
Felicity Savage, a WHO breastfeeding consultant.
On examination of the biochemical breast milk data, differences between breasts were 
important, as indicated by significant differences between individual pairs of breast milk 
samples, particularly in the South African study (Willumsen et al., 2000). Despite this 
mean values for left and right breasts overlapped considerably. Consequently, although no 
consideration was needed as to whether the sample originated from the left or the right 
breast, separate data for both right and left breasts are included in all analyses (except the 
Tanzanian study were breast milk samples were combined at sampling). Analysis of data 
was therefore on repeated samples from each woman. When several measurements are 
taken on the same experimental unit (in this case the same woman over time), the 
measurements tend to be correlated with each other and may lead to random error.
However, that this study was not designed specifically for repeated measures analysis and 
this may have implications for the results of the analysis. Although some differences were 
seen between specific time points after repeated measures analysis, no significant 
differences were seen on combined time point analysis.
In the Zambian community based study, breast milk samples were taken at 11 time points 
over 16 weeks postpartum, although breast milk IL-8 was only analysed at 3 time points 
(weeks 2, 5 and 9). In order to increase the available sample size and allow sensible 
analysis, time points were merged into 5 time points (time point 1: days 3&7; time point 2:
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days 10&14; time point3: weeks 3&4; time point 4: weeks 5 &6 ; time point 5: weeks 
9,12&16). Unfortunately sample size was too small to allowing for meaningful analysis. It 
was decided to also analyse the samples over 2 time points (<day 14, >day 14) and this is 
what has been presented in the results chapter. In the case of breast milk Na/K and CRP, 
samples taken before day 14 postpartum were significantly different from samples taken 
after day 14 postpartum. No differences were seen between time points after day 14 
postpartum in Na/K, CRP and IL-8  (see Appendix 3.1 for individual and 5 merged time 
point descriptives).
3.4.2 Stage 2
This intermediate analysis stage used the statistical procedure of principal component factor 
analysis with varimax rotation to determine the weights for an index of the socio economic 
variables. The first principal component of a set of variables is the linear index of all the 
variables that capture the largest amount of information that is common for all the 
variables. This involved grouping the various independent variables based on logical 
assumptions. Data was recoded as necessary, such that all variables were numbered and 
ordered in the correct direction. For example, for the question of maternal employment, yes 
was coded as positive (equal to one) and no was coded as negative (equal to zero). A 
detailed table of how each variable was recorded can be seen in Appendix 4 for the data 
from both the Zambian community study and the South African study. No intermediate 
analyses were completed on the Zambian pilot and the Tanzanian study.
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For the Zambian community study the data factors for the status of women (maternal 
control) such as maternal income, marital status, decision making, gravidity and education 
level formed one group. The second set of socio economic factors combined wealth aspects 
including electricity, goods, number of meals eaten, husband’s employment, maternal
employment, housing density and gravidity giving 2  variables connected to wealth (see 
table 3.3).
Table 3.3 Components generated by principal component factor analysis - Zambian 
community study
Components No. of
factors
generated
No. of 
independent 
variables included
Variables included
Maternal 
control aspects
1 6 Gravidity
Main income source 
Marital status 
Household decision maker 
Maternal education 
Maternal religion
Wealth aspects 2 8 Fridge 
Electricity 
Maternal education 
Husband’s employment 
Maternal employment 
Housing density 
Religion
See Appendix 4 for detailed analysis information.
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As with the Zambian community study, the data for the South African* study was grouped 
around socio economic aspects, where factors for maternal control such as maternal 
employment, occupation and housing became one group. Combined aspects of wealth 
including water supply, electricity and housing became the second group (see table 3.4).
Table 3.4 Components generated by principal component factor analysis - South 
African study
Components No. of factors 
generated
No. of independent 
variables included
Variables included
Maternal 
control aspects
2 4
No. people living in the 
home
No. of rooms in the home 
Maternal employment 
Type of maternal 
employment
Wealth aspects 1 6
No. people living in the 
home
No. of rooms in the home
Electricity
Fridge
Telephone
Water supply
See Appendix 4 for detailed analysis information.
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3.4.3 Stage 3
Further statistical methods used included independent t-tests to compare breast milk 
biological data against HIV status, maternal morbidity and infant feeding practices in the 
Zambian community based study, using both 5 and 2 time points as detailed previously 
(only data from the 2 time points are presented in the final analysis).
Univariate analysis of variance was used to investigate:
a) The association of HIV-infection with social, biological and feeding variables in 
the Zambian community study
b) The association of maternal CD4 counts, taken at the time of delivery, with 
social, biological and feeding variables in the South African study.
See Appendix 5 for detailed information.
The final step in the analysis was to use forward conditional regression analysis to 
determine which variables predicted maternal HIV status (Zambian community study) and 
low maternal CD4 counts in HIV infected women (South African study). Univariate and 
multivariate regression analysis was not completed on the Zambian pilot and the Tanzanian 
study. Forward conditional stepwise regression analysis was used as it was the most 
appropriate technique when analysing case control data. A total of 31 factors were 
generated for the main analysis in the Zambian community study and 29 in the South 
African study. Given that all the variables could not be entered in a single regression 
analysis, several models were used (see Appendix 5).
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The first model for the Zambian community study used non biological variables collected 
up to and at the time of delivery, including socio-economic factors, maternal age, infant sex 
and problems at delivery. The second model used all the biological variables collected in 
the antenatal period, including plasma AGP and CRP and haemoglobin. The third model 
used all the variables taken in the early postnatal period (before day 14 postpartum) 
including breast milk CRP and Na/K, maternal haemoglobin and breastfeeding indicators. 
The fourth model used all the variables taken in the later postpartum period (>day 14 
postpartum) including breast milk CRP, IL-8 and Na/K, breastfeeding indicators and 
maternal plasma CRP and AGP taken at 6 weeks postpartum. A final model was tested 
entering all the data from the previous four that were significantly associated (p <0.05, odds 
ratio >1) with maternal HIV status (see Appendix 5 for details).
The first model for the South African study used all the variables collected up to and at the 
time of delivery, including socio-economic factors, maternal age, infant sex and mode of 
delivery. The second model used all the variables collected in the postpartum period, 
including biological variables, infant feeding and infant weight gain. A final model was 
tested entering all the data from the previous two that were significantly associated (p 
<0.05, odds ratio >1) with maternal CD4 count taken at the time of delivery (see Appendix 
5 for details).
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3.5 Ethical Considerations
Ethical considerations for the Tanzanian study and the South African study have been 
reported in previously (Filteau et al., 1999b;Willumsen et al., 2000). The Ethics Committee 
of Great Ormond Street Hospital NHS Trust gave ethical permission for the Zambian pilot 
and community study. Local ethical approval was also obtained from the University of 
Zambia Ethics Committee. Informed verbal (and if possible written) consent was a 
condition for inclusion in both of the Zambian studies. Translations of the questionnaire 
from English to one of the locally spoken dialects (including Chinanja, Bemba and Tonga) 
were done in situ with the staff at the collaborating centre.
The study budget provided necessary medication for the participating women of the 
Zambian pilot study (if this medication was unavailable at the hospital) from admission 
until recovery. The Zambian medical health service provided a basic cover of medication 
and health care when admitted into hospital, but if the medication was not available in the 
hospital it was normally necessary for the patient to purchase it from a pharmacy. All 
women participating in the community study received free medical attention for the period 
of the study and a consultant obstetrician was on call 24 hours a day for the period of the 
study.
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3.6 Project limitations
3.6.1 Zambian hospital based pilot study
Over four months of the pilot study there was a doctors strike taking place in the hospital 
where the study was situated and this may have affected the quality of patient care. 
However, as the study employed two part time midwives and any further medical care 
needed was paid for by the project, it was hoped that disruption to the services supplied to 
the mothers was limited.
As this was a pilot study and, therefore, consisted of relative few subjects (n=22), time 
since delivery was not included in the analysis and this may have had an impact on the 
breastfeeding practices of the women. In addition no matched time point plasma samples 
were collected, so breast milk inflammatory factors could not be compared to indicators of 
systemic inflammation in the plasma. The women admitted into hospital were very sick 
and it was felt inappropriate to cause them any further discomfort or pain by taking venous 
blood samples. The major limitation of the study was that HIV status was unknown 
although it was expected to be at least similar, if not higher, than that of the community of 
Lusaka as a whole (approximately 30%). Due to the small study size, the limited resources 
available for treatment and the stigma HIV status may bring it was decided it was 
inappropriate to test these women.
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3.6.2 Tanzanian Study
As breast milk samples from both left and right breasts were combined immediately at the 
point of sampling no between breast differences could be analysed.
3.6.3 South Africa Study
The sample size of available breast milk RNA viral load data was too small to allow 
meaningful analysis of the association with inflammatory markers. Gut permeability data 
was not available for analysis in this thesis so we were unable to determine a relationship 
between breast milk CRP and infant intestinal permeability.
3.6.4 Zambian community study
During the first three months of the Zambian community based study there was a nurses 
strike taking place throughout all of Lusaka and this may have affected the quality of the 
patient care. However, as we employed part time midwives throughout the period of the 
study, disruption to the services supplied to the mothers was limited.
Due to a combination of the large number of breast milk samples to be taken from each 
woman and the fact that the women included in this nested study were the first 112 of the 
women from the larger cohort, not all women supplied every sample at the required time 
point. Before day 14 postpartum, 56% of women gave samples from all time points and 
64% of women gave samples from all time points on and after day 14. This reduced sample
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size may have had implications for the results of the analysis. There was no difference in 
the number of samples given between HIV infected and uninfected women.
A limited number of samples for haemoglobin were taken from the women, with sampling 
taking place at only 3 time points (36 weeks antenatally, and days 3 and 7 postpartum). The 
relationship between systemic inflammation and anaemia could therefore not be fully 
examined. Due to the small sample size, haemoglobin could not be included in the final 
logistical regression analysis so its influence on HIV infection could not be fully studied. 
Because of budgetary and time constraints, breast milk IL-8 was analysed only at 3 time 
points (weeks 2, 5 and 9) and due to the small sample size IL-8 could not be included in the 
final regression analysis.
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Chapter 4 
Results
As described previously (chapter 3) the results are an analysis o f data from 4 studies to 
answer 3 main project questions. The order o f presentation is given below:
I To determine indicators associated with maternal HIV status.
Objective 1: To determine the social indicators associated with maternal HIV 
status.
Objective 2: To determine the biological indicators associated with maternal 
HIV status.
Objective 3: To determine the infant feeding indicators associated with 
maternal HIV status.
The data has been generated from the Zambian community based study and is 
presented in section 4.1
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II To determine the indicators associated with severity o f maternal HIV 
infection.
Objective 1: To determine the social indicators associated with severity o f 
maternal HIV infection.
Objective 2: To determine the biological indicators associated with 
severity o f maternal HIV infection.
Objective 3: To determine the infant feeding indicators associated with 
severity o f maternal HIV infection.
The data has been generated from the South African study and is presented in 
section 4.2
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I l l  To determine if  breast milk CRP could be a suitable surrogate measure for
systemic inflammation and a potential indicator o f  increased risk o f  MTCT, as 
measured by non-invasive breast milk sampling.
Objective 1: To determine the relationship between breast milk CRP and 
plasma and breast milk inflammatory factors.
Objective 2: To determine the relationship between breast milk CRP and 
infant feeding indicators.
Objective 3: To determine the relationship between breast milk CRP and risk 
factors for MTCT.
The data has been generated from the Zambian pilot study, the 
Tanzanian study, the Zambian community based study and the South African 
study and is presented in section 4.3
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4.1 Indicators associated with maternal HIV status
All the results presented in this section are generated from the Zambian community based 
study.
4.1.1 Social indicators
In univariate analysis of variance, maternal age, infant sex, maternal control, 2 indicators of 
maternal wealth and maternal weight were analysed to determine their associations with 
maternal HTV status. A summary of the results can be seen in table 4.1. Maternal age was 
significantly associated with HIV status (pO.OOl) with the HIV infected mothers being 
almost 2 years older than HIV uninfected mothers. This was the predicted outcome as the 
risk of infection in women of reproductive age would increase year on year. This was 
accounted for in the multivariate regression model. Both variables of maternal wealth were 
highly significant (PO.OOl) with HIV infected women scoring higher on the indices than 
HIV uninfected. Infant sex was also found to be significantly associated with maternal HIV 
status, with HIV infected women more likely to give birth to boys than HIV uninfected 
women (pO.OOl). The antenatal maternal weight was found to be significantly associated 
with HIV status (pO.OOl) with HTV infected mothers being almost 3kg lighter at 36 weeks 
antenatally that HIV uninfected mothers. Maternal control was not significantly associated 
with maternal HIV infection.
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Table 4.1: Analysis to determine associations between maternal HIV status and
social factors
Variable n Mean(95% Cl) p value
Maternal age (years) HIV-
HIV+
944
960
22.66 (22.35, 22.97) 
24.33 (24.07, 24.59)
<0.001
Infant sex HIV-
HIV+
896
896
34% Males 
55% Males
<0.001
Maternal control HIV-
HIV+
944
960
-0.02 (-0.09, 0.05) 
0.02 (-0.04, 0.08)
0.384
Maternal wealth 1 HIV-
HIV+
896
896
-0.42 (-0.82, 0.05) 
0.53 (-0.05, 0.08)
<0.001
Maternal wealth 2 HIV-
HIV+
896
896
2.96 (2.10,3.82) 
6.95 (5.95, 7.96)
<0.001
Maternal weight antenatal (kg) HIV-
HIV+
944
960
65.50 (64.85, 66.15) 
62.77 (62.34, 63.21)
<0.001
4.1.2 Biological indicators
Of the 112 women whose data was included in this study, 56% gave samples from all time 
points before day 14 and 64% of women gave samples from all time points on and after day 
14. There was no statistical difference in the number of samples given between HIV 
infected and uninfected women.
116
Samples were analysed in a number of ways including at each of the 11 time points and 
combined to form 5 time points (see Appendices 3 and 5). As described in the methods for 
the final analysis the data was condensed into 2 time points: <dl4 and > dl4 and the 
resultant descriptives of the milk biological variables can be seen in table 4.2.
Table 4.2: Breast milk biological variables
Variable < d l4  mean (min, max) 
n
>dl4 mean (min, max) 
n
Milk C-Reactive Protein 
(mg/L) a’
0.47 (0.001,3.10) 
342
0.04 (0.001,2.05) 
1082
Milk sodium/potassiumb’ 0.60 (0.41,0.96) 
407
0.44 (0.34, 0.63) 
1236
Milk IL-8 (pg/mL)a n/a 17.25 (0.001,6768.34) 
554
aGeometric means presented 
b median and 25th and 75th percentiles presented 
* pO.OOl
There was a significant difference between CRP<dl4 and CRP>dl4 (pO.OOl). As breast 
milk Na/K has been found to be non-normally distributed it was analysed using Wilcoxon 
signed rank test (a non-parametric analysis). There was a significant difference between 
Na/K<dl4 and Na/K >dl4 (pO.OOl). Breast milk CRP and Na/K were high for both 
infected and uninfected women during the first few days postpartum and then decreased 
(see figures 4.1 and 4.2). After day 10, Na/K levels dropped significantly (pO.OOl) 
independent of HIV status and then tended to level out up to 16 weeks postpartum (see
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table 4.2). The breast milk IL-8 concentrations show no significant differences at 2, 5 and 9 
weeks postpartum (see figure 4.3). In all three scatter graphs (figures 4.1-4.3) graphs 
significant differences can be seen in concentration of CRP, Na/K or IL-8 between HTV 
infected and HIV uninfected women (see table 4.3).
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On analysis by independent t-test (table 4.3), there were significant differences in breast 
milk CRP concentrations between HIV infected and uninfected women at both the 
combined time points of <dl4 and >dl4 postpartum (pO.OOl), with mean concentrations 
being significantly higher in the HIV infected women. As Na/K is non-normally distributed 
it has been categorised by ROC curve analysis (see Appendix 3.2). At >dl4 postpartum 
there was a significant difference between Na/K, with HIV infected women having a 
significantly higher percentage of raised Na/K ratio >0.9 (p=0.017), this was not seen 
before day 14 postpartum. In HIV infected women the mean concentration of breast milk 
IL-8 >dl4 was significantly lower than in HIV uninfected women (p=0.017). Consequently 
for further independent t-test analyses, HIV infected and uninfected women were 
considered separately. For details of analysis of data combined into 5 time points (days 
3&7, days 10&14, weeks 3&4, weeks 5&6 and weeks 9,12&16) please Appendix 5.
Table 4.3: HTV status and breast milk biological variables
Variable n Mean (SD) 95% C l p-value
CRP (mg/L) <dl4a HIV-ve 175 0.387 (0.09) (-0.20, -0.06) <0.001
HIV+ve 167 0.569 (0.11)
CRP (mg/L) > d l4 a HIV-ve 549 0.028 (6.33) (-0.71, -0.27) <0.001
HIV+ve 533 0.045 (6.26)
Na/K < d l4 b HIV-ve 211 73% Na/K <0.9; 27% Na/K > 0.9 (-0.10, 0.07) 0.722
HIV+ve 196 81% Na/K <0.9; 29% Na/K > 0.9
Na/K > d l4 b HIV-ve 605 89% Na/K <0.9; 11% Na/K > 0.9 (-0.08, -0.01) 0.017
HIV+ve 631 84% Na/K <0.9; 16% Na/K > 0.9
IL-8 (pg/mL) > d l4 a HIV-ve 282 26.91 (54.23) (0.16, 1.62) 0.017
HIV+ve 272 11.05(112.85)
a Means(SD) presented geometrically
b Breast milk Na/K presented categorically (using ROC Curve analysis)
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Morbidity was analysed in a number of different ways. A time point specific morbidity was 
initially devised, although it was thought that due to the long-term complications that occur 
in the postpartum period this was not a sensitive enough measure. Project midwives and 
obstetricians developed a morbidity scale running from labour until 16 weeks postpartum. 
Women were then allocated into one of 8 groups: well, advice only, treatment with 
paracetamol or iron supplementation, treatment with antibiotics or antimalarials, 
hospitalised and recovered, hospitalised, and in hospital after 16 weeks postpartum, or dead. 
For this study the women were divided into 2 groups, well or sick. This was analysed in 3 
ways:
Morbidity classification A at any time up to 16 weeks postpartum 
Well: ‘well’, ‘advice only’ and ‘treatment with paracetamol or iron’
Sick: ‘treatment with antibiotics or antimalarials’, ‘hospitalised and recovered’, 
‘hospitalised and in hospital after 16 weeks postpartum’
Morbidity classification B at any time up to 16 weeks postpartum 
Well: ‘well’ and ‘advice only’
Sick: ‘treatment with paracetamol or iron’, ‘treatment antibiotics/antimalarials’, 
‘hospitalised and recovered’, ‘hospitalised and in hospital after 16 weeks postpartum’
Time point specific morbidity classification B (result presented in Appendix 5)
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In the final analysis, morbidity classification B was used as it seemed a more accurate 
representation of health seeking behaviour in a developing country. Details of the other 
analyses can be found in Appendix 5.
Table 4.4: Morbidity and breast milk biological variables
HIV uninfected
Variable n Mean (SD) 95% C l p-value
CRP (mg/L) < d l4 a Well 75 0.42 (0.11) (-0.06, 0.14) 0.419
Sick 91 0.37 (0.09)
CRP (mg/L) >dl4* Well 241 0.02 (6.82) (-0.85, -0.24) 0.001
Sick 290 0.04 (5.42)
Na/K < d l4 b Well 87 71% Na/K <dl4; 29% Na/K > 0.9 (-0.12, 0.14) 0.883
Sick 108 72% Na/k <dl4; 28% Na/K > 0.9
Na/K > d l4 b Well 271 91% Na/K <dl4; 9% Na/K > 0.9 (-0.09, 0.02) 0.178
Sick 314 87% Na/K <dl4; 13% Na/K > 0.9
IL-8 (pg/mL) > d l4 8 Well 120 9.69 (78.44) (-2.68, -0.80) <0.001
Sick 151 55.37 (32.97)
HIV infected
Variable n Mean (SD) 95% C l p-value
CRP (mg/L) < d l4 8 Well 28 0.370 (0.07) (-0.31, -0.04) 0.011
Sick 139 0.614 (0.12)
CRP (mg/L) > d l4 8 Well 126 0.045 (5.81) (-0.39, 0.35) 0.923
Sick 403 0.046 (6.45)
Na/K < d l4 b Well 43 82% Na/K <dl4; 28% Na/K > 0.9 (-0.17, 0.14) 0.849
Sick 153 81% Na/K <dl4; 29% Na/K > 0.9
Na/K > d l4 b Well 147 94% Na/K <dl4; 6% Na/K > 0.9 (-0.18, -0.05) 0.001
Sick 478 82% Na/K <dl4; 18% Na/K > 0.9
IL-8 (pg/mL) > d !4 a Well 62 34.230 (88.37) (0.13,2.80) 0.032
Sick 210 7.917(86.05)
a Means(SD) presented geometrically
b Breast milk Na/K presented categorically (using ROC Curve analysis)
The biological variables analysed according to morbidity are shown in table 4.4. The mean 
concentrations of CRP <dl4 of HIV infected women who have suffered morbidity at any 
time during the 16 week postpartum period, were significantly increased when compared to
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healthy HIV infected women, with mean CRP concentrations higher in the sick women 
(p=0.011). However, there was no difference in the mean CRP concentrations > dl4 
postpartum. For HIV uninfected women the converse was true with sick HIV uninfected 
women having higher mean CRP concentrations >dl4 (p=0.001) but no significant 
difference being seen before dl4. In HIV uninfected women no significant differences in 
the percentage of sick women with raised Na/K ratio (>0.9) were seen at each time point, 
however, the HIV infected sick women had a significantly increased proportion of raised 
Na/K compared to healthy women > day 14 (p<0.001). HIV uninfected sick women had 
significantly raised mean concentrations of IL-8 compared to their healthy counterparts 
(p<0.001), whereas HIV infected sick women had significantly lower mean concentrations 
of IL-8 compared to the well women (p=0.032).
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Table 4.5: Analysis to determine associations between maternal HIV status and
biological variables
Variable n Mean(95% Cl) p value
BP systolic antenatal HIV-
HIV+
944
960
110.17(109.68, 110.66) 
109.57(108.98, 110.15)
0.121
BP diastolic antenatal HIV-
HIV+
944
960
68.14(67.54, 68.73) 
68.07 (67.51,68.62)
0.867
Haemoglobin antenatala HIV-
HIV+
944
960
10.84(10.76, 10.94) 
10.56(10.46, 10.66)
<0.001
Plasma CRP 36 weeks antenatala HIV-
HIV+
832
784
3.28 (3.08, 3.49) 
2.79 (2.52, 3.08)
0.006
Plasma AGPb 36 weeks antenatal8 HIV-
HIV+
752
752
0.61 (0.59, 0.62) 
0.57 (0.35, 0.59)
0.002
Problems at delivery HIV-
HIV+
896
896
32% problems 
29% problems
0.100
Overall morbidity (up to week 16pp) HIV-
HIV+
816
896
55% sick 
77% sick
<0.001
Maternal temperature <dl4  HIV-
HIV+
294
288
36.29 (36.22, 36.37) 
36.43 (36.37, 36.50)
0.004
Haemoglobin <d 148 HIV -
HIV+
194
180
11.34(11.08, 11.61) 
10.39(10.15, 10.65)
<0.001
Na/K < d l4 b HIV-
HIV+
211
196
27% >0.9 
29% >0.9
0.722
Milk CRP < d l4 a HIV-
HIV+
175
167
0.39 (0.33, 0.45) 
0.57 (0.49, 0.65)
<0.001
Maternal temperature >d 14 HI V-
HIV+
756
778
36.29 (36.27, 36.32) 
36.32 (36.29, 36.36)
0.180
Plasma CRP 6 weeks postpartum8 HIV-
HIV+
640
688
1.21 (1.09, 1.33) 
1.64(1.45, 1.86)
<0.001
Plasma AGP 6 weeks postpartum8 HIV-
HIV+
592
672
0.79(0.76, 0.81) 
0.92 (0.88, 0.94)
<0.001
Na/K > d l4 b HIV-
HIV+
605
631
11% >0.9 
16% >0.9
0.017
IL-8 > d l4 a HIV-
HIV+
282
272
26.91 (16.85,42.97) 
11.05 (6.29, 19.43)
0.017
Milk CRP > d l4 a HIV-
HIV+
549
533
0.03 (0.02, 0.03) 
0.05 (0.04, 0.05)
<0.001
8 Means(SD) presented geometrically
b Breast milk Na/K presented categorically (using ROC Curve analysis) 
pp: postpartum
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In the univariate analysis (see table 4.5) haemoglobin, both antenatal (at 36 weeks) and in 
the early postnatal period was significantly associated with HIV status (p<0.001) with HIV 
infected women having significantly lower haemoglobin levels than the HTV uninfected 
women at both time points. Antenatally both groups of women were mildly anaemic with a 
mean haemoglobin level of 10.84g/dL for HIV uninfected women and 10.56g/dL for HIV 
infected women. WHO international guidelines recommend haemoglobin at a level of no 
less than 11 .Og/dL in pregnant and lactating women (WHO 2004). Following delivery, the 
haemoglobin levels of HIV uninfected women increased to 11.34 (sample taken at days 3 
and 7 postpartum), whereas in the HIV infected mothers the mean haemoglobin level fell to 
10.39 g/L. No significant differences were seen in maternal antenatal blood pressure taken 
at 36 weeks.
Overall morbidity (taking data antenatally to 16 weeks postpartum) was significantly higher 
in HIV infected than uninfected women (p<0.001) with 77% HTV infected mothers having a 
morbid incident over the period of the study compared to 55% in the HIV uninfected group. 
This was also reflected in maternal temperature with HIV infected women having 
significantly higher temperatures before day 14 than HIV uninfected women (p=0.004). 
However, in this univariate analysis no significant differences were seen in problems at 
delivery (p=0.10). Significant differences were seen in the concentrations of acute phase 
proteins with both plasma CRP and AGP being significantly lower in the HIV infected 
mothers in the antenatal period (p<0.01). However, when these acute phase proteins were 
measured again at 6 weeks postpartum the converse was seen with both significantly 
increased concentrations of the proteins in the HIV infected than uninfected women.
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Breast milk CRP concentrations both before and after day 14 were significantly higher in 
HIV infected women (p<0.001), indicating postnatal CRP concentrations both in breast and 
plasma were significantly associated with the HIV status of the mother. There was a 
significant difference between the IL-8 concentrations of infected and uninfected women, 
with HIV infected women having significantly lower mean IL-8 concentrations than HIV 
uninfected women (p=0.017). Before day 14 postpartum there were no significant 
difference between the percentage of raised Na/K levels in HIV infected and uninfected 
women. However, after day 14 there was a significantly greater percentage of raised Na/K 
in HIV infected women (16%) when compared to HIV uninfected women (11%) (p=0.017).
4.1.3 Infant feeding indicators
Three variables relating to breastfeeding were analysed in this research question: infant 
feeding technique, type of infant feed given and maternal breast inflammation. Infant 
feeding technique was assessed by the study midwives using a checklist (see chapter 3 for 
details and Appendix 2 for questionnaires), from this a score was calculated and further 
categorised into 2 variables: good feeding technique and poor feeding technique. The type 
of infant feed was reported by the mothers to the study midwives and was categorised into 2 
variables: exclusive breastfeeding, mixed feeding. The final variable was maternal breast 
inflammation, which was reported by the mother and scored by the study midwives using a 
checklist. From this score 2 categories were devised: high level of breast pain and low 
level of breast pain.
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Table 4.6: Differences in feeding technique and breast milk biological variables
HIV uninfected
Variable n Mean (SD) 95% C l p-value
CRP (mg/L) < d l4 a good 132 0.36 (0.08) (-0.23,-0.01) 0.039
poor 35 0.52 (0.11)
CRP (mg/L) > d l4 a good 414 0.03 (5.93) (-0.86, -0.10) 0.013
poor 115 0.04 (7.34)
Na/K < d l4 b good 151 76% Na/K <0.9; 24% Na/K >0.9 (-0.30, -0.01) 0.042
poor 46 61% Na/K <0.9; 39% Na/K >0.9
Na/K > d l4 b good 460 89% Na/K <0.9; 11% Na/K >0.9 (-0.08, 0.04) 0.566
poor 126 87% Na/K <0.9; 13% Na/K >0.9
IL-8 (pg/mL) > d l4 a good 206 17.09 (60.27) (-2.64, -0.37) 0.009
poor 64 76.55 (38.88)
HIV infected
Variable n Mean (SD) 95% C l p-value
CRP (mg/L) < d l4 a good 121 0.58(0.10) (-0.130, 0.18) 0.741
poor 23 0.54 (0.23)
CRP (mg/L) > d l4 a good 372 0.04 (6.32) (-0.98, -0.20) 0.003
poor 114 0.07 (7.57)
Na/K < d l4 b good 141 74% Na/K <0.9; 26% Na/K >0.9 (-0.19, 0.16) 0.898
poor 30 73% Na/K <0.9; 27% Na/K >0.9
Na/K > d l4 b good 444 85% Na/K <0.9; 15% Na/K >0.9 (-0.07, 0.07) 0.935
poor 132 85% Na/K <0.9; 15% Na/K >0.9
IL-8 (pg/mL) > d l4 8 good 194 6.71 (79.32) (-3.30, -0.53) 0.007
poor 59 45.43 (29.52)
a Means(SD) presented geometrically
b Breast milk Na/K presented categorically (using ROC curve analysis)
The biological variables analysed according to feeding technique are shown in table 4.6. 
The 25th percentile was used as the cut off points for division between ‘good feeding 
technique’ and ‘poor feeding technique’. Differences in mean concentrations tended to be 
more pronounced in the HIV uninfected group and this was thought to be due to differences 
in mean maternal age (see table 4.1), with HIV infected women being older with more 
children and therefore more experienced at breastfeeding. In all cases where ‘poor
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technique’ was found in the HTV infected group the mean maternal age was lower than the 
‘good technique’ group. In the HTV uninfected group, the mean concentration of CRP was 
significantly higher at both time points in those women with poor feeding technique 
(p<0.05). The same was the case for IL-8 (>dl4) (p<0.01). HIV uninfected women (<dl4) 
with poor feeding technique had a significantly higher percentage of raised Na/K (>0.9) 
than those with good feeding technique (p<0.05). HIV infected women with poor feeding 
technique had significantly greater mean CRP and IL-8 concentration >dl4 (p<0.01) than 
those with good feeding practice but the Na/K ratio showed no significant difference.
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Table 4.7: Differences in type o f infant feed breast milk biological variables
HIV uninfected
Variable n Mean (SD) 95% C l p-value
CRP (mg/L) < d l4 a ebf 163 0.39 (0.09) (-0.18, 0.18) 0.968
mixed 12 0.39 (0.12)
CRP (mg/L) > d l4 a ebf 498 0.03 (6.15) (-1.18,0.23) 0.243
mixed 25 0.05 (8.15)
Na/K < d l4 b ebf 200 73% Na/K <0.9; 27% Na/K > 0.9 (-0.37, 0.18) 0.501
mixed 11 64% Na/K <0.9; 36% Na/K > 0.9
Na/K > d l4 b ebf 551 89% Na/K <0.9; 11% Na/K > 0.9 (-0.08, 0.16) 0.535
mixed 27 93% Na/K <0.9; 7% Na/K > 0.9
IL-8 (pg/mL) > d l4 8 ebf 256 23.46 (57.96) (-3.73,0.93) 0.237
mixed 12 95.18(8.63)
HIV infected
Variable n Mean (SD) 95% C l p-value
CRP (mg/L) <dl4 ebf 154 0.58 (0.12) (-0.10, 0.28) 0.371
mixed 13 0.45 (0.08)
CRP (mg/L) >dl4 ebf 473 0.04 (6.30) (-0.81,0.46) 0.581
mixed 35 0.05 (6.76)
Na/K <dl4 ebf 178 70% Na/K <0.9; 30% Na/K > 0.9 (-0.09, 0.36) 0.226
mixed 18 73% Na/K <0.9; 17% Na/K > 0.9
Na/K >dl4 ebf 553 16% Na/K > 0 .9 (-0.03,0.19) 0.134
mixed 49 8% Na/K > 0 .9
IL-8 (pg/mL) >dl4 ebf 245 9.08 (122.47) (-5.40, -0.78) 0.009
mixed 17 199.82(4.18)
8 Means(SD) presented geometrically
b Breast milk Na/K presented categorically (using ROC Curve analysis) 
ebf: exclusive breastfeeding
On analysis by independent t-test according to type of infant feed (see table 4.7), no 
significant differences were seen in the HTV uninfected group. In the HIV infected group, 
the only significant difference was that women who mixed fed had significantly higher 
mean IL-8 concentration than those who exclusively breastfed (p<0.01). In both groups, the 
number of women who mixed fed was, however, low as one aim of this study was to 
promote exclusive breastfeeding.
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Table 4.8: Differences in maternal breast inflammation and breast milk biological
variables
HTV uninfected
Variable n Mean (SD) 95% C l p-value
CRP (mg/L) < d l4 a low pain 123 0.36(0.11) (-0.18, 0.02) 0.092
high pain 52 0.46 (0.09)
CRP (mg/L) > d l4 a low pain 449 0.03 (6.34) (-1.06, -0.16) 0.008
high pain 74 0.05 (5.19)
Na/K < d l4 b low pain 154 27% Na/K > 0.9 (-0.15, 0.13) 0.909
high pain 57 28% Na/K > 0.9
Na/K > d l4 b low pain 495 10% Na/K > 0 .9 (-0.14, 0.01) 0.069
high pain 83 17% Na/K > 0.9
IL-8 (pg/mL) > d l4 a low pain 232 25.55 (56.75) (-1.25, 1.58) 0.815
high pain 36 21.59(45.10)
HIV infected
Variable n Mean (SD) 95% C l p-value
CRP (mg/L) <dl4 low pain 120 0.58(0.11) (-0.10, 0.13) 0.785
high pain 47 0.55 (0.13)
CRP (mg/L) >dl4 low pain 456 0.04 (6.59) (-1.43,-0.38) 0.001
high pain 52 0.10(3.17)
Na/K <dl4 low pain 139 25% Na/K > 0 .9 (-0.27,0.01) 0.061
high pain 57 39% Na/K > 0.9
Na/K >dl4 low pain 541 12% Na/K > 0.9 (-0.47, -0.28) <0.001
high pain 61 49% Na/K > 0.9
IL-8 (pg/mL) >dl4 low pain 236 10.78(124.11) (-2.22, 1.63) 0.766
high pain 26 14.44 (44.60)
a Means(SD) presented geometrically
b Breast milk Na/K presented categorically (using ROC Curve analysis)
On analysis by independent t-test for differences in maternal breast inflammation (see table 
4.8), the mean concentration of CRP in both the HIV infected and uninfected women was 
significantly higher in those with high pain >dl4 (p<0.01). The percentage of HIV infected 
women with raised Na/K ratio (>0.9) was significantly greater in those with high breast 
pain >dl4 than with low breast pain (p<0.001), with no significant differences seen in the
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HIV uninfected women. There were no significant differences in breast milk IL-8 
concentrations in either the HIV infected or uninfected women with breast pain.
Table 4.9: Analysis to determine associations between maternal HIV status and infant
feeding indicators
Variable n Mean(95% Cl) p value
Good feeding practice <dl4 HIV-
HIV+
284
270
8.95 (8.52, 9.38) 
9.47 (9.10, 9.85)
0.071
EBF or mixed feeding <dl4 HIV-
HIV+
302
308
95% EBF 
88% EBF
0.011
Maternal breast inflammation 
<dl4
HIV-
HIV+
300
308
55% healthy 
58% healthy
0.622
Feeding practice >dl4 HIV-
HIV+
800
800
11.54(11.41 11.67) 
11.30(11.14, 11.46)
0.023
EBF or mixed feeding >dl4 HIV-
HIV+
784
816
96% EBF 
90% EBF
<0.001
Maternal breast inflammation 
>dl4
HIV-
HIV+
784
816
80% healthy 
96% healthy
<0.001
a Means(SD) presented geometrically
b Breast milk Na/K presented categorically (using ROC Curve analysis) 
ebf: exclusive breastfeeding
In univariate analysis of HIV status and infant feeding indicators (see table 4.9), good 
feeding practice was associated with HIV infectivity after day 14 (p=0.02), and approaching 
significance before day 14 (p=0.07) when analysed continuously. Before day 14 
postpartum, HIV infected women have a better mean score for feeding technique than HIV 
uninfected women, but from day 14 onwards the converse was true. The increased levels of 
breast milk inflammatory factors seen in the HIV infected mothers with poor feeding 
technique after day 14 (see table 4.6) may have indicated systemic inflammation thereby 
reducing the mother’s ability to successfully breastfeed.
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The type of infant feed was associated with HIV infectivity both before day 14 postpartum 
and from day 14 onwards with fewer HIV infected women exclusively breastfeeding than 
HIV uninfected women (p<0.05). HIV infection was also associated with better breast 
health from day 14 onwards (p<0.001) but no difference was seen before day 14 (p=0.62). 
This may again be an indication of the HIV infected women being more experienced at 
breastfeeding.
4.1.4 Logistical regression model
Stepwise regression modelling was used entering all the factors from the previous models 
described in the methods chapter (section 3.4.3) that were significantly associated (p <0.05, 
odds ratio >1) with maternal HIV status (see table 4.10). Details of the methods can be 
found in chapter 3. For full details of each model and stepwise techniques used please see 
Appendix 5.
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Table 4.10a Associations with maternal HIV infecition -  non biological
Variable Odds ratio p-value
Maternal age
Continuous scale per year increase
1.18 <0.001
Infant sex Male
Female
2.61 <0.001
Maternal weight antenatally 
Continuous scale per kg increase
0.93 <0.001
Maternal height antenatally 
Continuous scale per cm increase
1.02 0.03
Systolic blood pressure antenatally 
Continuous scale
0.97 <0.001
Diastolic blood pressure antenatally 
Continuous scale
0.76
Maternal control 
Continuous scale
0.77 <0.001
Maternal wealth 1 
Continuous scale
0.48
Maternal wealth 2 
Continuous scale
1.03 <0.001
n = 1680
Odds ratios for non significant variables are not shown
135
Table 4.10b Associations with maternal HIV infecition -  antenatal
Variable Odds ratio p-value
Delivery problems No
Yes
1.30 0.04
Haemoglobin antenatally 
Continuous scale
0.81 <0.001
Plasma CRP antenatally 
Continuous scale per mg/L increase
0.183
Plasma AGP antenatally 
Continuous scale per g/L increase
0.57 <0.001
n =  1360
Odds ratios for non significant variables are not shovs 
Table 4.10c Associations with maternal HIV infeci
m
tion -  early postnatal variables
Variable Odds ratio p-value
Feeding technique 
Continuous scale
0.20
Type of feeding EBF
Mixed
0.30
Maternal breast inflammation 
Continuous scale
0.68 0.02
Maternal temperature 
Continuous scale per °C increase
0.14
Breast milk CRP <dayl4 postpartum 
Continuous scale per mg/L increase
4.57 <0.001
Breast milk Na/K < day 14 postpartum <0.9
>0.9
0.22
Morbidity incident Yes
No
0.23 <0.001
n = 292
Odds ratios for non significant variables are not shown
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Table 4.10dAssociations with maternal HIV infection -  late postnata
Variable Odds ratio p-value
Feeding technique 
Continuous scale
0.19
Type of feeding EBF
Mixed
0.99 0.002
Maternal breast inflammation 
Continuous scale
0.51 <0.001
Maternal temperature 
Continuous scale per °C increase
0.60
Plasma CRP postnatally 
Continuous scale per mg/L increase
0.79 <0.001
Plasma AGP postnatally 
Continuous scale per g/L increase
8.79 <0.001
Breast milk CRP <dayl4 postpartum 
Continuous scale per mg/L increase
0.50
Breast milk Na/K < day 14 
postpartum
0.48 0.003
variables (>day 14)
n = 723
Odds ratios for non significant variables are not shown
Table 4.10e Associations with maternal HIV infection
Variable Odds ratio p-value 95% Cl
Milk CRP <dl4 (mg/L) 
Continuous scale per mg/L 
increase
3.91 0.005 (1.50, 10.17)
Problems at delivery No
Yes
3.06 0.001 (1.60,5.85)
Infant sex Male
Female
2.53 0.003 (1.38, 4.64)
Maternal wealth 1 
Continuous scale
1.12 0.001 (1.05, 1.12)
Maternal Age 
Continuous scale per year 
increase
1.10 0.001 (1.04, 1.16)
n = 237
137
In the logistical regression analysis (see table 4.10), mean concentrations of milk CRP 
(<dl4) had the strongest association with maternal HIV infection with an odds ratio (OR) of 
3.91 (p=0.005). Problems at delivery and the sex of the infant were also important with 
ORs of 3.06 and 2.53 respectively (p<0.01), with HIV infected women encountering less 
problems at delivery and more likely to give birth to a male infant. Maternal wealth and 
maternal age were also significantly associated with HIV infection (p=0.001). Included in 
the final analysis but not significant was maternal wealth 2 (p=0.525), systolic blood 
pressure (p=0.258) and AGP at 6 weeks postnatal (p=0.079).
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4.1.5 Summary
Objective 1: Social indicators associated with maternal HIV infection were older maternal 
age, male infants, greater maternal wealth and lower maternal weight in the antenatal 
period. In the logistical regression model infant sex was independently associated with 
maternal HIV status, with HIV infected women over twice as likely to give birth to a male 
infant, greater maternal age and maternal wealth.
Objective 2: Biological indicators associated with HIV infection were lower haemoglobin 
antenatally and postnatally, lower plasma CRP and AGP concentrations in the antenatal 
period and higher CRP and AGP concentrations in the postnatal period, higher overall 
morbidity, higher maternal temperature, higher milk CRP concentrations <dl4 and >day 14, 
higher percentage of raised milk Na/K >day 14 and lower breast milk IL-8 concentrations 
>day 14. In the logistical regression model breast milk CRP <dl4 was independently 
associated with maternal HIV status, presenting nearly a four fold risk.
Objective 3: Infant-feeding indicators associated with HIV infection were lower rates of 
exclusive breastfeeding and better maternal breast health >day 14. These factors were not 
independently associated with HIV status in the logistical regression model.
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4.2 Indicators associated with severity of maternal HIV infection
All the results presented in this section were generated from the South African study.
Data was available on both breast milk viral load and maternal CD4 counts taken at 
delivery. Unfortunately when using breast milk viral load as a proxy indicator of severity of 
HIV the final sample size was too small (1 week n=50; 6 weeks n=41; 3 months n=44), 
consequently maternal CD4 counts are presented here (for analysis using viral load as a 
proxy indicator please see Appendix 5).
Maternal CD4 counts were analysed in 2 ways:
• <500 cells per mm3 and >500 cells per mm .
• <200 cells per mm3 and >200 cells per mm3.
These women were still healthy with none showing any symptomatic signs of AIDS, so 
very few had a cell count of below 200 (see Appendix 5 for details). Following 
examination of the literature, it was decided to use the first category for data analysis (i.e. 
<500 cells per mm and > 500 cells per mm ), as Leroy et al., (2003) found that maternal
CD4 counts below 500 cells per mm in plasma close to the time of delivery were
associated with a 3 fold increase in the risk of late postnatal transmission (Leroy et al., 
2003).
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4.2.1 Social indicators
In univariate analysis (see table 4.11) there was no significant difference in maternal age, 
mode of delivery and sex of the infant between the two groups of women (those with CD4 
counts below 500 mm3 and those with CD4 counts > 500 mm3). One of the variables for 
maternal control approached significance (p=0.059) with women with greater control 
having lower CD4 counts. The only variable significantly associated with low CD4 counts 
in the univariate analysis was maternal wealth, with wealthier women having lower CD4 
counts (p<0.02).
Table 4.11: Analysis to determine associations between severity of maternal HIV and
social factors
Variable n Mean (95% Cl) p value
Infant sex CD4>500 84 50%male; 50% female 0.765
CD4<500 146 48% male; 52% female
Mode o f delivery CD4>500 84 64% vaginal; 36% other 0.212
CD4<500 144 72% vaginal; 28% other
Maternal age CD4>500 82 25.02 (24.05,26.00) 0.352
CD4<500 146 25.62 (24.85, 26.38)
Wealth CD4>500 60 0.22 (-0.02, 0.46) 0.015
CD4<500 96 -0.18 (-0.04, 0.03)
Maternal control 1 CD4>500 84 0.09 (-0.14, 0.32) 0.319
CD4<500 138 -0.05 (-0.21,0.11)
Maternal control 2 CD4>500 84 -0.14 (-0.35, 0.07) 0.059
CD4<500 138 0.11 (-0.05,0.27)
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4.2.2 Biological indicators
Table 4.12: Analysis to determine associations between severity of maternal HIV and
biological factors
Variable n Mean(95% Cl) p value
Plasma CD8a taken at delivery CD4>500
CD4<500
84
146
972.37(822.87, 1038.11) 
679.77 (642.12, 755.73)
<0.001
Maternal body temp lw  (°C) CD4>500
CD4<500
36
94
37.01 (36.73,37.29) 
36.78 (36.64, 36.93)
0.114
Maternal body temp 6w (°C) CD4>500
CD4<500
48
94
36.63 (36.48, 36.78) 
36.57 (36.44, 36.69)
0.540
Maternal body temp 3m (°C) CD4>500
CD4<500
42
76
36.53 (36.39, 36.68) 
36.59 (36.44, 36.74)
0.606
CRP 1 w (mg/L)a CD4>500
CD4<500
72
116
0.33 (0.25, 0.45) 
0.36 (0.28, 0.46)
0.691
CRP 6w (mg/L)a CD4>500
CD4<500
70
112
0.06 (0.05, 0.08) 
0.11 (0.08, 0.14)
0.004
CRP 3m (mg/L)a CD4>500
CD4<500
48
82
0.05 (0.03, 0.07) 
0.08 (0.06, 0.14)
0.011
Na/K 1 w (mg/L)b CD4>500
CD4<500
70
129
<0.9=73%; >0.9=27% 
<0.9=74%; >0.9=26%
0.812
Na/K 6w (mg/L) b CD4>500
CD4<500
72
114
<0.9=90%; >0.9=10% 
<0.9=82%; >0.9=18%
0.142
Na/K 3m (mg/L) b CD4>500
CD4<500
52
82
<0.9=90%; >0.9=10% 
<0.9=78%; >0.9=22%
0.066
IL-8 1 w (pg/mL)a CD4>500
CD4<500
72
130
231.37(163.83,326.94) 
251.12(188.69, 334.21)
0.727
IL-8 6w (pg/mL)a CD4>500
CD4<500
72
115
169.15(125.94, 227.17) 
193.55(150.24,249.34)
0.500
IL-8 3m (pg/mL)a CD4>500
CD4<500
54
84
209.18(145.73,300.26)
262.87(196.55,351.56)
0.328
Breast milk RNA viral load lw a CD4>500 
(copies/mL) CD4<500
43
104
488.31 (321.61,741.42) 
1046.45 (734.93, 1490.03)
0.014
Breast milk RNA viral load 6wa CD4>500 
(copies/mL) CD4<500
56
99
594.52 (335.28, 1059.34) 
1257.76(871.60, 1815.03)
0.023
Breast milk RNA viral load 3ma CD4>500 
(copies/mL) CD4<500
48
80
600.38(351.26, 1026.18) 
907.13 (622.06, 1322.85)
0.200
aMeans(95%CI) presented geometrically
bBreast milk Na/K presented categorically (using ROC curve analysis)
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Despite the well-documented strong interrelationship between CD4 and CD8, CD8 was 
included in the above univariate analysis (see table 4.12) to show the results were not 
spurious and that they were being presented in the correct direction. Lower CD8 counts 
were significantly associated with lower CD4 counts in the univariate analysis (p<0.001). 
CD8 counts were not included in multivariate regression analysis as it was considered a 
confounding factor.
Maternal body temperature was included in univariate analysis as a proxy indicator of 
morbidity as no morbidity data was available. Unfortunately this may not be a sensitive 
enough measure and no clear association was found between maternal temperature and low 
CD4 counts in the women.
As expected there was a significant association between breast milk RNA viral load at both 
1 week and 6 weeks (but not at 3 months) postpartum and maternal CD4 counts (p<0.05). 
Women with low CD4 counts at 1 and 6 weeks had viral loads twice as large as women 
with CD4 counts > 500 cells per mm3 (p=0.023).
Milk CRP at 6 weeks and 3 months postpartum correlated inversely with maternal CD4 
counts, indicating a level of systemic inflammation. However, milk Na/K and milk IL-8 
showed no associations with maternal CD4 counts.
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4.2.3 Infant feeding indicators
The only information regarding breastfeeding that was taken during this study was that of 
feeding type. Mother’s were asked at every visit whether they exclusively breastfed, mixed 
fed or did not breastfeed their child. In the univariate analysis (see table 4.13) feeding type 
was not associated with maternal CD4 count.
Table 4.13: Analysis to determine associations between severity of maternal HIV and 
infant feeding factors
Variable n Mean(95% C l) p value
Breastfeeding 1 week CD4>500
CD4<500
78
140
77%ebf; 18%mixed;5%none 
76%ebf;23%mixed; 1 %none
0.193
Breastfeeding 6 weeks CD4>500
CD4<500
82
138
56%ebf;37%mixed;7%none 
74%ebf; 13%mixed; 13%none
0.517
Breastfeeding 3months CD4>500
CD4<500
72
112
64%ebf; 17%mixed; 19%none 
64%ebf; 14%mixed;22%none
0.780
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4.2.4 Maternal CD4 logistical regression model
Table 4.14: Associations with CD4 counts <500 cells mm
Variable Odds ratio p-value 95% CIs
Milk CRP at 6w postpartum(mg/L) 
Continuous scale per mg/L increase
2.491 <0.001 (1.61,3.87)
Breast milk RNA viral load at 6w postpartum 
Continuous scale per copies/mL increase
1.278 0.05 (0.10,1.63)
n=102
Results of the forward conditional logistical regression (see table 4.14), showed 
associations of maternal CD4 count with milk CRP at 6 weeks postpartum with an odds 
ration (OR) of 2.491 (p<0.001) and breast milk viral load at 6 weeks postpartum with an 
OR of 1.278 (p=0.05). Also included in the regression model but not significant were 
infant feeding at 6 weeks postpartum (p=0.123) and maternal wealth (p=0.331).
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4.2.5 Summary
Objective 1: The social indicator associated with severity of HIV infection was maternal 
wealth. No social factors were independently associated with HIV status in the logistical 
regression model.
Objective 2: Biological indicators associated with severity of HIV infection were breast 
milk CRP, at 6 weeks and 3 months postpartum, and breast milk RNA viral load at 1 week 
and 6 weeks postpartum. In the logistical regression model breast milk CRP and RNA viral 
load at 6 weeks postpartum were independently associated with severity of maternal HIV 
infection.
Objective 3: No breastfeeding indicators were associated with severity of maternal HIV 
infection.
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4.3 To determine if breast milk CRP could be a suitable surrogate measure for 
systemic inflammation and a potential indicator of increased risk of mother-to-child 
transmission of HIV.
The data presented has been generated from the Zambian pilot study, the Tanzanian study, 
the Zambian community based study and the South African study.
4.3.1 The relationship between breast milk and plasma CRP; breast milk CRP and other 
inflammatory factors
Data from the Tanzanian study (see figure 4.4) showed breast milk CRP was significantly 
correlated with plasma CRP for samples taken at 1 and 3 months postpartum. The data 
could not be normalised, so Spearman’s rank correlations are presented (rs=0.651, n=157, 
p<0.001). Significant correlations were also seen with the matched breast milk and plasma 
samples taken in the Zambian community study (see figure 4.5) at 6 weeks postpartum (rs= 
0.693; r:0.658, n = l15, p<0.001).
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Figure 4.4 Comparison of breast milk CRP and plasma CRP in Tanzanian women at
1 and 3 months postpartum
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Spearman’s rank correlation coefficient (rs): 0.651, n = 157, p < 0.001 
Laboratory cut o ff point for breast milk CRP assay was 0.035mg/L
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Figure 4.5 Comparison of breast milk CRP and plasma CRP in HIV infected and
uninfected Zambian women at 6 weeks postpartum
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Spearman’s rank correlation coefficient (rs): 0.693, n = 115, p < 0.001 
Pearson’s correlation coefficient (r) on normalised data: 0.658, n= l 15, p< 0.001
Laboratory cut o ff point was 0.01 and milk CRP values below 0.01 were given arbitrary numbers from 0-0.01.
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In the Zambian pilot study 22 women were studied for a mean of 3.82 days (SD±2.85, 
range=2-l 1 days). They were admitted to hospital a mean of 19.05 days postpartum (range: 
3-127). All but one infant (bom at 28 weeks) were bom at term and the mean birth weight 
was 2.9kg (SD±0.70). Of the 22 women admitted to hospital with systemic infection, 12 
had puerperal sepsis, 5 had malaria and 5 were admitted with a range of symptoms 
including postpartum complications and suspected but unconfirmed malaria. All women 
received appropriate treatment for the infection. All biological indicators were analysed by 
breast and not by woman.
There was a positive correlation between milk CRP and milk IL-8 (see figure 4.6) in 
Zambian women admitted to hospital with systemic inflammation in the postpartum period. 
However, CRP on admission did not correlate with Na/K on admission (p=0.34).
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Figure 4.6 Comparison of breast milk CRP and breast milk IL-8 in Zambian
women admitted to hospital with systemic inflammation in the postpartum 
period.
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Spearman’s rank correlation coefficient (rs): 0.423, n = 30, p=0.008 
Pearson’s correlation coefficient (r) on normalised data: 0.486, n=38, p=0.002
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For all 3 breast milk biological factors analysed in the Zambian pilot study there was a 
significant difference between the mean concentrations on admission and discharge 
(p<0.05), with concentrations decreasing on treatment of the systemic infection (see table 
4.15).
Table 4.15: Difference in milk biological indicators on admission and discharge in
Zambian women admitted to hospital with systemic inflammation in the 
postpartum period
Variable n Mean (SD) Mean Difference 
(95%CI)
CRPb (mg/L) Admission 30 0.82 (0.003) 0.82 (0.52,1.40)**
Discharge 30 0.65 (0.005)
Na/Ka Admission 37 1.53 (2.26) -2.32*
Discharge 37 0.78(1.29)
IL-8b (pg/L) Admission 36 420.37 (7.60) 0.22 (0.01,0.44)*
Discharge 36 184.71 (10.08)
aNa/K is non-normally distributed so is analysed non-parametrically by Wilcoxon signed rank test. Z-score is
presented instead o f mean difference
bGeometric means and SD presented for CRP and IL-8
*p<0.05, **p<0.01
n= number o f samples taken (per breast not per woman). As some women provided very small samples o f  
breast milk not all the assays could be completed on all the samples.
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Table 4.16 Correlations between breast milk CRP taken at 1 and 6 weeks and 3
months postpartum and breast milk inflammatory factors in HIV infected 
South African women
C R Plw CRP 6w CRP 3m
Variable
CRP lw 8 Mean(SD)
r
n
0.34 (3.56)
n/a
230
0.34 (3.56) 
0.29**
230
0.34 (3.56)
0.04
230
CRP6w8 Mean(SD)
r
n
0.08(4.11)
0 .29**
220
0.083 (4.11)
n/a
220
0.083 (4.11) 
0.46***
220
CRP3ma Mean(SD)
r
n
0.06 (3.59) 
0.04 
160
0.06 (3.59) 
0.46*** 
160
0.06 (3.59) 
n/a 
160
Na/Klwb Median(percentiles)
r s
n
0.57 (0.41,0.95) 
0.26***
255
0.57(0 .41,0 .95)
0.15*
255
0.57 (0.41,0.95)
-0.002
255
Na/K6wb Median(percentiles)
rs
n
0.49 (0.37, 0.71)
0.04
233
0.49 (0.37,0.71) 
0.33***
233
0.49 (0.37, 0.71) 
0.16*
233
Na/K3mb Median(percentiles)
rs
n
0.46 (0.36, 0.67) 
0.13 
166
0.46 (0.36, 0.67) 
0.17*
166
0.46 (0.36, 0.67) 
0.12 
166
IL-81wa Mean(SD)
r
n
291.75 (5.85) 
0.19**
258
291.75 (5.85) 
-0.01 
258
291.75 (5.85)
-0.03
258
IL-86wa Mean(SD)
r
n
192.37 (4.29) 
0.006 
234
192.37 (4.29) 
0.29***
234
192.37 (4.29) 
0.22**
234
IL-83ma Mean(SD)
r
n
233.71 (3.99)
0.10
172
233.71 (3.99) 
0.06 
172
233.71 (3.99)
0.09
172
aMeans(95%CI) presented geometrically
bBreast milk Na/K non normally distributed so median and 25th/75th percentiles presented 
*p<0.05, **p<0.01, ***p<0.001
r= Pearson’s correlation coefficient 
rs= Spearman’s rank correlation coefficient
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As can be seen from table 4.16, milk CRP concentrations in breast milk at 1 week 
postpartum were significantly associated with breast milk CRP concentration at 6 weeks, 
breast milk Na/K ratio at 1 week and breast milk IL-8 concentration at 1 week postpartum. 
CRP at 6 weeks postpartum was associated with breast milk CRP at 3 months, Na/K ratio at 
1 week, 6 weeks and 3 months and IL-8 at 6 weeks (p<0.05). At 3 months, breast milk 
CRP concentration was associated with milk Na/K at 6 weeks and IL-8 at 6 weeks (p<0.05).
4.3.2 The relationship between breast milk CRP and infant feeding indicators
In the Zambian pilot study all of the 22 women breastfed their infants and due to the small 
number of women admitted to the study infant-feeding details did not take into account 
length of time between delivery and admission to hospital. Infant-feeding technique was 
scored by the midwife using a breastfeeding checklist (see Appendix 2). The maximum 
score was 12 indicating good feeding practice. In this pilot study the median score was 9.67 
with a range of 5-12 (SD±1.83). Feeding technique did not correlate with Na/K levels on 
admission or discharge (rs=-0.051, p=0.762, n=38; rs =-0.118, p=0.481, n=38 respectively) 
or CRP on discharge (rs =-0.135, p=0.432, n=36). However, it approached significance 
with breast milk IL-8 on admission (rs =0.327, p=0.051, n=36) and was significantly 
positively correlated with IL-8 on discharge (rs =0.519, p=0.005, n=28) with the mean 
concentration of IL-8 increasing with better feeding technique. CRP on admission showed 
a significant inverse relationship between feeding technique and milk CRP, with milk CRP 
concentrations increasing with poorer feeding practice (rs =-0.345, p=0.029, n=40).
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At the time of sample collection, twelve infants in this group were reported to be 
exclusively breastfed, 7 received water only in addition to breast milk and 3 received other 
foods as well. There was no effect of these different feeds on milk Na/K ratio on admission 
or discharge (rs =-0.247, p=0.189, n=30; rs =-0.166, p=0.389, n=29 respectively), or milk 
IL-8 on admission or discharge (rs =-0.204, p=0.281, n=30; rs =-0.285, p=0.168, n=25 
respectively). However, there was a positive correlation between feeding type and CRP on 
admission and discharge, with the mothers feeding their infants water or other foods having 
higher CRP than those who exclusively breastfed (rs =0.379, p=0.036, n=31; rs =0.438, 
p=0.020, n=28 respectively). This may be indicative of a reluctance to exclusively 
breastfeed in the mother’s suffering from a systemic inflammation.
Maternal breast inflammation was scored by the midwife using a checklist (see Appendix 
2). The maximum score was 4 indicating higher levels of inflammation (as perceived by 
the mother) and the minimum score was 0 indicating no problems (median=0.68, SD±1.16). 
Breast inflammation was not associated with Na/K ratio on admission or discharge. It was 
also not associated with mean concentrations of IL-8 and CRP on admission. However, it 
was correlated with increased CRP and IL-8 concentrations on discharge (rs =0.385, 
p=0.017, n=38; rs =0.378, p=0.039, n=30 respectively).
As has been previously seen (see tables 4.6 and 4.8), breast milk CRP was associated with 
poor feeding technique and maternal breast inflammation in the Zambian community based 
study.
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Limited infant feeding data was collected in the South African study. The data did, 
however, show a correlation at 1 week and 3 months between breast milk CRP 
concentration and choice of infant feed, with women who exclusively breastfed having an 
inverse correlation with breast milk CRP (a 1 week rs=-0.151, p=0.022, n=230 and 3 
months rs=-0.266, p=0.001, n=157). Breast milk CRP at 6 weeks and 3 months was also 
inversely correlated with infant weight gain: infant weight gain from 1-6 weeks had a 
Spearman’s rank correlation coefficient o f -0.217, p=0.003, n=190 with milk CRP at 6 
weeks; infant weight gain from 6 weeks -  3 months had a Spearman’s rank correlation 
coefficient of -0.226, p=0.007, n=143 with milk CRP at 3 months.
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4.3.3 The relationship between breast milk CRP and risk factors for mother-to-child
transmission of HTV
Table 4.17: Correlations between milk CRP and risk factors for mother to child
transmission of HIV in South African HIV infected women
Mean
(SD)
n
CRPlw
0.34 (3.56) 
230
CRP 6w
0.08 (4.11) 
220
CRP 3m
0.06 (3.59) 
160
Variable
Maternal
CD4
Mean(SD)
r
n
459.33 (240.26) 
-0.01 
230
459.33 (240.26) 
-0.22**
230
459.33 (240.26) 
-0.11 
230
Breast milk 
Viral load 
lw a
Mean(SD)
r
n
1093.64 (6.84) 
0.02 
185
1093.64 (6.84) 
0.23*
185
1093.64 (6.84)
0.04
185
Breast milk 
Viral load 
6wa
Mean(SD)
r
n
1038.91 (6.95)
0.03
193
1038.91 (6.95) 
0.17*
193
1038.91 (6.95) 
0.10 
193
Breast milk 
Viral load 
3ma
Mean(SD)
r
n
913.87 (6.12) 
-0.01 
160
913.87 (6.12) 
0.13 
160
913.87 (6.12) 
0.13 
160
aMeans(95%CI) presented geometrically
*p<0.05, **p<0.01, ***p<0.001 
r= Pearson’s correlation coefficient
Milk CRP at 6 weeks postpartum correlated inversely with maternal CD4 count (see table 
4.17) indicating a level of systemic inflammation. Milk CRP at 6 weeks postpartum 
significantly positively correlated with breast milk RNA viral load at 1 and 6 weeks 
(p<0.05).
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In the univariate analysis (see table 4.12) higher mean concentrations of milk CRP at 6 
weeks and 3 months postpartum was significantly associated with low maternal CD4 counts 
and in the final logistical regression a lmg/L increase in breast milk CRP (see table 4.14).
4.3.4 Summary
Objective 1: Matched time point breast milk and plasma CRP concentrations showed 
significant correlation in both the Tanzanian and Zambian mothers. Breast milk CRP also 
correlated with breast milk IL-8 in Zambian mothers with systemic inflammation and HIV 
infected South African mothers. On treatment of the systemic inflammation in Zambian 
mothers, CRP concentrations in the breast milk significantly decreased.
Objective 2: CRP in the breast milk has been shown to be significantly associated with 
poor infant feeding technique in the Zambian community study and the Zambian hospital 
based pilot study. It is also associated with mixed feeding of the infant in the Zambian 
hospital based pilot study and in the South African study and reduced infant weight gain in 
the South African study. It was also related to maternal breast inflammation in both the 
Zambian community study and the Zambian hospital based pilot study.
Objective 3: Breast milk CRP taken at 6 weeks postpartum strongly correlated with 
mother-child-transmission risk factors (CD4 and breast milk viral load). It has also been 
shown to be independently associated with maternal CD4 count taken at the time of 
delivery.
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4.4 Results summary
Aim I:
Aim II:
Aim III:
HIV status was independently associated with raised breast milk CRP, fewer 
problems at delivery, giving birth to a male infant, higher maternal age and 
greater maternal wealth.
Severity of HIV infection was independently associated with raised breast 
milk CRP and RNA viral load.
Breast milk CRP was associated with plasma CRP and breast milk IL-8, 
poor feeding technique, mixed feeding and poor infant weight gain. It 
showed a strong correlation with breast milk RNA viral load and was 
independently associated with maternal CD4 count.
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Chapter 5 
Discussion
Since the beginning of the HIV pandemic, four million children under 15 years of age 
worldwide have been infected with HTV and in the year 2003 alone an estimated 800,000 
children were newly infected (UNAIDS 2003). In the absence of effective interventions 
(such as antiretroviral therapy), breastfeeding by an HIV mother for 2 years or more can 
double the overall risk of mother-to-child transmission of HIV to about 40% (Newell, 1998; 
Nduati et al., 2000).
Large-scale reduction in transmission of HIV-1 from mother to child has now been 
achieved in the more developed world using a combination of antiretroviral regimes, 
elective caesarean section and replacement infant feeds (The European mode of delivery 
collaboration group, 1999; The European Collaborative Study, 2001; The International 
Perinatal HIV Group, 2002; Read et al., 2001). Most of these interventions are not possible 
in many developing country settings. However, strategies are now being put into place to 
prevent transmission before and during birth by reducing maternal viral load in the 
antenatal and peripartum period using antiretrovirals e.g. Zidovudine and Nevirapine (Leroy 
et al., 2002; Jackson et al., 2003; Petra study team, 2002), but even after peripartum 
antiretroviral therapy children remain at risk at acquisition of infection through 
breastfeeding (Leroy et al., 2002; Jackson et al., 2003; Petra study team, 2002; John et al., 
2001; Leroy et al., 2003). Risk factors for transmission through breastfeeding include high 
maternal RNA viral load in the breast milk and plasma, low maternal CD4 counts in 
plasma, breast inflammation and mixed feeding (Leroy et al., 2003; Read, 2003; Willumsen 
et al., 2003; Embree et al., 2000; Coutsoudis et al., 2001). Inflammatory factors present in
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the breast may be associated with to transmission, however, these have not been sufficiently 
compared in HIV infected and HIV uninfected women.
This thesis presents findings from a multi-factored study designed to look at a number of 
issues potentially of interest in mother to child transmission of HIV, comparing HIV 
infected and uninfected women and examining data from three sub Saharan African 
countries. Two of these studies were fully undertaken by the author (Zambian community 
based study and Zambian pilot study) and two of the studies involved laboratory analysis by 
the author of stored samples from other studies in Tanzania (Filteau et al., 1999b), and 
South Africa (Willumsen et al., 2000).
Results from these studies were used to answer three principle project aims:
I To determine the social, biological and breastfeeding indicators associated with 
maternal HIV status (section 5.1).
II To determine the social, biological and breastfeeding indicators associated with 
severity of HIV in the mother (section 5.2).
III To determine if breast milk CRP could be a suitable surrogate measure for systemic 
inflammation and a potential indicator of increased risk of mother-to-child 
transmission, measured by non-invasive breast milk sampling (section 5.3.).
Social indicators in the Zambian community study and the South African study and 
maternal HIV status was associated with characteristics similar to those described in other 
studies. As the social indicators were found to be similar, then it may be possible to draw
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comparisons between biological and feeding indicators. Social factors are discussed 
although the majority of the discussion will focus on the novel findings of biological 
and feeding variables, areas where there has been limited research.
5.1 Indicators associated with maternal HIV infection
The main findings from this research question come from the Zambian community based 
study, a nested study of 56 HIV infected and 56 uninfected women recruited antenatally and 
followed to 16 weeks postpartum.
5.1.1 Social indicators
Six indicators were used in the final adjusted logistical regression model to determine any 
associations with HIV status. These were maternal age, infant sex, maternal weight 
antenatally and three variables predicting socio economic status (maternal control and 2 
variables for maternal wealth). All of the women recruited into this study were living in 
relatively poor conditions with communal toilet areas and communal water supplies being 
the norm. However, compared to other townships in Lusaka, Chilenje is relatively wealthy 
with a stable population and permanent housing (Lusaka health district management team, 
2002). The discussion of social indicators focuses on the final model. Much research into 
HIV transmission has occurred in this area, and as the primary aim of this discussion was to 
focus on novel findings, the social indicators were designed to be used to see if population
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data from this study was comparable to that of other studies researching into similar subject
areas.
Maternal age was significantly associated with HIV infection in both univariate and 
multivariate regression analysis with the mean age of HIV-infected women being almost 2 
years older than the HIV-uninfected women, as has also been seen elsewhere (Gaillard et 
al., 2000). This would be consistent with older women having a greater number of sexual 
partners and, therefore, having a greater lifetime risk of acquiring infection. Socio­
economic factors indicating the maternal control included maternal income, marital status 
(with unmarried women having more control), decision-making, gravidity and education 
level. Increased maternal control may translate into increased maternal rights in aspects 
around reproductive health, however, in this study it was not significantly associated with 
HIV infection status. The lack of association may be due to a limited sample size or a 
relatively homogenous population of women studied. In a country such as Zambia where 
social stereotypes of women are reinforced, women are seen to have a lack of control over 
their sexuality and sexual relationships (WHO, 2000; Gomez and Marin 1996; Potts 2003). 
Variables used to describe maternal wealth included marital status, employment of the 
women and their partners, housing density and electricity. In this study women with greater 
wealth were more likely to be HIV infected than those of a lower economic status. This 
result has been reflected in other studies, which have shown that in areas of poor economic 
status wealthier women are at an increased risk of being HIV infected (WHO, 2004a; 
Kirunga and Ntozi, 1997; UNAIDS-WHO Joint publication, 1998; Gisselquist et al., 2003; 
Potts 2003). Cultural pressures are reinforced by gender inequalities in income and wealth
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and for many women their economic and social security is often dependent on a social 
partner. In such circumstances women may appear wealthier but with little control over 
issues such as frequency of intercourse, safer sex, their partners fidelity or no sex at all 
(WHO, 2004a; Potts 2003; Gomez and Marin, 1996; Gisselquist et al., 2003; Sobo, 1995). 
Gender, culture and power may be barriers to maintaining safer sex practices with a primary 
partner (Gomez and Marin, 1996), where the struggle for daily survival takes precedence 
over concerns about HIV infection whose effects may not be seen for years (Sobo, 1995). 
In communities where HIV is firmly embedded in the general population, the only high risk 
behaviour of many women is having sex with their husbands (UNAIDS-WHO Joint 
publication, 1998).
The weight of HIV infected mothers taken at 36 weeks antenatally was almost 3 kg lower 
than the HIV uninfected mothers in the univariate analysis. This is consistent with data 
from West Africa showing HTV infected women weighed significantly less than HIV 
uninfected women at 28 weeks and 32 weeks antenatally (Castetbon et al., 1999), and 
evidence showing that HIV infection significantly and substantially affects growth in 
children (Newell et al., 2003a). Nutritional status of HIV infected women could be 
impaired by different mechanisms including decreased dietary intake, malabsorbtion and 
metabolic disturbances (Coodley et al., 1994). However, the HIV infected women in this 
study were wealthier than the HIV uninfected women and this could be an indirect 
argument against poorer dietary intake. Similar results have been seen in a study in 
Rwanda where the HIV infection itself may impair weight gain (Ladner et al., 1998), with 
wasting a specific sign of HIV disease progression in chronically infected individuals.
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HIV infected mothers in this study were over twice as likely to give birth to male infants. 
This could be associated with maternal hormonal imbalances caused by HIV infection 
affecting gender selection at conception (James, 1999), or that girls are more likely to be 
infected in utero, as has been seen in a recent European study (ECS collaborators, 2004). 
Mothers of infected infants in utero may be at an increased risk of spontaneous abortions 
and still births (Urass et al., 1992), consequently if female infants are more likely to be 
infected in utero, they would be at greater risk of being miscarried and HIV uninfected male 
infants (in utero) would be more likely to be carried to term.
5.1.2 Biological indicators
A number of biological indicators were measured in the Zambian community study 
including haemoglobin, plasma acute phase proteins and inflammatory factors in the breast 
milk. Differences between HIV infected and HIV uninfected women were seen in many of 
these biological factors. There was a much reduced sample size in the final model (n=237) 
due to both a limited number of samples taken for some variables (e.g. IL-8 and 
haemoglobin) and matching biological data. This coupled with the lack of previously 
published data on CRP in breast milk means that discussion of the biological data does not 
focus exclusively on the final adjusted logistical regression model. The results of this 
analysis, the influence of the factors on each other and the implications of these findings 
will be discussed below.
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In the antenatal period (36 weeks) both groups of women were mildly anaemic, which is 
expected due to the haemodilution that occurs during pregnancy. Following delivery (at 
days 3 and 7 postpartum), HIV uninfected women showed an increase in haemoglobin 
levels, whereas the HIV infected mothers showed a continued decrease in their mean 
haemoglobin levels. At each time point HIV infected women had significantly lower 
concentrations of haemoglobin than their HIV uninfected counterparts. Anaemia in the 
HIV infected women may have been due to a number of factors including systemic 
inflammation, nutritional deficiencies and the impact of the HIV virus itself (van den Broek 
et al., 1998b). In this study, HIV infected women suffered from an increased risk of 
morbidity and were found to have higher concentrations of CRP in the postnatal period 
when compared to the uninfected women, indicating at least a proportion of the anaemia 
may have been due to systemic inflammation. As discussed previously, the HIV infected 
women in this study did weigh less than the uninfected women so nutritionally induced 
anaemia cannot be completely discounted, although whether the nutritional differences can 
be attributed to the HIV infection or diet would be difficult to determine (Coodley et al., 
1994). The HIV infection itself has been associated with a variety of haematological 
abnormalities including depletion in cell lines such as thrombocytes and red blood cells and 
this also may be a factor in the reduced haemoglobin levels seen in this study (van den 
Broek et al., 1998a). Previous studies have shown increased levels of anaemia in HIV 
infected women and an inverse correlation between maternal haemoglobin and plasma 
RNA viral load (Friis et al., 2001; Semba et al., 2001b). However, treatment with 
antiretroviral therapy has shown conflicting results with highly active antiretroviral therapy 
associated with reduced anaemia in HIV infected North American women (Semba et al.,
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2001a), and antiretrovirals shown to increase the risk of anaemia in a study in Europe (The 
European Collaborative Study, 2003).
Morbidity, defined by any incidence of ill health during 16 weeks postpartum, was 
significantly higher in HIV infected than uninfected women with a greater proportion of 
HIV infected mothers having a morbid event compared to the HIV uninfected group. In 
both groups the percentage of women reporting a morbid incident was high (55% in HIV 
uninfected and 77% in HIV infected women), and may be due to a number of factors 
including self reporting and possible over reporting by the women, and the classification of 
morbidity as any morbid incident (ranging from a severe headache to hospitalisation with 
severe malaria) occurring at any time in the 16 weeks postpartum. HIV-infected mothers 
are at an increased risk of puerperal sepsis and fever related to tuberculosis or of unknown 
origin and other indicators of postpartum morbidity (Verkuyl DA, 1995; WHO, 2004d; 
Read et al., 2001; Landers et al., 1997; Temmerman et al., 1994). In this study HIV 
infected women were shown to have a significantly higher mean maternal temperature and 
mean concentrations of breast milk CRP before day 14 postpartum when compared to the 
uninfected women indicating either a prolonged inflammatory response to labour or a more 
general increased risk of sustained systemic inflammation in the postpartum period in 
women with HIV infection.
Mean concentrations of plasma AGP and CRP were significantly lower in the HIV infected 
women in the antenatal period than the HIV uninfected women in a univariate analysis, but 
in the postnatal period the reverse was seen. Univariate analysis of plasma samples taken at
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6 weeks postnatally showed HIV infected women had significantly increased mean 
concentrations of plasma AGP and CRP when compared to the uninfected cohort. Plasma 
acute phase proteins both at 36 weeks antenatally and 6 weeks postpartum were not found 
to be significantly associated with HIV infection in the multivariate regression analysis 
despite previously published literature showing AGP and CRP in plasma were 
independently associated with HIV status (Baeten et al., 2002). Acute phase reactants are 
known to be affected during HIV disease progression, with asymptomatic HIV infection 
eliciting an increase in whole body protein turnover with this increased protein turnover 
including changes in the kinetics of acute-phase proteins (Jahoor F et al., 1999; Feldman JG 
et al., 2003b; Fauci, 1988a), thus differences were expected to be seen between HIV 
infected and uninfected women. Previously published literature has shown plasma AGP 
and CRP concentrations to be higher in HIV infected women than uninfected women in the 
antenatal period (Semba et al., 2000). As immunological markers are known to change 
throughout pregnancy due to the haemodilution effect, timing of the samples may explain 
this discrepancy as Semba et al., 2000 tested for AGP and CRP in the second trimester, and 
in my study blood samples were taken in the third trimester. Mean concentrations of acute 
phase proteins may have been lower in HIV-infected women pre-delivery due to a greater 
down regulation in the immune response in HIV infected women in the antenatal period, as 
is seen in CD4 levels in HIV infected women (Bums et al., 1996). In the postpartum period 
the results of this study agreed with previously published reports in both Malawian and 
Kenyan women (Semba et al., 2000; Baeten et al., 2002).
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The increased morbidity, increased acute phase response and lower mean concentrations of 
haemoglobin in the postpartum period associated with the HIV infected women in this 
study may be indicative of chronic inflammation. When CRP concentrations are 
significantly raised without a significant nutritional deficiency, any anaemia seen may be 
the result of chronic inflammation (van den Broek et al., 1998a). Anaemia of inflammation 
is a frequent complication in patients suffering from chronic inflammatory disorders 
including infections, autoimmune and malignant disease (van den Broek et al., 1998a; 
Feldman et al., 2003a).
As with other inflammatory factors (Filteau et al., 1999a), CRP is thought to pass into the 
breast milk via leaky epithelium during systemic inflammation. This is the first study that 
has measured CRP in the breast milk and there is no information available to compare the 
results from either HIV infected or uninfected breastfeeding women. Measuring CRP in the 
breast milk is a non-invasive method of measuring systemic inflammation in the mother 
over 16 weeks postpartum. Geometric mean concentrations of natural log normalised CRP 
in the breast milk, although increased in the HTV infected women, was raised in both 
infected and uninfected women during the first few days postpartum. After day 10, CRP 
levels decreased significantly in both groups and levelled out up to 16 weeks postpartum. 
The concentrations are thought to decrease due to a combination of the establishment of 
proper lactation and the maternal inflammatory response returning to normal after labour 
(Lawrence R, 1999). In the univariate analysis, breast milk CRP both before and after day 
14 was significantly higher in HIV infected than uninfected women. Postnatal CRP both in 
breast and plasma was significantly associated with HIV status of the mother. In the
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multivariate regression analysis, including all biological indicators, breast milk CRP was 
independently associated with maternal HIV status, with infected women having 
significantly greater mean concentrations of breast milk CRP than the HIV uninfected 
women. This difference in CRP in the breast milk between HIV infected and uninfected 
women may be indicative of changes in the immunological constituent of breast milk due to 
HIV infection. This may have implications for the immuno protective role of the breast 
milk offered to children of HIV infected women.
Due to the limited availability of breast milk and budgetary constraints, IL-8 was only 
analysed in the breast milk at three time points after proper establishment of lactation 
(weeks 2, 5 and 9). A significant difference in the IL-8 concentration of infected and 
uninfected women was seen with HIV infected women having significantly lower mean IL- 
8 concentrations than HTV uninfected women. When examining morbidity a similar result 
was found with HIV infected women with a morbid event having significantly lower IL-8 
concentrations than healthy HIV infected women. In univariate analysis, lower mean IL-8 
concentrations were significantly associated with maternal HIV infection. IL-8 is produced 
locally within the breast, either to maintain breast health or in an immunoprotective role for 
the infant (Michie et al., 1998), and systemically. Little in vivo research has been completed 
on the impact of HIV on IL-8. The results are in line with in vitro data showing that 
latently HIV-1 infected cells have a marked reduction in IL-8 secretion when compared to 
HIV uninfected cells (Ohashi et al., 1994), and that cytokine induced IL-8 production is 
depressed in chronic HIV infection of promonocytic cells (Tiemessen and Martin, 2000). If 
IL-8 production is depressed due to HIV infection then, as with breast milk CRP, this may
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be indicative of changes in the immunological constituent of breast milk from HIV infected 
mothers and have implications in the immuno protective role of the breast milk.
Breast milk Na/K was also analysed over 16 weeks postpartum. Raised milk Na/K ratios 
have been used as a measure of leakage across the blood/milk barrier, with the potassium 
level (as it is a larger molecule and unable to permeate the blood/milk barrier) remaining 
constant but with a rise in the level of sodium (a much smaller molecule) in the breast milk 
(Georgeson and Filteau, 2000; Lawrence R. 1999; Linzell, J.L. and M.Peaker, 1975). There 
is some literature linking this with sub clinical breast inflammation, known as sub clinical 
mastitis (Filteau et al., 1999a; Filteau et al., 1999b). Poor feeding practice and localised 
inflammation of the breast have been hypothesised for the rise in breast milk sodium, and it 
has been found to be occur in all breastfeeding populations of women (Filteau et al., 1999a; 
Filteau et al., 1999b; Willumsen et al., 2000). In this study, as with breast milk CRP, Na/K 
in the breast milk was high for both infected and uninfected women during the first few 
days postpartum. After day 10, Na/K levels decreased significantly independent of HIV 
status and stayed relatively constant up to 16 weeks postpartum. Before day 14 postpartum, 
no difference was found between the percentages of raised Na/K of HIV infected or 
uninfected women. However, after day 14, Na/K in univariate analysis was significantly 
associated with HIV status, with the percentage of raised Na/K in HIV infected women 
higher than in HIV uninfected women.
Overall Na/K was not found to be associated with HIV status, and was removed from the 
stepwise regression once morbidity was entered. This was consistent with a previous
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finding showing no significant difference in prevalence of sub clinical mastitis between 
HIV-infected and HTV uninfected Zimbabwean women in a multimicronutrient 
supplementation trial (Gomo et al., 2003). On analysis of data from all four of the data sets 
used for this thesis Na/K was found to be non-normally distributed. Na/K was therefore 
analysed non-parametrically using cut off points defined by ROC curve analysis (see 
Appendix 3.2). Analysis from the South African data set has been previously published, 
using naturally logged values of Na/K, which unfortunately did not normalise the data, and 
Na/K ratios categorised into 3 groups (<0.6, 0.6-1.0, >1.0) (Willumsen et al., 2000, 2001 
and 2003). Therefore, results presented in this thesis may therefore differ somewhat from 
previously published work as only 2 cut off were used.
Problems at delivery were defined by a variety of criteria including prolonged labour, 
instrumental extraction, 3 rd degree tears and excessive bleeding. In the initial analysis no 
differences were seen in problems at delivery between the HIV-uninfected and infected 
women in this study. However, after allowing for age and number of births in the 
multivariate regression analysis, the HIV uninfected women were at a significantly higher 
risk of problems at delivery. Primigravida are at a much higher risk of experiencing 
complications at delivery (WHO, 2004d). The HIV uninfected women enrolled in this 
study were significantly younger than the HIV infected subjects and were significantly more 
likely to be pregnant for the first time. In this study, this not only influenced problems at 
delivery but also affected the analysis when looking at breastfeeding technique, as the HIV 
uninfected women had a significantly poorer breastfeeding technique, as assessed by the
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study midwives, than HTV infected women reflecting the maternal inexperience of this 
group of women.
Biological indicators significantly associated with maternal HIV infection in the final 
adjusted logistical regression model were problems with delivery and raised CRP in breast 
milk. The almost four fold increase in the risk of having raised milk CRP may be indicative 
of changes in the immunological constituent of breast milk due to HIV infection and merits 
further investigation.
5.1.3 Breastfeeding Indicators
All women in the Zambian community study breastfed their children. Detailed 
questionnaires were regularly taken by experienced midwives on feeding practice, the type 
of feed given to the child and whether there was pain or inflammation around the breast 
area. There is little published data containing in-depth information on breastfeeding 
indicators and their relationship to breast milk biological variables in HIV infected and 
uninfected women, and consequently there is very limited information available from which 
comparisons can be drawn. Breastfeeding indicators were not included in the final 
logistical regression model and so discussion of these indicators focuses on the descriptive 
data set.
Data was initially analysed for differences in mean breast milk biological variables (CRP, 
IL-8 and Na/K) between the groups. However, the results should be looked at with caution
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as the HIV infected women were older and with more children and potentially more 
experienced at breastfeeding. Inflammatory markers associated with poorer breastfeeding 
indicators such as IL-8 and Na/K, although raised in HIV uninfected women, may be a 
reflection of breastfeeding experience rather than HIV infection status. In the final 
multivariate regression, after allowing for the confounders of age and gravidity, no 
significant differences between feeding indicators were seen.
In the HIV uninfected women before and after day 14, and the HIV infected women from 
day 14, women with poor feeding technique had higher mean concentrations of breast milk 
CRP. If CRP is leaking into the breast from the blood stream, what is interesting about 
these results is that poor feeding technique may be causing a systemic inflammatory 
response as can be seen in cases of clinical mastitis (Livingstone and Stringer, 1999), or an 
underlying chronic inflammatory response may be affecting the mother’s ability to 
successfully breastfeed. Before day 14 postpartum, this response could possibly be 
attributed to the maternal recovery post childbirth. Both in HIV-infected and HIV- 
uninfected women increased IL-8 levels were associated with poor feeding technique. In 
HIV uninfected women suffering from a morbid event, IL-8 levels were increased 
compared with HIV uninfected women with no morbid incident. Although lower IL-8 
levels were seen in the HIV infected women suffering from a morbid event, the inverse was 
seen in HIV infected women with poor feeding technique. This would suggest that IL-8 
was a local and not a systemic, inflammatory response to poor feeding technique.
The only other previously published research comparing mother’s breastfeeding technique 
and levels of IL-8 was in Bangladeshi women, and no differences were found in milk IL-8
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production in mothers with poor and good techniques (Flores and Filteau, 2002). This was, 
however, a small study and its sample size may have limited its findings. The final 
biological variable studied in relation to feeding technique was breast milk Na/K. Breast 
milk Na/K was thought to be the most responsive and sensitive method of evaluating the 
permeability of the blood/milk barrier in response to local inflammation (Filteau et al., 
1999a; Filteau et al., 1999b). In this study Na/K ratios were not significantly different in 
HIV infected women with poor or good feeding techniques. However, in HIV uninfected 
women before day 14 postpartum, women with poor feeding technique had a significantly 
increased percentage of raised Na/K. This was in agreement with data from the 
Bangladeshi study which reported significantly higher Na/K ratios in those with poorer 
feeding technique (Flores and Filteau, 2002), and in a study in South Africa showing raised 
Na/K levels are seen in women who mixed fed as an indirect measure of poorer feeding 
technique (Willumsen et al., 2000).
In univariate analysis of this study, feeding practice was not associated with HIV infection 
before day 14, with no differences seen between HIV infected and HIV uninfected women. 
However, from day 14, poor feeding practice was associated with HIV infection. This is 
consistent with the increased levels of breast milk CRP and IL-8 seen in the HIV infected 
mothers with poor feeding technique after day 14. Feeding technique was removed from 
the final stepwise regression once maternal age was included.
The effect of the type of infant feed on MTCT of HIV through breastfeeding has been 
previously investigated. In a study in South Africa it was reported that mixed feeding
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(giving the infant any food or fluids in addition to breast milk) increased the risk of HIV 
transmission through breastfeeding (Coutsoudis et al., 2001). In the Zambian community 
study when looking at differences in biological variables, the only significant difference 
was seen in breast milk IL-8, where mean concentrations were higher in the HIV infected 
women who mixed fed. This may be a cause for concern as breast milk IL-8 has been 
shown to correlate with breast milk RNA viral load (Willumsen et al., 2000), a risk factor 
for MTCT of HIV. Raised IL-8 in the breast milk may be an indicator of productive HIV-1 
infected cells (Ohashi et al., 1994), and this may account for the correlation between breast 
milk IL-8 and breast milk RNA viral load seen by Willumsen et al. (2000).
In both groups the number of women who mixed fed was extremely low as one aim of the 
larger study was to promote exclusive breastfeeding (although this was assessed by self 
reporting), as recommended by WHO (WHO, 2002). In the initial analysis, the type of 
infant feed was associated with HIV maternal HIV infection, both before day 14 postpartum 
and from day 14 onwards, with fewer HIV infected women exclusively breastfeeding than 
HIV uninfected women. As the HIV infected women had a significantly greater number of 
morbid events and increased indicators of chronic inflammation than HIV uninfected 
women, could it be conceivable that fewer HIV infected women exclusively breastfed due 
to poor health? Women may not necessarily be exhibiting clinical symptoms, but 
nevertheless suffer from an underlying inflammatory condition that may affect their ability 
to sustain exclusive breastfeeding. This would be in line with previously published analysis 
showing women who breastfed having higher CD4 counts at delivery than those women
177
who didn’t breastfeed, with increased duration of breastfeeding associated with higher CD4 
counts at delivery (Newell et al., 2003b).
Maternal breast health was the final feeding factor to be analysed. In the Zambian 
community study raised breast milk CRP concentrations were seen in both HIV infected 
and uninfected women suffering from pain in the breast area which would indicate a 
systemic inflammatory response as seen in cases of clinical mastitis (Livingstone and 
Stringer, 1999; Lawrence RA, 1999; Georgeson and Filteau, 2000). HIV infected women 
in this study suffering from pain in the breast area were more likely to have raised Na/K 
than HIV infected women with no pain. As Na/K is used as an indicator of increased 
permeability between the blood-milk barrier (Georgeson and Filteau, 2000) this may 
explain the leakage of CRP into the breast milk. In the preliminary analysis HIV infection 
was associated with better breast health from day 14 onwards with no significant difference 
was seen before day 14. This may again be an indication of the HIV infected women being 
more experienced at breastfeeding.
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5.2 Indicators associated with severity of HIV infection
The main findings addressing indicators associated with severity of HIV status come from 
the South African study, a cross sectional study of 144 HIV infected women recruited 
antenatally and followed to 3 months postpartum (Willumsen, 2000). In this South African 
study, data is available on breast milk HIV RNA viral load, at 1 and 6 weeks and 3 months 
postpartum, and maternal plasma CD4 counts were taken at delivery. Breast milk RNA 
viral load was available for fewer women than CD4 counts. When using breast milk viral 
load as a proxy indicator of severity of HIV in multivariate regression analysis, sample size 
was very low (n< 51 per time point), so consequently maternal CD4 counts were used as a 
measure of severity of maternal HIV status.
5.2.1 Social indicators
Six indicators were used in the final model to determine associations with HIV status. 
These were maternal age, infant sex, mode of delivery and three variables indicating socio 
economic status (1 maternal wealth and 2 maternal control, see methods section 3.4.2). 
Results reflect similar findings to those seen in the Zambian community study.
The only variable significantly associated with low CD4 counts in the univariate analysis 
was maternal wealth, with wealthier women having lower CD4 counts. One of the 
variables for maternal control approached significance, with women with greater control 
having lower CD4 counts. This may be a reflection on maternal wealth, with women with
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greater control over their lives choosing wealthier partners. As with the Zambian 
community study, in areas of poor economic status wealthier women are at an increased 
risk of being HIV infected ( WHO, 2004a; Kirunga and Ntozi, 1997; UNAIDS-WHO Joint 
publication, 1998). In the Zambian community study wealthier women were more likely to 
be HIV infected. In this study, wealth may be an indicator of the stage of HIV progression, 
with wealthier women being infected for a longer time than the less wealthy women. HIV 
infection is a progressive disease accompanied by a gradual decrease in CD4 counts over 
time, therefore the longer the women have been infected the lower their CD4 counts might 
be.
5.2.2 Biological indicators
A number of biological variables were analysed and as this was a cross sectional study 
much of the sample data in the postpartum period is time point specific (weeks 1 and 6, and 
3 months postpartum).
Maternal temperature was included as a proxy indicator of morbidity as there was no 
morbidity data available. Although in the Zambian community study maternal temperature 
was found to be associated with morbidity, no association was found between maternal 
temperature and low CD4 counts in these South African women. This may be due to the 
smaller sample size used in this South African data analysis, or that maternal temperature 
was lacked the sensitivity to be used as a proxy measure for morbidity.
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As expected there was a strong inverse association in univariate analysis between breast 
milk RNA viral load at both 1 week and 6 weeks (but not at 3 months) postpartum and 
maternal CD4 counts. Women with low CD4 counts at delivery (<500 cells per mm3)had 
breast milk RNA viral loads at 1 and 6 weeks postpartum double that of women with CD4 
counts > 500 cells per mm . In multivariate regression allowing for socio economic, 
biological and feeding variables, breast milk RNA was found to be independently 
associated with maternal CD4 count. Breast milk viral load has been shown to correlate 
positively with plasma viral load and negatively with maternal CD4 count taken at delivery 
in South African and Kenyan women (Pillay et al., 2000; Willumsen et al., 2003; Rousseau 
et al., 2003, Ekpini et al., 1997, John-Stewart et al., 2004). In one study in South Africa, 
mothers of HIV-infected children (n=16) were shown to have a higher proportion of 
detectable HIV RNA in their breast milk than mothers of uninfected children (n=63), and in 
multivariate analysis HIV RNA load in breast milk was significantly associated with the 
risk of mother-child transmission (Pillay et al., 2000).
In univariate analysis of the data, we found higher mean concentrations of milk CRP at 6 
weeks and 3 months postpartum were significantly associated with low maternal CD4 count 
(<500 cells/mm ) taken at delivery. In regression model, allowing for socio economic, 
biological and feeding variables, breast milk CRP at 6 weeks postpartum was found to be 
significantly associated with low maternal CD4 count. Chronic stimulation of the acute 
phase response appeared to a indicate worsening prognosis in a variety of chronic disease 
settings (Gabay and Kushner, 1999; Munford, 2001), and in a MTCT study in Kenya, both 
plasma AGP and plasma CRP were shown to be independently associated with higher viral
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HIV-1 plasma viral load and lower CD4 count (Baeten et al., 2002). As CRP in the breast 
milk has a strong correlation with plasma CRP, the resultant association seen in these South 
African women between higher mean concentrations of breast milk and low maternal CD4 
counts is in agreement with published data (Baeten et al., 2002). Low maternal plasma 
CD4 counts and high breast milk RNA viral load have been shown to be high risk factors 
for MTCT (Leroy et al., 2003; Pillay et al., 2000; Read, 2003, Ekpini et al., 2003). As 
breast milk CRP in this study has been shown to be independently associated with maternal 
CD4 count, it would be interesting to investigate further whether increased mean breast 
milk concentration of CRP are associated with risk of MTCT. The results of this study are 
of concern in view of the limited data that showed plasma CRP, in 209 HIV infected 
American women, was a powerful predictor of mortality (Feldman et al., 2003a). Whether 
breast milk CRP is a predictor of morbidity or mortality in HIV infected African women 
who are not receiving long-term antiretroviral therapy has never been investigated. 
However, CRP is not thought to be a causal factor, it may just be indicative of HIV disease 
progression.
Milk Na/K and milk IL-8 over the first 3 months postpartum were not significantly 
associated with maternal CD4 counts in the mother. Breast milk Na/K has been used as a 
measure of localised sub clinical inflammation of the breast (Filteau et al., 1999a; 
Willumsen et al., 2000). Whether there is a relationship between localised inflammatory 
responses and systemic measures of immune status, such as maternal CD4 count, would be 
difficult to measure and may require a larger sample size than was available in this study. 
However, breast milk IL-8 and Na/K have been shown to correlate with breast milk RNA
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viral load (Willumsen et al., 2000), indicating that breast milk viral load, unlike plasma 
CD4, may be influenced by local inflammatory responses in the breast. As has already been 
noted, in this project breast milk Na/K has been analysed differently from previously 
published research on this data set (Willumsen et al., 2000). Despite the lack of associations 
between maternal CD4 counts and IL-8, it is important to note that the South African 
women’s breast milk IL-8 was over 10 times greater then in the women in Zambian 
community study. As breast milk IL-8 has been measured in relatively few different 
populations of women and large variations in concentrations have been seen (Filteau et al., 
1999a; Filteau et al., 1999b; Willumsen et al., 2000; Willumsen, 2001), this may be an area 
of study that merits further research.
5.2.3 Breastfeeding indicators
The only information regarding breastfeeding that was taken during this study was that of 
feeding type. The mother’s were asked at every visit whether they exclusively breastfed, 
mixed fed or did not breastfeed their child since the last clinic visit. In most African 
countries, mixed feeding is the norm, however, women in both the South African and the 
Zambian community study were heavily advised and supported in exclusively breastfeeding 
their child. As a result the proportion of women exclusive breastfeeding was relatively high 
compared to that of the general population. It should be noted that self-reporting, as was 
used in this study, could overestimate the reported rates of exclusive breastfeeding. In this 
study, the type of breastfeeding was not associated with maternal CD4 count in univariate
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or multivariate analyses. This was in agreement with the results of previously published 
literature (Coutsoudis et al., 2001b). Coutsoudis et al., (2001b) showed that even though by 
15 months of age, the cumulative probability of HIV infection remained lower among those 
who exclusively breastfed for 3 months or more than among other breast feeders, any risk 
factors for MTCT did not differ between feeding group (exclusive breastfeeding, mixed 
feeding or formula feeding).
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5.3 To determine if breast milk CRP could be a suitable surrogate measure for
systemic inflammation and a potential indicator of increased risk of mother-to- 
child transmission.
CRP was measured in the breast milk rather than plasma. Repeat sampling of breast milk 
could be taken from the women in all four of the studies without pain or discomfort to the 
mother that may have been caused by taking venous blood samples. The mothers could 
donate the samples independently without specialist clinical staff being present and felt 
comfortable in doing so (personal communication Matron Kunda, University Teaching 
Hospital, Zambia).
One of the main aims of the project was to examine the mean concentrations of CRP in 
HIV infected mothers. Although CRP is not thought to be directly involved in the 
transmission process, there may be some merit in using it to indirectly measure increased 
risk of MTCT. CRP is known to increase dramatically in the face of inflammation, and 
raised levels of breast milk CRP could indicate the presence of plasma-induced HIV viral 
load in the breast milk. High concentrations of breast milk CRP may be associated with 
decreased infant gut integrity. By triggering an acute phase response in the infant that may 
activate the complement pathway resulting in intestinal epithelial damage. Women with 
chronic systemic inflammation (as measured by CRP) may also be less inclined to 
exclusively breastfeed, and as mixed feeding is a risk factor for transmission, high 
concentrations of breast milk CRP in mixed feeding women may be a indirect indicator of 
increased risk of MTCT.
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5.3.1 The relationship between breast milk CRP and plasma CRP: breast milk CRP and
other inflammatory factors
The production of CRP is presumed to be restricted to the liver, but extra hepatic 
expression by inflamed tissue has not been studied in detail (Jabs et al., 2003). There is 
currently no evidence to suggest it is produced in the mammary gland. It is hypothesised 
that during an inflammatory response the acute phase proteins activate the complement 
pathway, this opens the normally tight junction between the blood-milk barrier thereby 
allowing passage of CRP and other immune cells into the breast milk. High correlations 
between breast milk CRP and plasma CRP in both Tanzanian and Zambian women support 
this hypothesis.
CRP concentration increases rapidly following both infection and tissue injury caused by a 
variety of inflammatory diseases (Macintyre et al., 1982). In Zambian women admitted to 
hospital with systemic inflammation in the postpartum period (the Zambian pilot study), 
mean concentrations of breast milk CRP were much higher than in the Zambian community 
study (irrespective of HIV status) even before day 14 postpartum when CRP levels were at 
their highest. In the Zambian pilot study, breast milk CRP was shown to strongly correlate 
with breast milk IL-8 in women with systemic inflammation although there was no 
significant correlation between milk Na/K and milk CRP. Localised breast inflammation, 
as diagnosed by an elevated Na/K ratio in milk accompanied by an increased milk 
concentration of the inflammatory cytokine IL-8 was found to be common among 
breastfeeding women in Bangladesh and Tanzania (Filteau et al., 1999a; Filteau et al.,
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1999b). It has been hypothesised that it may result in leakage of plasma constituents into 
milk and the active recruitment of leukocytes into milk (Willumsen et al., 2000). Poor 
breastfeeding practice (comprised of a number of variables including incorrect latching on 
and poor infant suckling technique) has been associated with raised Na/K in the breast milk 
(Flores and Filteau, 2002), but little is known about the effect of systemic inflammation on 
these breast milk variables. IL-8 is produced both locally within the breast and also 
systemically so the correlation between breast milk CRP and breast milk IL-8 may result 
from systemically produced IL-8 and CRP leaking into the breast milk. Na/K is thought to 
respond to more localised fluctuations in the breast (Filteau et al., 1999a; Filteau et al., 
1999b; Flores and Filteau, 2002), and as CRP is a systemically produced biological 
variable, the relationship between breast milk Na/K and CRP may be more complex and 
harder to measure.
In the Zambian pilot study, treatment of the systemic inflammation resulted in a significant 
decrease in mean concentrations of breast milk CRP, this may indicate the breast milk 
constituents returning to their previous un-inflamed state. Similarly in the Zambian 
community study, breast milk CRP levels fell significantly after day 10 postpartum, with 
over a 10-fold reduction in mean concentration of breast milk CRP. This is hypothesised to 
be due to the closure of junctional complexes between mammary alveolar cells to prevent 
extra-cellular fluid components from entering the alveolar space (Linzell and Peaker, 1975). 
As CRP has never before been measured in breast milk, normal levels for both HIV 
infected and uninfected women have not yet been established.
187
In the South African study, breast milk CRP at 6 weeks postpartum was significantly 
positively correlated with breast milk RNA viral load at 6 weeks, breast milk IL-8 and 
breast milk Na/K at 6 weeks postpartum. The correlation between breast milk CRP and IL- 
8 was seen in the systemically infected women in the Zambian pilot study, but not in the 
Zambian community study. The correlation between breast milk IL-8 and CRP in the South 
Africa study may indicate a level of systemic inflammation, as was seen in the Zambia pilot 
study. However, as the pilot study was a small study with relatively few women and 
samples, no HIV data and no breast milk RNA viral load data it would be difficult to infer 
any such relationship.
5.3.2 Breast milk CRP and infant feeding indicators
In the Zambian pilot study of systemically infected women in the postpartum period, 
feeding technique showed a significant inverse correlation with milk CRP, with poor 
feeding technique associated with higher mean concentrations of CRP. This result was also 
seen in the Zambian community study. If CRP is leaking into the breast from the blood 
stream, this raises the question of the cause and the effect of this result. It could be that 
women who feel ill are less likely to exclusively breastfeed as indicated by previously 
published data (Newell et al., 2003b), or that the process of mixed feeding can have a 
systemic inflammatory effect. When feeding technique was examined in the Bangladeshi 
women, poorer technique was associated with raised breast milk Na/K indicating a level of 
inflammation occurring in the breast (Flores and Filteau, 2002).
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In the Zambian pilot study, women with systemic inflammation who mixed fed had 
significantly higher milk CRP concentrations than those who exclusively breastfed. 
Caution should be taken with these results as time since delivery was not accounted for due 
to limitations in sample size. However, a similar result was seen in the South African study 
with HIV infected mothers who mixed fed having increased breast milk CRP 
concentrations. In a trial in Kenya which randomised women to breastfeeding or formula 
feeding, it was shown that women who breastfed had an increased risk of morbidity and 
mortality (Nduati et al., 2001). There was, however, evidence that the formula fed and the 
breastfed groups may have differed in their underlying risk at the outset of the study and, 
therefore, results are thought to be methodologically flawed (WHO, 2001). In a study in 
South Africa, examining the risk of mortality and breastfeeding modality, the authors 
detected no deleterious effects of breastfeeding on the health of HIV-infected women 
(Coutsoudis et al., 2001a). The result presented in this thesis may indicate that women who 
are suffering from chronic systemic inflammation are less inclined to exclusively breastfeed 
their child.
In the Zambian community study significant differences were seen between all three of the 
biological variables measured in the breast milk indicating differences between HIV 
infected and HIV uninfected women’s breast milk composition. In a South African study 
(Bobat et al., 1997), looking at infants that were partially breastfed or exclusively formula 
fed, HIV-infected infants had similar frequencies of failure to thrive, diarrhoea and 
pneumonia as uninfected infants of HIV-infected mothers. However, in another South 
African study of HIV infected mothers and their infants, never breastfed infants, regardless
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of HIV status, were nearly twice as likely to have an illness episode than those who were 
breastfed (Coutsoudis et al., 2003), and in a study in Kenya breastfed children bom to HIV 
infected women were shown to have better nutritional status (Mbori-Ngacha et al., 2001). 
Limited information is available comparing breast milk composition of HIV infected and 
uninfected women, and conflicting data exists as to the benefits or otherwise of breast milk 
given to children bom to infected mothers irrespective of the infants HIV status. The 
nutritional and immunological properties of breast milk of HIV infected women needs to be 
studied in more detail.
In this study, breast milk CRP showed significant negative correlations with infant weight 
gain at 6 weeks and 3 months in South African women, indicating inflammatory factors in 
the breast milk may have a negative impact on infant growth. It may be hypothesised that a 
high concentration of CRP in the breast milk, as seen in women with more severe HIV 
infection, could by activating the complement pathway in the breastfed infant, result in 
intestinal epithelial damage which may increase the risk of transmission. This may be one 
explanation for South African breastfed infants diagnosed with HIV infection at 14 weeks 
having higher gut permeability at 6 and 14 weeks postpartum (Rollins et al., 2001).
In the Zambian hospital based study and the Zambian community study, women with breast 
inflammation had increased mean concentrations of IL-8 and CRP. It is conceivable the IL- 
8 may be produced both locally and systemically as a response to breast inflammation and 
in cases of mastitis a systemic inflammatory response is often seen (Linzell and Peaker, 
1975), which may explain the increased concentration of milk CRP.
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5.3.3 Breast milk CRP and risk factors for mother to child transmission of HIV
In this study CRP in breast milk at 6 weeks was shown to correlate negatively with maternal 
CD4 count taken at delivery and correlate positively with breast milk viral load at 6 weeks, 
and was independently associated with maternal CD4 count in the South African women. 
This is in agreement with previously published research that showed plasma CRP was 
independently associated with higher viral HIV-1 plasma viral load and lower CD4 count 
(Baeten et al., 2002).
Plasma CD4 counts and breast milk RNA viral loads are useful prognostic tools for 
measuring risk of MTCT through breastfeeding. With antiretroviral therapies slowly 
becoming more available in the developing world, it is conceivable that HIV infected 
mothers with low CD4 counts and high viral loads could be treated with antiretrovirals 
throughout the period of breastfeeding to reduce the risk of transmission to the infant 
(WHO, 2002b; Laniece et al., 2003). However, measuring of viral loads and CD4 counts 
are still cost prohibitive requiring specialised laboratories, expensive equipment and skilled 
laboratory personnel (WHO, 2002b). Alternative methods for HIV-patient monitoring other 
than CD4 counts and viral loads in the setting of sub-Saharan Africa are urgently required 
(WHO-AFRO, 2001). The WHO has proposed measuring total lymphocyte count (TLC) as 
a substitute indicator for initiating antiretroviral therapy in resource-limited settings using a 
relatively inexpensive automated blood counter (WHO, 2002b). TLC is an inexpensive and 
useful marker for disease staging and predicting progression to AIDS or death in HIV- 
infected patients (Beck et al., 1996). A high correlation between TLC and CD4 cell count
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both in asymptomatic and symptomatic HIV-infected patients has been observed (Badri and 
Wood, 2003; Kumarasamy et al., 2002). However, CRP can be measured in breast milk 
without the pain or discomfort that may be caused by venous blood sampling. Mothers can 
donate samples independently without specialist clinical staff and anecdotal evidence has 
shown that the women in this study were more willing to give breast samples than blood 
samples (Matron Kunda, personal communication). The relatively low cost of the CRP 
assay, and the ability to perform the assays in non-specialised laboratory units may mean 
that breast milk CRP could have a role in monitoring inflammatory status (as a proxy 
indicator of low maternal CD4 count and high breast milk viral load) in HIV-infected 
mothers. This could be used as a guide to either initiate antiretroviral therapy or to advise 
early cessation of breastfeeding.
In this study, breast milk CRP has been shown to correlate with maternal plasma CD4 
counts and breast milk viral load in South African women. The impact of systemic 
inflammation on CD4 counts and maternal viral load may merit some further investigation, 
particularly as in the Zambian pilot study it was shown that breast milk CRP was raised in 
the face of systemic inflammation. If maternal plasma CD4 counts and breast milk RNA 
viral load were found to be raised in the face of systemic inflammation, this may explain 
why CRP in HIV infected women was found to be a powerful predictor of mortality 
(Feldman et al., 2003a). As maternal plasma CD4 counts and breast milk viral load are risk 
factors for transmission and in this study CRP was independently associated with maternal 
CD4 counts taken at delivery, it may be possible to use milk CRP as an indirect measure of
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risk of MTCT, and to establish whether the risk of MTCT increases in the face of systemic 
inflammation.
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Chapter 6
Conclusions and recommendations for future research
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6.1 Conclusions
The following are the final conclusions o f my study.
• HIV infected women were significantly different in social, biological and breastfeeding 
indicators when compared to HIV uninfected women.
• HIV infection was more common in women with increased maternal age, maternal 
wealth, morbidity over 16 weeks postpartum, milk CRP, plasma AGP and CRP 
postpartum, mixed feeding, poor feeding practice and probability of giving birth to a 
male infant.
• HIV infection was associated with reduced maternal weight, problems at delivery, 
maternal haemoglobin, plasma AGP and CRP in the antenatal period, milk IL-8 and 
maternal breast inflammation.
• In order of magnitude, maternal HIV infection was independently associated with breast 
milk CRP before day 14 postpartum, fewer problems at delivery, and increased 
probability of giving birth to a male infant, higher maternal wealth and higher maternal 
age.
• HTV infected women with more severe HIV infection (plasma CD4 count at delivery
• i
<500 cells/mm ) showed significant differences in social and biological indicators when
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compared to HIV infected women with less severe HIV infection (plasma CD4 count at 
delivery > 500 cells/mm ).
• Increased severity of HIV infection was associated with increased maternal wealth, milk 
CRP at 6 weeks and 3 months postpartum, and breast milk viral load at 1 week and 6 
weeks postpartum.
• In order of magnitude, severity of maternal HIV infection was independently associated 
with breast milk CRP at 6 weeks postpartum and breast milk RNA viral load at 6 weeks 
postpartum.
• Breast milk CRP concentrations strongly correlated with matched time point plasma 
CRP concentrations and breast milk IL-8. Breast milk CRP decreased significantly on 
treatment of systemic inflammation.
• Breast milk CRP was significantly associated with poor infant feeding technique, mixed 
feeding and maternal breast inflammation and it was strongly correlated with poor 
infant growth in the South African infants.
• Breast milk CRP was strongly correlated with risk factors of mother to child 
transmission and was independently associated with maternal CD4 count.
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6.2 Recommendations for future research
The findings in this study show that breast milk CRP was strongly associated with risk 
factors for mother to child transmission of HIV. It would therefore be important to 
investigate further whether breast milk CRP could be used as an indirect measure of risk of 
mother to child transmission.
As breast milk CRP concentrations are increased in the face of systemic inflammation. It 
would be important to define ‘normal’ levels of CRP in breast milk in HIV infected and 
uninfected women and from this define a cut off to indicate raised breast milk CRP. From 
this information to investigate whether raised breast milk CRP is associated with high 
breast milk RNA viral load and low maternal CD4 counts. Further investigations would be 
needed to assess whether treatment of inflammation to reduce breast milk CRP have an 
indirect impact on maternal risk factors for MTCT.
As breast milk CRP in HIV infected women has been seen to strongly correlate with infant 
weight gain it would be interesting to further investigate breast milk CRP and intestinal gut 
permeability in HIV infected and uninfected infants bom to HIV infected mothers.
Further work is needed to see if breast milk CRP could be used a sensitive measure to 
indirectly measure risk factors for MTCT through breastfeeding to advise early cessation of 
breastfeeding or commencement on antiretroviral therapy.
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Appendices
Appendix 1 
Published Literature
Appendix 2.1 
Zambian Community Study
Breastfeeding and Postpartum Health
Recruitment Questionnaire
INSTRUCTIONS
Midwife please answer all the questions from parts 1-3, by filling in the blank spaces or 
ticking the appropriate box as indicated.
PART 1 DEMOGRAPHIC DATA
Name (official)
Alternative name by
which you are ..........................................................
known 
Date of Birth 
(dd/mm/yyyy)
Age (years)
Address (next 6 
months)
Housing density (L) low
(M) medium 
(H) high
(L)
(M)
(H)
Electricity in home?
Refrigerator in 
home?
Marital status
Subject's
employment
Husband/partner's
employment
00 yes 
(N) no
(Y)
(N)
0 0  yes 
(N) no
00
(N)
(M) married
(C) co-habiting
(S) Single/never married
(D) Divorced/Separated 
(W) Widow
(M)
(C)
(S)
<P)
(W)
(FE) formal employment 
(IE) informal employment 
(UN) unemployed
(FE)
(IE)
(UN)
(FE) formal employment 
(IE) informal employment 
(UN) unemployed 
(NA) not applicable (no partner)
(FE)
(IE)
(UN)
(NA)
Do you consider (NP) not poor 
your household to be (PO) poor
(VP) very poor
(NP)
(PO)
(VP)
Main source of 
income
(OE) own employment 
(HE) husband/partner's employment 
(FA) other family 
(OT) other; specify
(OE)
(HE)
(FA)
(OT)
Who is the main person 
in your household who 
makes the decisions 
about spending on food 
and household 
essentials?
(SE) self
(HU) husband/partner 
(FA) other family 
(OT) other; specify
(S)
(H)
(F)
(O)
Last grade of education 
completed?
(0) none
(1-12) for school grades
(13) for any college or university
(0)
(1-12)
(13)
Subject's religious (C) Christian
denomination (M) Moslem
(O) other; specify
(C)
(M)
(O)
PART 2 MEDICAL AND OBSTETRIC HISTORY
Date last menstrual 
period
(dd/mm/yyyy)
Estimated date of
delivery
(dd/mm/yyyy)
Chronic illness Diabetes (Y) yes
(N) no 
(Y) yes 
(N) no 
(Y) yes 
(N) no 
(Y) yes 
(N) no
Other; specify............................(Y) yes
(N) no
Hypertension
Tuberculosis
Gastroenteritis
/ /
/ /
oo
(N)
00
(N)
00
(N)
00
(N)
00
(N)
Gravity
Parity
Number of still births
Number of spontaneous abortions/miscarriages 
Number of previous premature infants 
Number of previous caesarean sections
□
□
□
□
□
□
Postnatal complications during 6 weeks after birth of 
previous infant
Severe anemia (Y) yes
(N) no
(Y)
(N)
Postpartum hemorrhage (Y) yes 
(N) no
CO
(N)
Puerperal sepsis (Y) yes 
(N) no
CO
(N)
Malaria (Y) yes 
(N) no
(Y)
(N)
Breast infection/ abscess 
needing treatment
(Y) yes 
(N) no
(Y)
(N)
Breastfeeding problems (Y) yes 
(N) no
(Y)
(N)
Other; specify (Y) yes 
(N) no
PART 3 CLINICAL EXAMINATION
Weight (kg)
Height (cm)
Temperature (°C)
Blood pressure
(mm/Hg)
Oedema (Y) yes 
(N) no
ir
(Y)
(N)
Lymphadenopathy (Y) yes 
(N) no
(Y)
(N)
Height of fundus 
(weeks)
Vaginal discharge
Breast tenderness
(NO) none
(OS) offensive smelling 
(IT) itchy
(BO) both offensive smelling and 
itchy
Left (Y)yes
(N) no
(NO)
(OS)
(IT)
(BO)
00
(N)
Right 0 0  yes 
(N) no
(Y)
(N)
PART 4 LABORATORY TESTS
Hemoglobin (g/dL) 
RPR
Malaria parasites 
Urinalysis
(Y)yes = '+ ’ 
(N)no =
CO
(N)
0 = none
1=  +
2 =  + +
3 = -H-+ or numerous
(0)
(1)
(2)
(3)
Protein (Y)yes
(N)no
CO
(N)
Sugar (Y)yes
(N)no
00
(N)
leukocytes (Y)yes
(N)no
(Y)
(N)
Other Other; specify (Y)yes
(N)no
Breastfeeding and Postpartum Health
Delivery Questionnaire
Date of delivery 
(dd/mm/yyyy)
Place of delivery
If UTH, reason for 
referral
/ /
(CHI) Chilenje Clinic 
(UTH)
(HOM) home 
(OTH) other; specify
(NOT) not at UTH
(APH) antepartum hemorrhage
(PEE) preeclampsia/eclampsia
(FED) fetal distress
(BRE) breech
(SEL) self referral
(OTH) other; specify
(CHI)
(UTH)
(HOM)
(OTH)
(NOT)
(APH)
(PEE)
(FED)
(BRE)
(SEL)
(OTH)
Temperature on admission (°C)
Mode of delivery (VA) spontaneous vaginal 
(EP) episiotomy 
(IN) instrumental *
(CS) C-section
□
(VA)
(EP)
(IN)
(CS)
Number of infants
Infant sex
(1) singleton
(2) twins 
(M) male 
(F) female
a )
(2)
(M)
(F)
Infant weight (kg)
Infant length (cm)
Apgar score (5 minutes)
Infant abnormalities (NO) none 
(SB) still birth 
(PR) premature 
(PH) physical anomalies
(NO)
(SB)
(PR)
(PH)
Maternal temperature just post delivery (°C)
Labour/delivery
complications
(NON) none
(PRO) prolonged labour
(PPH) postpartum hemorrhage
(RET) retained placenta
(ECL) eclampsia/intrapartum
convulsions
(OTH) other; specify
□
□
(NON)
(PRO)
(PPH)
(RET)
(ECL)
(OTH)
When was the infant first put to the breast? 
(minutes after birth)
Breast feeding and Postpartum Health 
Infant Feeding Questionnaire
Day post partum 1 2 3 4 5 6 7 8 9 10 11 12 13 14
Are you breastfeeding? (Y/N)
When did your milk first come in? (V day first reported)
Have you had any pain in your breasts or nipples? (N=no/L/R/B=both)
Have your breasts felt full or uncomfortable? (N=no/L/R/B=both)
Have you had any cracked nipples? (N=no/L/R/B=both)
Does the infant have any feeding problem? (Y/N)
What else has the infant eaten? (V all that apply)
water?
formula?
juice?
cow's milk?
solids? (eg nshima, porridge)
Remaining questions for days 3 + 7 visits only; code on column for exact day
Does your baby sleep with you?
Which breast does your baby prefer? (L/R/B=both)
Which breast do you usually offer the baby first? (L/R/RAN=random order/ALT=altemate 
order)
How do you decide the right time to change breasts?
(EMP=breast feels empty; TEME=after certain time; BABY=baby cries etc)
Do you often hand express milk? (D=daily/regularly; OOoccasionally; N=never)
How much extra salt have you added to your own food in the last 24 hours? (approxteaspoons)
Breast feeding and Postpartum Health 
Breast feeding observations
Instructions: Observe a breastfeeding session as unobtrusively as possible and answer the questions Y=yes or N=no. I f  you cannot assess a particular 
point, please leave the space blank.
Day 3 Day 7 Other day- 
specify
Other day- 
specify
Date (dd/mm/yyyy)
Position of mother and baby
Mother is relaxed and comfortable
Baby is close to mother’s body
Head and shoulders are facing the breast and neck is extended
Mother is correctly supporting the baby/bottom is supported
Mother is holding her breast correctly
Position of baby’s mouth
Mouth is wide open
Chin is touching the breast
Baby has a good mouthful (lower lip is enclosing more of bottom part o f the areola; more areola above 
the baby's mouth)
Lower lip is turned outwards and tongue cupped around breast
Baby's suckling
Baby starts with small fast sucks
Baby then takes slow deep sucks
Can see or hear baby swallowing
Baby releases breast spontaneously
EARLY POST NATAL CHECK-UP LIST
Instructions: Fill in the boxes below. Indicate “y” for yes or “n” for no or code as appropriate.
DAY POSTPARTUM I 2 3 4 5 6 7 8 9 10 11 12 13
Indicate state o f lochia: (R) bright red, (B) redish brown, (P) Pink, (Y) yellowish/cream 
(N) Not examined
Lochia foul smelling?
Pain on micturition?
Perineal pain?
Urine incontinence?
Convulsions?
Visual disturbance?
Fever?
Severe fatigue?
Chest pain?
Productive cough?
Pain in the bones?
Diarrhoea? (more than 3 loose motions/ day or presence o f blood)
EARLY POST NATAL CHECK-UP LIST
Instructions: Fill in the boxes below. Indicate “y” for yes or “n” for no or code as appropriate
DAY POST PARTUM 1 2 3 4 5 6 7 8 9 10 11 12 13 14
Temperature (°c )
Dyspnoea
Cyanosis
Palpable uterus?
Tender uterus?
Indicate if wound appearance 
N=normal healing, I=inflamed, S=septic
Indicate whether breast milk has been taken on days 3,7,10 & 14 
Left Breast- 
Right Breast-
Indicate whether malaria smear has been taken on days 3 & 7
LATER POST NATAL CHECK-UP LIST
Instructions: Fill in the boxes below. Indicate “y” for yes or “n” for no or code as appropriate.
DAY POSTPARTUM 3 4 5 6 9 12 16
Date (dd/mm/yyyy)
Indicate state o f lochia: (R) bright red, (B) redish brown, (P) Pink, (Y) yellowish/cream (N) Not examined
Lochia foul smelling?
Pain on micturition?
Perineal pain?
Urine incontinence?
Convulsions?
Visual disturbance?
Fever?
Severe fatigue?
Chest pain?
Productive cough?
Pain in the bones?
Diarrhoea? (more than 3 loose motions/ day or presence o f blood)
LATER POST NATAL CHECK-UP LIST
Instructions: Fill in the boxes below. Indicate “y” for yes or “n” for no or code as appropriate
DAY POST PARTUM 3 4 5 6 9 12 16
Date (dd/mm/yyyy)
Temperature (°c )
Dyspnoea
Cyanosis
Palpable uterus?
Tender uterus?
Indicate if wound appearance 
N=normal healing, I=inflamed, S=septic
Indicate whether breast milk has been taken 
Left Breast- 
Right Breast-
Indicate whether fingerprick blood sample has been taken for malaria on weeks 6 and 16
Indicate whether venous blood has been taken for micronutrients on week 6
INFANT CHECK LIST
Instructions: Fill in the boxes below. Indicate “y” for yes or “n” for no or code as appropriate
DAY/WEEK d3 7 10 14 wk3 4 5 6 7 9 12 16
Date (dd/mm/yyyy)
Any convulsions since last visit?
Diarrhoea (more than 3 loose motions or with blood) since last visit?
Rapid breathing (more than 50 breaths/min.), measured on day o f visit
Indicate temperature (°c)
Take the following measurements in weeks 6 & 16:
Weight (Kg)
Length (Cm)
Appendix 2.2 
Zambian Pilot Study
CONSENT FORM
PILOT 
BREAST MILK SAMPLES 
CERTIFICATE OF INFORMED CONSENT FOR PARTICIPATION IN A STUDY ENTITLED 
'SYSTEMIC INFLAMMATION IN BREASTFEEDING ZAMBIAN WOMEN'
Information
Some mothers after delivery develop problems with their breasts. Examples include, sore and 
cracked nipples, redness around the breast and breast abscess. In many women this process 
develops gradually and only a few of the above are present in early stages. We call this sub- 
clinical mastitis. It is possible to prevent sub-clinical mastitis from becoming more serious by 
appropriate advice on how to breastfeed correctly and also by giving suitable and safe antibiotics. 
The aim of the study is to further understanding of the causes of sub-clinical mastitis and of any 
interventions which could decrease its prevalence, for th e  benefit of both the m other and the 
child.
W hether you have any of the above or not presently we would be grateful to be able to obtain 
from you some breast milk samples (only a few drops). We will analyse the milk for its salt 
content to  see if it has altered in your condition. There a re  no blood samples th a t will be 
required to be taken from you or your baby.
We will provide counselling on the ways of minimising th e  risk of breast problems while you are 
breastfeeding. This should decrease the risk of getting any breast problems.
Statem ent
I have been fully informed of this study and I am aw are th a t should i not wish to participate in 
this study it will not affect the treatm ent of m e or my child in any way. Equally should I consent 
to  participation I will not be given any special services or given any paym ent or gifts.
This authorisation is valid only for this study.
I hereby consent to participate.
Signature of the participant Name (in print)
If the  participant cannot write she should make a cross or a thumbprint
Signature of the research midwife Name (in print)
Q uestionnaire  for co n sen tin g  w om en partic ipating  in a s tu d y  entitled  ‘sy s tem ic  
inflam m ation in b reastfeed in g  Z am bian w o m en ’
M other’s  nam e:  T oday’s  date:.
Home a d d re s s :_______________________________________________________
M other’s  d a te  o f  b irth :_______________ M other’s  w eight:________
M other's h e ig h t:___________
Date of ad m iss io n :______ '
R eason  fo r ad m issio n :_________________________________________ ______
B aby’s  nam e:  B aby’s  d a te  of birth:.
G esta tional ag e :_____________  Sex:______ Birth weight:.
C urrent w e ig h t :_ __________
P lace of delivery: HOSPITAL DISTRICT CLINIC HOME
1. Is this your first baby? YES NO
1.1 How many children do you h a v e ? _________________
2. Did you breastfeed your last child? YES NO
2.2 For how long?___________________
3. Did you receive any information on breastfeeding from any of the following:
MOTHER YES NO
MOTHER-IN-LAW YES NO
GRANDMOTHER YES NO
HOSPITAL YES NO
CLINIC YES NO
HEALTHWORKER YES NO
FRIEND YES NO
COUNSELLOR YES NO
OTHER YES NO If yes, who.
4. What w as your baby’s first feed?_______
5. When did you put your baby to the breast for the first time?
0-1 HOUR POSTPARTUM YES NO
1-6 HOURS POSTPARTUM YES NO
6-24 HOURS POSTPARTUM YES NO
1-2 DAYS POSTPARTUM YES NO
2-4 DAYS POSTPARTUM YES NO
6. Have you experienced any pain on your b reasts and nipples whilst feeding your baby? 
YES NO If yes, which-breast: LEFT RIGHT BOTH
7. Have your b reasts felt full and/ or uncomfortable?
YES NO If yes, which breast: LEFT RIGHT BOTH
8. Do you have any injury on your areola or nipples?
YES NO If yes, which breast: LEFT RIGHT BOTH
9. Have you had any problems which have stopped you from breastfeeding your baby? 
YES NO If yes, explain:______________________________
10.Has your baby had any problems sucking? 
YES NO If yes, explain:______________
11. Does your baby prefer one breast to the other?
YES NO If yes, which breast: LEFT RIGHT
12.Do you have a schedule to feed your baby, or do you let him feed every time he w ants? 
SCHEDULE ON DEMAND
13. Does your baby sleep with you?
YES NO
14.When do you change your baby to feed from one breast to the other?
15.Do you give water or any other food or drink to your baby?
YES NO If yes, what?___________________________________ _______________
16. How do you offer it?
BOTTLE CUP Other__________________
17.How many times a day does your baby receive something different to your milk?
18.Does your baby get enough milk everytime you feed him?
YES NO If no, why?_________________________________________________ __
19.Do you ever hand express milk from your breast?
YES NO If yes, why?___________________________ _ ______________________
When w as the last time you expressed  milk?________
How often do you express milk?_________________
Mother’s  age______________
Mother’s  occupation:________
Number of years of schooling:.
Father’s  age:________________
Father’s  occupation:_________
Number of years of schooling:. 
Total monthly income:_______
Breastfeeding Technique Evaluation
The woman will breastfeed her baby whilst the researcher is assessing  her technique
1. Position of the mother and her baby:
a) Mother is relaxed and comfortable YES NO
b) Baby is close to the mother’s  body YES NO
c) Head and shoulders are facing the breast YES NO
the neck is extended
d) Mother is correctly supporting the baby, YES NO
baby’s bottom is supported
e) Mother is holding her breast correctly YES NO
2. Position of the baby’s  mouth on the areola and nipple:
a) Mouth is wide open YES NO
b) Chin is touching the breast YES NO
c) Lower lip is enclosing more of the bottom YES NO
part of the areola (more areola above the baby’s mouth).
Baby has a good mouthful
d) Lower lip is turned outwards, and tongue YES NO
cupped around breast
3. Baby’s  suckling
a) Baby starts with small fast sucks YES NO
b) Baby takes slow deep sucks YES NO
c) Can see  or hear baby swallowing YES NO
d) Baby re leases breast spontaneously YES NO
4. Other observations
Milk Sampling
Sample 1 
Left breast
Date of milk sampling:________________
Time of milk sampling:________________
Time of last feed from breast:__________
Moment of expression: BEFORE FEED
Right breast
Date of milk sampling:________________
Time of milk sampling:________________
Time of last feed from breast:__________
Moment of expression: BEFORE FEED
Sample 2 
Left breast
Date of milk sampling:________________
Time of milk sampling: ___________
Time of last feed from breast:__________
Moment of expression: BEFORE FEED
Right breast
Date of milk sampling:________________
Time of milk sampling:________________
Time of last feed from breast:__________
Moment of expression: BEFORE FEED
Sample 3 
Left breast
Date of milk sampling:________________
Time of milk sampling:________________
Time of last feed from breast:__________
Moment of expression: BEFORE FEED
Right breast
Date of milk sampling:________________
Time of milk sampling:________________
Time of last feed from breast:__________
Moment of expression: BEFORE FEED
Sample 4 
Left breast
Date of milk sampling:________________;
Time of milk sampling:________________
Time of last feed from breast:________
Moment of expression: BEFORE FEED
Right breast
Date of milk sampling:________________
Time of milk sampling:________________
Time of last feed from breast:__________
AFTER FEED
AFTER FEED
AFTER FEED
AFTER FEED
AFTER FEED 1
AFTER FEED
AFTER FEED
Moment of expression: BEFORE FEED AFTER FEED
Sample 5 
Left breast
Date of milk sampling:________________
Time of milk sampling:_________________
Time of last feed from breast;
Moment of expression: BEFORE FEED
Right breast
Date of milk sampling:________________
Time of milk sampling:________________
Time of last feed from breast:__________
Moment of expression: BEFORE FEED
Sample 6 
Left breast
Date of milk sampling:________________
Time of milk sampling: _______ ■ .
Time of last feed from breast:
Moment of expression: BEFORE FEED
Right breast
Date of milk sampling:________________
Time of milk sampling:________________
Time of last feed from breast:__________
Moment of expression: BEFORE FEED
Sample 7 
Left breast
Date of milk sampling:________________
Time of milk sampling:________________
Time of last feed from breast:__________
Moment of expression: BEFORE FEED
Right breast
Date of milk s a m p lin g :_ _____________
Time of milk sampling:________________
Time of last feed from breast:__________
Moment of expression: BEFORE FEED
AFTER FEED
AFTER FEED
AFTER FEED
AFTER FEED
AFTER FEED
AFTER FEED
Prescribed Drugs and Tonics
Please include any given by a local healer or any generally taken
Date__________Drug prescribed Dosage_______ Number given________ Daily Dose
Appendix 3 
Stage 1 Analysis
Appendix 3.1 
Descriptive Data Analysis
Appendix 3.1.1 
Zambian community study
Breast milk CRP
Table 1: Descriptive statistic of milk CRP (measured in mg/L)
Sample Description n Mean Standard
deviation
(Minimum,
Maximum)
Skewness
Day 3 left breast 53 0.75 0.70 (0.00,2.96) 1.53
Day 3 right breast 51 0.70 0.59 (0.00, 3.07) 1.86
Day 7 left breast 52 0.66 0.51 (0.10,2.65) 1.65
Day 7 right breast 52 0.74 0.68 (0.05, 3.10) 1.60
Day 10 left breast 68 0.38 0.31 (0.01, 1.58) 1.57
Day 10 right breast 66 0.35 0.29 (0.00, 1.25) 1.04
Day 14 left breast 73 0.25 0.33 (0.00, 2.01) 3.03
Day 14 right breast 69 0.24 0.27 (0.00, 1.29) 2.34
Week 3 left breast 65 0.15 0.25 (0.00, 1.57) 3.74
Week 3 right breast 66 0.18 0.26 (0.00, 1.25) 2.49
Week 4 left breast 72 0.12 0.22 (0.00, 1.59) 4.95
Week 4 right breast 69 0.12 0.20 (0.00,1.23) 3.71
Week 5 left breast 64 0.10 0.20 (0.00, 1.08) 4.02
Week 5 right breast 61 0.08 0.16 (0.00, 1.08) 4.51
Week 6 left breast 67 0.11 0.16 (0.00, 0.79) 2.20
Week 6 right breast 64 0.15 0.29 (0.00, 2.05) 4.78
Week 9 left breast 74 0.08 0.14 (0.00,0.81) 3.02
Week 9 right breast 76 0.10 0.21 (0.00,1.39) 4.28
Week 12 left breast 72 0.07 0.09 (0.00, 0.35) 1.69
Week 12 right breast 70 0.08 0.13 (0.00, 0.82) 3.21
Week 16 left breast 59 0.06 0.09 (0.00, 0.46) 2.58
Week 16 right breast 61 0.05 0.08 (0.00,0.39) 2.49
Descriptives o f milk CRP levels (mg/1) are presented above. Skewness is shown to check for normal 
distribution o f the data, if  the data is normally distributed values for skewness should fall between -1.00  
and +1.00. The above data is positively skewed.
I
Table 2: Descriptive statistic o f natural logged (In) milk CRP (measured in mg/L) to normalise the data
apart from d3 and dlO which have been square rooted. Please note that means, standard deviations and
minimum, maximum values have been represented geometrically.
Sample Description n Mean Standard
deviation
(Minimum,
Maximum)
Skewness
Day 3 left breast 53 0.60 0.16 (0.00,2.97) 0.41
Day 3 right breast 51 0.59 0.12 (0.00,3.07) 0.36
Day 7 left breast 52 0.50 2.17 (0.10,2.64) -0.16
Day 7 right breast 52 0.50 . 2.55 (0.05,3.10) -0.20
Day 10 left breast 68 0.32 0.06 (0.01,1.58) 0.50
Day 10 right breast 66 0.30 0.06 (0.10,1.12) 0.29
Day 14 left breast 73 0.13 3.48 (0.00, 2.01) -0.38
Day 14 right breast 69 0.13 3.22 (0.00, 1.28) -0.67
Week 3 left breast 65 0.05 5.66 (0.00,1.57) -0.76
Week 3 right breast 66 0.06 5.56 (0.00, 1.25) -0.74
Week 4 left breast 72 0.04 5.23 (0.00, 1.58) -0.70
Week 4 right breast 69 0.04 5.85 (0.00,1.23) -0.54
Week 5 left breast 64 0.03 5.52 (0.00,1.08) -0.26
Week 5 right breast 61 0.02 6.16 (0.00,1.08) -0.28
Week 6 left breast 67 0.03 7.09 (0.00, 0.79) -0.47
Week 6 right breast 64 0.04 6.86 (0.00, 2.05) -0.33
Week 9 left breast 74 0.02 5.94 (0.00, 0.80) -0.32
Week 9 right breast 76 0.02 6.64 (0.00, 1.39) -0.28
Week 12 left breast 72 0.02 5.87 (0.00, 0.35) -0.34
Week 12 right breast 70 0.02 6.54 (0.00,0.82) -0.27
Week 16 left breast 59 0.02 7.48 (0.00, 0.46) -0.28
Week 16 right breast 61 0.02 6.98 (0.00, 0.39) -0.31
All o f the samples have a skewness o f between -1.00 and +1.00 so samples shall now be logged (In) 
throughout, apart from d3 and dlO that were not normalised by logging but were by square rooting. They 
shall be square rooted throughout.
Now the data is normalised, it has been analysed to see whether there is a correlation between left and right 
breasts at the same time point.
Table 3: Paired sample descriptives comparing left and right breasts (logged) at same time point (CRP
measured in mg/L). Days 3 and 10 have been square rooted. Please note that means, standard deviations
and minimum, maximum values have been represented geometrically.
Sample Description n Mean Standard
deviation
Correlation
Day 3 left breast 49 0.59 0.15 0.83*
Day 3 right breast 49 0.59 0.12
Day 7 left breast 49 0.51 2.16 0.92*
Day 7 right breast 49 0.53 2.46
Day 10 left breast 64 0.34 0.06 0.85*
Day 10 right breast 64 0.31 0.06
Day 14 left breast 69 0.13 3.50 0.91*
Day 14 right breast 69 0.13 3.22
Week 3 left breast 63 0.06 5.39 0.92*
Week 3 right breast 63 0.06 5.76
Week 4 left breast 69 0.04 5.40 0.84*
Week 4 right breast 69 0.04 5.85
Week 5 left breast 58 0.03 5.55 0.82*
Week 5 right breast 58 0.02 6.17
Week 6 left breast 62 0.03 7.12 0.91*
Week 6 right breast 62 0.04 7.06
Week 9 left breast 71 0.02 6.09 0.85*
Week 9 right breast 71 0.03 6.54
Week 12 left breast 68 0.02 5.76 0.92*
Week 12 right breast 68 0.02 6.36
Week 16 left breast 58 0.01 7.33 0.79*
Week 16 right breast 58 0.01 7.02
*P < 0.0005
At all time points there is a strong correlation between left and right breasts. A paired T test has been used 
to test whether there is a difference between the two variables or not.
Table 4: Paired sample T test determining whether the means o f left and right breast at the same time point 
are not different (difference denoted by P<0.05). Mean difference and 95% Confidence Intervals (Cl) 
remain in logged (In) format and square root format for day 3. ___________________ _________ ______
Sample description n Mean difference 95% C l 
(upper, lower)
Significance
(2-tailed)
Day 3 48 -0.01 (-0.06, 0.06) 0.89
Day 7 48 -0.04 (-0.14,0.06) 0.44
Day 10 63 <0.01 (<-0.01, <0.01) 0.86
Day 14 68 -0.05 (-0.18,0.07) 0.37
Week 3 62 -0.12 (-0.29, 0.06) 0.19
Week 4 68 0.12 (-0.12, 0.35) 0.32
Week 5 57 0.06 (-0.22, 0.34) 0.66
Week 6 61 -0.19 (-0.40, 0.02) 0.08
Week 9 70 -0.05 (0.12,-0.29) 0.68
Week 12 67 -0.06 (-0.24, 0.12) 0.50
Week 16 57 -0.06 (-0.28, 0.39) 0.73
In all cases is no significant difference between the samples. Left and right breast samples have been 
averaged to give 1 sample per time point.
Table 5: Descriptive statistic o f mean (logged) left and right breast milk CRP(measured in mg/L) at each
time point except time points d3 and dlO that have been square rooted. Please note that means, standard
deviations and minimum, maximum values have been represented geometrically.
Sample Description n Mean Standard
deviation
(Minimum,
Maximum)
Skewness
Day 3 55 0.60 0.13 (0.00, 3.02) 0.36
Day 7 55 0.48 2.36 (0.05,2.64) -0.26
Day 10 70 0.31 0.06 (0.00,1.34) 0.25
Day 14 73 0.13 3.26 (0.00,1.21) -0.46
Week 3 68 0.06 5.49 (0.00,1.27) -0.81
Week 4 72 0.04 5.08 (0.00, 1.17) -0.55
Week 5 67 0.03 5.45 (0.00, 1.07) -0.26
Week 6 69 0.03 6.61 (0.00, 0.79) -0.36
Week 9 79 0.02 5.87 (0.00, 0.80) -0.24
Week 12 74 0.02 6.10 (0.00, 0.82) -0.31
Week 16 62 0.02 6.57 (0.00, 0.38) -0.27
n values are different from those o f the paired test as SPSS includes all samples including those that are not 
paired. All the data’s skewness falls between 1.00 and +1.00
Table 6: Left over rightDescriptive statistic of mean (logged) left and right breast milk CRP(measured in 
mg/L) at each time point except time points d3 and dlO that have been square rooted. Please note that 
means, standard deviations and minimum, maximum values have been represented geometrically.
Sample Description n Mean Standard
deviation
(Minimum,
Maximum)
Skewness
Day 3 104 0.88 0.61 (0.18, 1.32) 0.39
Day 7 104 0.50 2.35 (0.05, 3.10) -0.18
Day 10 134 0.75 0.49 (0.18, 1.12) 0.38
Day 14 142 0.13 3.34 (0.00,2.01) -0.51
Week 3 131 0.06 5.59 (0.00, 1.57) -0.74
Week 4 141 0.04 5.50 (0.00, 1.58) -0.61
Week 5 125 0.03 5.81 (0.00, 1.08) -0.28
Week 6 131 0.03 6.94 (0.00, 2.05) -0.40
Week 9 150 0.03 6.25 (0.00,1.39) -0.30
Week 12 142 0.02 6.16 (0.00,0.81) -0.30
Week 16 120 0.02 7.16 (0.00, 0.46) -0.29
n values are different from those o f the paired test as SPSS includes all samples including those that are not 
paired. All the data’s skewness falls between 1.00 and +1.00
Following this preliminary analysis o f the data and with physiological implications o f lactation the data has 
been regrouped as follows:
Mean L and R of day 3 and 7: Time point 1 
Mean L and R o f days 10 and 14: Time point 2 
Mean L and R of weeks 3 and 4: Time point 3 
Mean L and R o f weeks 5 and 6: Time point 4 
Mean L and R o f weeks 9 ,12 ,16: Time point 5
Table 7: Descriptive statistics o f regrouped milk CRP (mg/L) data (logged (In) data for time points 3-5 and
square rooted for time points 1 and 2. Please note means, standard deviations and min, max values have
been presented geometrically. CRP expressed in mg/L.
Sample
Description
n Mean Standard
deviation
(Minimum,
Maximum) Skewness
Time point 1 110 0.59 0.11 (0.00, 3.02) 0.52
Time point 2 143 0.24 0.06 (0.00, 1.34) 0.59
Time point 3 140 0.05 5.28 (0.00, 1.27) -0.66
Time point 4 136 0.03 6.01 (0.00, 1.07) -0.29
Time point 5 215 0.02 6.14 (0.00, 0.82) -0.28
Table 8: Left over right Descriptive statistics o f  regrouped milk CRP (mg/L) data (logged (In) data for 
time points 3-5 and square rooted for time points 1 and 2. Please note means, standard deviations and min, 
max values have been presented geometrically. CRP expressed in mg/L.
Sample
Description
n Mean Standard
deviation
(Minimum,
Maximum) Skewness
Time point 1 208 0.88 0.59 (0.18, 1.33) 0.57
Time point 2 276 0.70 0.50 (0.18, 1.19) 0.77
Time point 3 272 0.05 5.57 (0.00, 1.58) -0.66
Time point 4 256 0.03 6.39 (0.00, 2.05) -0.32
Time point 5 412 0.02 5.51 (0.00, 1.39) -0.31
Further to this analysis o f the data and with physiological implications o f lactation the data has been 
regrouped as follows:
All samples before day 14 postpartum: <dl4  
All samples from day 14 postpartum onwards: >dl4
Table 9: Left over right Descriptive statistics o f  regrouped milk CRP (mg/L) data (logged (In) data for 
> d l4  and square rooted for <dl4. Please note means, standard deviations and min, max values have been 
presented geometrically. CRP expressed in mg/L.
Sample
Description
n Mean Standard
deviation
(Minimum,
Maximum) Skewness
<dl4 342 0.47 0.11 (0.00, 3.10) 0.73
>dl4 1082 0.04 6.39 (0.00, 1.08) -0.49
Breast milk Na/K
Table 1: Descriptive statistic o f milk Na/K
Sample Description n Median Range (Minimum
Maximum)
Skewness Kurtosis
Day 3 left breast 66 0.77 3.55 (0.29, 3.84) 2.22 6.30
Day 3 right breast 65 0.76 4.01 (0.24, 4.25) 2.17 6.49
Day 7 left breast 64 0.48 6.08 (0.24, 6.32) 3.79 16.45
Day 7 right breast 63 0.53 3.78 (0.22, 4.00) 3.41 12.23
Day 10 left breast 77 0.55 4.09 (0.20,4.29) 3.10 14.03
Day 10 right breast 72 0.55 5.40 (0.23, 5.63) 2.75 7.12
Day 14 left breast 79 0.53 7.46 (0.21, 7.67) 6.06 44.64
Day 14 right breast 77 0.57 9.05 (0.20, 9.24) 4.21 18.92
Week 3 left breast 73 0.47 3.34 (0.19,3.53) 2.55 6.68
Week 3 right breast 72 0.46 7.77 (0.21, 7.98) 6.33 46.42
Week 4 left breast 75 0.44 2.18 (0.17, 2.35) 3.19 14.92
Week 4 right breast 76 0.47 13.68 (0.18,13.86 6.82 50.50
Week 5 left breast 75 0.45 13.97 (0.23,14.20 8.01 67.03
Week 5 right breast 74 0.45 12.81 (0.19,13.00 8.14 68.46
Week 6 left breast 76 0.40 16.12 (0.15, 16.27 8.25 70.33
Week 6 right breast 74 0.44 14.94 (0.21, 15.15 6.27 41.80
Week 9 left breast 89 0.45 9.01 (0.15, 9.16) 8.29 73.68
Week 9 right breast 87 0.40 13.53 (0.16, 13.69 5.09 26.00
Week 12 left breast 79 0.38 0.74 (0.13, 0.87) 0.85 0.62
Week 12 right breast 79 0.39 13.34 (0.15, 13.49 4.56 21.60
Week 16 left breast 76 0.41 4.02 (0.10, 4.13) 3.98 6.98
Week 16 right breast 76 0.37 11.70 (0.09, 11.74 17.13 52.65
Descriptives of milk Na/K.levels are presented above. Skewness is shown to check for normal distribution 
of the data, if  the data is normally distributed values for skewness should fall between -1.00 and +1.00. 
The above data is positively skewed.
Table 3: Non parametric paired sample correlations.
Sample Description n Correlation
Day 3 left breast 63 0.748**
Day 3 right breast 63
Day 7 left breast 61 0.512**
Day 7 right breast 61
Day 10 left breast 72 0.446**
Day 10 right breast 72
Day 14 left breast 76 0.612**
Day 14 right breast 76
Week 3 left breast 73 0.542**
Week 3 right breast 73
Week 4 left breast 74 0.590**
Week 4 right breast 74
Week 5 left breast 73 0.630**
Week 5 right breast 73
Week 6 left breast 73 0.442**
Week 6 right breast 73
Week 9 left breast 86 0.470**
Week 9 right breast 86
Week 12 left breast 79 0.571**
Week 12 right breast 79
Week 16 left breast 73 0.238*
Week 16 right breast 73
*P < 0.05, **P< 0.001
Table 5: Descriptive statistic o f mean (logged) left and right breast milk Na/K. Please note that means,
standard deviations and minimum, maximum values have been represented geometrically.
Sample
Description
n Median Range (Minimum,
Maximum)
Skewness Kurtosis
Day 3 68 0.77 2.52 (0.27, 2.79) 1.35 1.61
Day 7 66 0.52 4.51 (0.23, 4.73) 3.61 14.90
Day 10 77 0.64 4.60 (0.24,4.85) 3.00 10.86
Day 14 80 0.58 4.67 (0.20, 4.88) 3.06 9.77
Week 3 75 0.52 4.11 (0.24, 4.35) 3.41 15.28
Week 4 77 0.47 6.94 (0.21,7.16) 6.22 43.94
Week 5 76 0.46 7.32 (0.22, 7.54) 5.58 31.83
Week 6 77 0.45 8.40 (0.20, 8.60) 5.98 25.47
Week 9 89 0.44 6.92 (0.16,7.08) 4.28 18.01
Week 12 79 0.40 6.75 (0.17, 6.92) 4.46 20.87
Week 16 79 0.41 5.97 (0.10, 6.07) 5.42 36.00
Table 6: Descriptive statistic o f both (logged) left and right breast milk Na/K. Please note that means, 
standard deviations and minimum, maximum values have been represented geometrically.
Sample
Description
n Median Range (Minimum,
Maximum)
Skewness Kurtosis
Day 3 131 0.76 4.01 (0.24, 4.25) 2.17 6.17
Day 7 127 0.51 6.10 (0.22, 6.32) 3.84 17.39
Day 10 149 0.55 5.43 (0.20, 5.63) 3.24 11.49
Day 14 156 0.56 9.05 (0.20, 9.24) 4.94 26.92
Week 3 145 0.46 7.79 (0.19,7.98) 5.49 41.32
Week 4 151 0.47 13.69 (0.17,13.86) 9.21 94.87
Week 5 149 0.45 14.02 (0.19,14.20) 8.01 65.91
Week 6 150 0.42 16.12 (0.15,16.27) 7.10 52.53
Week 9 175 0.43 13.54 (0.15, 13.69) 6.32 41.40
Week 12 158 0.39 13.35 (0.13,13.49) 6.55 45.93
Week 16 152 0.39 11.70 (0.09,11.79) 7.76 72.05
n values are different from those o f the paired test as SPSS includes all samples including those that are not 
paired. Data is approximately normalised.
Following this preliminary analysis o f  the data and with physiological implications o f lactation the data has 
been regrouped as follows:
Mean L and R o f day 3 and 7: Time point 1 
Mean L and R o f days 10 and 14: Time point 2 
Mean L and R o f weeks 3 and 4: Time point 3 
Mean L and R o f weeks 5 and 6: Time point 4 
Mean L and R o f weeks 9 ,12 ,16: Time point 5
Table 7: Descriptive statistics of regrouped milk Na/K data (logged (In) data for all time points. Please
note means, standard deviations and min, max values have been presented geometrically.
Sample
Description
n Median Range (Minimum,
Maximum) Skewness Kurtosis
Time point 1 134 0.66 4.51 (0.23, 4.73) 2.67 9.75
Time point 2 157 0.59 4.67 (0.20, 4.88) 3.03 10.16
Time point 3 152 0.49 6.94 (0.21, 7.16) 5.56 39.85
Time point 4 153 0.46 8.40 (0.20, 8.60) 5.22 27.72
Time point 5 247 0.42 6.98 (0.10, 7.08) 4.65 22.30
Table 8: Descriptive statistics of regrouped milk Na/K data (logged (In) data for all time points left and 
right breast are not meaned, both are included. Please note means, standard deviations and min, max values 
have been presented geometrically.
Sample
Description
n Median Range (Minimum,
Maximum) Skewness Kurtosis
Time point 1 258 0.62 6.10 (0.22, 6.32) 3.14 13.19
Time point 2 305 0.55 9.05 (0.20, 9.24) 4.55 24.86
Time point 3 296 0.47 13.69 (0.17,13.86) 8.68 95.04
Time point 4 299 0.44 16.12 (0.15,16.27) 7.51 58.16
Time point 5 485 0.40 13.60 (0.09,13.69) 6.80 49.50
Further to this analysis o f the data and with physiological implications o f lactation the data has been 
regrouped as follows:
All samples before day 14 postpartum: <dl4  
All samples from day 14 postpartum onwards: >d l4
Table 9: Left over right Descriptive statistics o f  regrouped milk Na/K samples. All data presented is non 
parametric, medic
Sample
Description
n Median Range (Minimum,
Maximum) Skewness
<dl4 407 0.61 6.12 (0.02, 6.32) 3.20
>dl4 1236 0.44 16.18 (0.09, 16.27) 7.40
Breast milk IL-8
Table 1: Descriptive statistic of milk IL-8 (measured in pg/L)
Sample Description n Mean Std
dev
(Minimum,
Maximum)
Skew Kurtosis
Day 14 left breast 100 297.79 567.09 (0.00, 2654.80) 2.66 6.41
Day 14 right breast 92 478.73 1425.81 (0.00,11655.11) 5.91 42.39
Week 5 left breast 85 289.29 710.69 (0.00, 5226.64) 4.79 28.50
Week 5 right breast 89 516.33 1130.42 (0.00, 6745.92) 3.34 12.68
Week 9 left breast 94 305.42 656.91 (0.00, 3360.00) 2.92 8.25
Week 9 right breast 94 377.89 763.47 (0.00,3173.36) 2.35 4.42
Descriptives o f milk IL-8 levels (pg/L) are presented above. Skewness is shown to check for normal 
distribution o f  the data, if  the data is normally distributed values for skewness should fall between -1 .00  
and +1.00. The above data is positively skewed.
Table 2: Descriptive statistic o f natural logged (In) IL-8 milk (measured in pg/L) to normalise the data. 
Please note that means, standard deviations and minimum, maximum values have been represented 
geometrically.
Sample Description n Mean Std
dev
(Minimum,
Maximum)
Skew Kurtosis
Day 14 left breast 100 34.02 34.35 (0.00,2643.87 -1.95 3.70
Day 14 right breast 92 17.60 89.75 (0.00, 11614.39) -1.38 0.83
Week 5 left breast 85 16.25 72.91 (0.00, 5218.68) -1.49 1.14
Week 5 right breast 89 20.41 102.43 (0.00, 6768.27) -1.38 0.73
Week 9 left breast 94 12.56 96.10 (0.00,3361.02) -1.32 0.49
Week 9 right breast 94 10.62 117.77 (0.00, 3165.29) -1.10 -0.02
The data is still not normalised, however it is approaching normalisation. It has been analysed to see 
whether there is a correlation between left and right breasts at the same time point.
Table 3: Paired sample descriptives comparing left and right breasts (logged) at same time point (IL-8 
measured in pg/L). Please note that means, standard deviations and minimum, maximum values have been 
represented geometrically.
Sample Description n Mean Standard
deviation
Correlation
Day 14 left breast 92 29.48 37.67 0.264*
Day 14 right breast 92 17.60 89.76
Week 5 left breast 80 16.74 67.08 0.230*
Week 5 right breast 80 17.56 104.24
Week 9 left breast 90 13.21 94.20 0.507***
Week 9 right breast 90 9.11 121.55
*P <0.05, ***P< 0.0005
At all time points there is a strong correlation between left and right breasts. A paired T test has been used 
to test whether there is a difference between the two variables or not.
Table 4: Paired sample T test determining whether the means o f left and right breast at the same time point 
are not different (difference denoted by PO .05).
Sample description n Mean difference 95% C l 
(upper, lower)
Significance
(2-tailed)
Day 14 92 0.52 (-0.52, 1.55) 0.323
Week 5 . 80 -0.05 (-1.27, 1.18) 0.939
Week 9 90 0.37 (-0.60,1.35) 0.449
In all cases is no significant difference between the samples. Left and right breast samples have been 
averaged to give 1 sample per time point.
Table 5: Descriptive statistic o f mean (logged) mean left and right breast milk IL-8 (measured in pg/L) at 
each time point. Please note that means, standard deviations and minimum, maximum values have been 
represented geometrically.
Sample
Description
n Mean Standard
deviation
(Minimum,
Maximum)
Skewness Kurtosis
Day 14 100 26.83 21.11 (0.00, 2368.47) -1.45 2.395
Week 5 94 19.27 41.02 (0.00, 5943.18) -1.21 1.021
Week 9 98 12.11 59.75 (0.00, 2643.87) -1.15 0.49
n values are different from those o f the paired test as SPSS includes all samples including those that are not 
paired.
Table 6: Descriptive statistic o f  mean (logged) breast milk IL-8 (measured in pg/L) at each time point and 
both breasts (right under left). Please note that means, standard deviations and minimum, maximum values 
have been represented geometrically.
Sample
Description
n Mean Standard
deviation
(Minimum,
Maximum)
Skewness Kurtosis
Day 14 192 24.81 56.17 (0.00, 11614.39) -1.64 1.936
Week 5 174 18.26 86.05 (0.00, 6768.27) -1.41 0.847
Week 9 188 11.55 105.26 (0.00, 3361.02) -1.20 0.178
n values are different from those of the paired test as SPSS includes all samples including those that are not 
paired.
Table 7: Descriptive statistics o f regrouped IL-8 data (pg/mL); all data, day 14 only and weeks 5 & 9 
combined. Both left and right breasts are included.
Sample
Description
n Mean Standard
deviation
(Minimum,
maximum) Skewness
Kurtosis
All samples 554 17.46 80.64 0.00,11614.39 -1.40 0.85
Day 14 only 192 24.78 56.26 0.00,11614.39 -1.64 1.94
Weeks 5 & 9 362 14.44 95.58 0.00, 6768.27 -1.29 0.45
Breast milk factor correlations
Table 1: Paired sample T test all time points and both breasts comparing breast milk CRP and maternal 
temperature____________________________________________________________________
Sample Description n Mean Standard
deviation
Correlation
Day 3 left breast CRP 50 0.89 0.63 -0.137
Day 3 temperature .50 36.35 0.44
Day 3 right breast CRP 48 0.88 0.58 -0.058
Day 3 temperature 48 36.35 0.43
Day 7 left breast CRP 50 0.51 2.18 0.085
Day 7 temperature 50 36.41 0.46
Day 7 right breast CRP 50 0.51 2.57 -0.038
Day 7 temperature 50 36.40 0.50
Day 10 left breast CRP 67 0.75 . 0.49 -0.183
Day 10 temperature 67 36.37 0.44
Day 10 right breast CRP 65 0.74 0.49 0.307*.
Day 10 temperature 65 36.37 0.43
Week 2 left breast CRP 70 0.12 3.48 0.170
Week 2 temperature 70 36.38 0.42
Week 2 right breast CRP 68 0.13 3.25 0.196
Week 2 temperature 68 36.38 0.43
Week 3 left breast CRP 63 0.05 5.81 -0.067
Week 3 temperature 63 36.36 0.43
Week 3 right breast CRP 64 0.07 5.67 -0.107
Week 3 temperature 64 36.37 0.44
Week 4 left breast CRP 68 0.04 5.22 -0.267*
Week 4 temperature 68 36.29 0.38
Week 4 right breast CRP 66 0.04 5.84 -0.203
Week 4 temperature 66 36.29 0.38
Week 5 left breast CRP 59 0.03 5.43 0.032
Week 5 temperature 59 36.30 0.37
Week 5 right breast CRP 57 0.02 5.93 0.064
Week 5 temperature 57 36.28 0.37
Week 6 left breast CRP 66 0.03 7.19 0.096
Week 6 temperature 66 36.36 0.40
Week 6 right breast CRP 64 0.04 6.86 0.057
Week 6 temperature 64 36.38 0.39
Week 9 left breast CRP 74 0.02 5.94 0.068
Week 9 temperature 74 36.16 0.42
Week 9 right breast CRP 76 0.02 6.64 0.003
Week 9 temperature 76 36.18 0.43
Week 12 left breast CRP 70 0.02 5.79 0.231*
Week 12 temperature 70 36.25 0.39
Week 12 right breast CRP 68 0.02 6.46 0.201
Week 12 temperature 68 36.25 0.38
Week 16 left breast CRP 56 0.02 7.38 0.078
Week 16 temperature 56 36.25 0.40
Week 16 right breast CRP 58 0.02 6.76 -0.010
Week 16 temperature 58 36.23 0.44
♦PO.05
Table 2: Paired sample T test all time points comparing breast milk CRP and maternal temperature
Sample Description n Mean Standard
deviation
Correlation
Day 3 breast CRP 52 0.89 0.60 -0.155
Day 3 temperature 52 36.35 0.43
Day 7 breast CRP 53 0.49 2.37 0.064
Day 7 temperature 53 36.40 0.45
Day 10 breast CRP 69 0.74 0.49 0.235*
Day 10 temperature 69 36.38 0.43
Day 14 breast CRP 70 0.13 3.25 0.189
Day 14 temperature 70 36.38 0.42
Week 3 breast CRP 66 0.06 5.61 -0.085
Week 3 temperature 66 36.37 0.43
Week 4 breast CRP 68 0.04 5.08 -0.245*
Week 4 temperature 68 36.29 0.38
Week 5 breast CRP 62 0.03 5.34 0.045
Week 5 temperature 62 36.29 0.39
Week 6 breast CRP 68 0.03 6.70 0.114
Week 6 temperature 68 36.37 0.40
Week 9 breast CRP 79 0.02 5.87 -0.005
Week 9 temperature 79 36.17 0.43
Week 12 breast CRP 72 0.02 5.83 -0.235*
Week 12 temperature 72 36.26 0.39
Week 16 breast CRP 59 0.02 6.40 0.031
Week 16 temperature 59 36.23 0.44
*P<0.05
Table 3: Paired sample T test all time points and both breasts comparing breast milk CRP and maternal
haemoglobin
Sample Description n Mean Standard
deviation
Correlation
Day 3 left breast CRP 50 0.88 0.66 -0.345*
Day 3 haemoglobin 50 10.75 1.75
Day 3 right breast CRP 49 0.88 0.59 -0.245
Day 3 haemoglobin 49 10.84 1.71
Day 7 left breast CRP 47 0.51 2.16 -0.193
Day 7 haemoglobin 47 10.80 1.78
Day 7 right breast CRP 47 0.50 2.50 -0.218
Day 7 haemoglobin 47 10.99 1.72
*P<0.05
Table 4: Paired sample T test all time points comparing breast milk CRP and maternal haemoglobin
Sample Description n Mean Standard
deviation
Correlation
Day 3 breast CRP 52 0.88 0.60 -0.269*
Day 3 haemoglobin 52 10.72 1.72
Day 7 breast CRP 50 0.49 2.34 0.120
Day 7 haemoglobin 50 10.81 1.82
Table 5: Paired sample T test all time points and both breasts comparing breast milk CRP and breast milk
IL-8
Sample Description n Mean Standard
deviation
Correlation
Day 3 left breast CRP 73 0.13 3.51 -0.096
Day 3 left breast IL-8 73 26.21 44.55
Day 14 right breast CRP 667 0.13 3.27 0.016
Day 14 right breast IL-8 67 17.59 107.57
Week 5 left breast CRP 61 0.03 5.74 0.192
Week 5 left breast IL-8 61 16.99 66.48
Week 5 right breast CRP 59 0.02 6.23 0.054
Week 5 right breast IL-8 59 18.44 90.31
Week 9 left breast CRP 72 0.02 5.89 0.053
Week 9 left breast IL-8 72 11.97 107.67
Week 9 right breast CRP 73 0.02 6.79 0.015
Week 9 right breast IL-8 73 9.90 135.87
Table 6: Paired sample T test all time points comparing breast milk CRP and breast milk IL-8
Sample Description n Mean Standard
deviation
Correlation
Day 14 breast CRP 73 0.13 3.26 -0.023
Day 14 breast IL-8 73 23.63 26.52
Week 5 breast CRP 66 0.03 5.52 0.113
Week 5 breast IL-8 66 18.92 48.38
Week 9 breast CRP 77 0.02 • 5.96 0.041
Week 9 breast IL-8 77 11.75 72.27
Table 7: Non parametric correlations between breast milk CRP and breast milk Na/K left and right breasts
Sample Description n Correlation
Day 3 left breast 
Day 3 left
51 0.229
Day 3 right breast 
Day 3 right breast
49 0.147
Day 7 left breast 
Day 7 left breast
39 0.101
Day 7 right breast 
Day 7 right breast
37 0.359*
Day 10 left breast 
Day 10 left breast
44 -0.128
Day 10 right breast 
Day 10 right breast
42 -0.091
Week 2 left breast 
Week 2 left breast
44 0.028
Week 2 right breast 
Week 2 right breast
43 -0.083
Week 3 left breast 
Week 3 left breast
49 0.153
Week 3 right breast 
Week 3 right breast
48 0.042
Week 4 left breast 
Week 4 left breast
47 0.160
Week 4 right breast 
Week 4 right breast
49 -0.022
Week 5 left breast 
Week 5 left breast
52 0.165
Week 5 right breast 
Week 5 right breast
51 -0.021
Week 6 left breast 
Week 6 left breast
52 0.150
Week 6 right breast 
Week 6 right breast
51 0.306*
Week 9 left breast 
Week 9 left breast
55 -0.124
Week 9 right breast 
Week 9 right breast
55 -0.052
Week 12 left breast 
Week 12 left breast
50 -0.258
Week 12 right breast 
Week 12 right breast
50 -0.005
Week 16 left breast 
Week 16 left breast
50 -0.022
Week 16 right breast 
Week 16 right breast
50 -0.114
Table 8: Non parametric correlations between breast milk CRP and Na/K averaged left and right breasts
Sample Description n Correlation
Day 3 breast 53 0.194
Day 3
Day 7 
Day 7
55 0.053
Day 10 69 0.166
Day 10
Day 14 73 0.194
Day 14
Week 3 66 0.092
Week 3
Week 4 70 0.066
Week 4
Week 5 67 0.224
Week 5
Week 6 68 0.217
Week 6
Week 9 78 0.084
Week 9
Week 12 72 0.307**
Week 12
Week 16 61 -0.005
Week 16
Table 9: Non parametric correlations between breast Na/K and maternal temperature left and right breasts
Sample Description n Correlation
Day 3 left breast 
Day 3 left
64 0.022
Day 3 right breast 
Day 3 right breast
63 -0.134
Day 7 left breast 
Day 7 left breast
62 0.093
Day 7 right breast 
Day 7 right breast
61 -0.024
Day 10 left breast 
Day 10 left breast
76 -0.002
Day 10 right breast 
Day 10 right breast
71 0.031
Week 2 left breast 
Week 2 left breast
76 -0.020
Week 2 right breast 
Week 2 right breast
76 0.034
Week 3 left breast 
Week 3 left breast
73 0.200
Week 3 right breast 
Week 3 right breast
71 0.252*
Week 4 left breast 
Week 4 left breast
72 0.072
Week 4 right breast 
Week 4 right breast
73 -0.059
Week 5 left breast 
Week 5 left breast
70 0.208
Week 5 right breast 
Week 5 right breast
69 0.153
Week 6 left breast 
Week 6 left breast
68 0.046
Week 6 right breast 
Week 6 right breast
67 0.161
Week 9 left breast 
Week 9 left breast
84 0.015
Week 9 right breast 
Week 9 right breast
85 -0.047
Week 12 left breast 
Week 12 left breast
76 -0.006
Week 12 right breast 
Week 12 right breast
76 0.062
Week 16 left breast 
Week 16 left breast
72 -0.110
Week 16 right breast 
Week 16 right breast
72 -0.012
Table 10: Non parametric correlations between breast milk Na/K and maternal temperature averaged left
and right breasts
Sample Description n Correlation
Day 3 breast 66 -0.048
Day 3
Day 7 64 -0.008
Day 7
Day 10 76 0.080
Day 10
Day 14 77 0.043
Day 14
Week 3 73 0.250*
Week 3
Week 4 74 0.012
Week 4
Week 5 71 0.177
Week 5
Week 6 75 -0.040
Week 6
Week 9 87 -0.083
Week 9
Week 12 77 0.153
Week 12
Week 16 76 0.038
Week 16
Table 11: Non parametric correlations between breast milk Na/K and maternal haemoglobin left and right
breasts
Sample Description n Correlation
Day 3 left breast 62 -0.152
Day 3 left 62 -0.033
Day 3 right breast 58 0.011
Day 3 right breast 57 -0.052
Table 12: Non parametric correlations between breast milk Na/K and maternal haemoglobin averaged left 
and right breasts
Sample Description n Correlation
Day 3 breast 64 -0.078
Day 3
Day 7 60 -0.036
Day 7
Table 13: Non parametric correlations between breast milk Na/K and IL-8 both left and right breasts
Sample Description n Correlation
Day 3 left breast 
Day 3 left
77 0.106
Day 14 right breast 
Day 14 right breast
75 -0.047
Week 5 left breast 
Week 5 left breast
67 0.244*
Week 5 right breast 
Week 5 right breast
66 0.104
Week 9 left breast 
Week 9 left breast
73 0.100
Week 9 right breast 
Week 9 right breast
73 -0.009
Table 14: Non parametric correlations between breast milk CRP and Na/K averaged left and right breasts
Sample Description n Correlation
Day 14 breast 78 0.133
Day 14
Week 5 73 0.085
Week 5
Week 9 86 0.136
Week 9
Table 15: Paired sample T test all time points and both breasts comparing breast milk IL-8 and maternal 
temperature
Sample Description n Mean Standard
deviation
Correlation
Day 3 left breast IL-8 92 30.08 37.99 0.168
Day 3 temperature 92 36.39 0.44
Day 14 right breast IL-8 87 16.41 100.20 0.078
Day 14 temperature 87 36.39 0.45
Week 5 left breast IL-8 78 13.83 82.96 0.090
Week 5 temperature 78 36.29 0.37
Week 5 right breast IL-8 82 21.70 108.76 -0.102
Week 5 temperature 82 36.28 0.37
Week 9 left breast IL-8 90 11.14 101.32 0.062
Week 9 temperature 90 36.18 0.41
Week 9 right breast IL-8 91 9.56 121.90 0.026
Week 9 temperature 91 36.19 0.42
Table 16: Paired sample T test all time points comparing breast milk IL-8 and maternal temperature
Sample Description n Mean Standard
deviation
Correlation
Day 14 breast IL-8 92 23.86 26.49 0.152
Day 14 temperature 92 36.38 0.44
Week 5 breast IL-8 86 17.89 45.46 0.007
Week 5 temperature 86 36.29 0.37
Week 9 breast IL-8 94 10.75 61.79 0.053
Week 9 temperature 94 36.18 0.41
Plasma acute phase proteins
Table 1 Non-normalised data
Sample
Description
n Mean Range (Minimum,
Maximum) Skewness
Plasma CRP an 278 4.56 90.91 (0.06, 90.97) 6.91
Plasma CRP pn 196 2.91 44.71 (0.00, 44.71) 5.21
ELISA AGP an 165
ELISA AGP pn 116
COBAS AGP an 165 0.43 1.46 (0.01, 1.47) 1.43
COBAS AGP pn 116 0.57 0.98 (0.14, 1.12) 0.45
Table 2 Normalised data by natural logging (In). Data presented geometrically.
Sample
Description
n Mean Range (Minimum,
Maximum) Skewness
Plasma CRP an 278 2.58 90.31 (0.61, 90.92) -0.29
Plasma CRP pn 196 1.23 44.70 (0.00, 44.70) -1.03
ELISA AGP an 165
ELISA AGP pn 116
COBAS AGP an 165 0.34 1.47 (0.01, 1.48) -1.24
COBAS AGP pn 116 0.52 0.98 (0.14, 1.12) -0.48
Although CRP and COBAS AGP are not within +/- 1.00 skewness they are approaching normalisation. 
ELISA AGP is not so COBAS values are used throughout.
Table 3: Paired sample descriptives comparing milk CRP (mg/L) data (logged (In) data for time points 3-5 
and square rooted for time points 1 and 2) and plasma CRP (36 weeks antenatally and 6 weeks postnatally) 
at the same time points as described previously on page 4 (CRP measured in mg/L) independent of HTV 
status. Please note that as both plasma and milk CRP values have been logged means and standard 
deviations have been represented geometrically.
Sample Description n Mean Standard
deviation
Correlation
Time point 1 milk CRP 92 0.59 0.12 0.16
3 6weeks plasma CRP 92 2.69 3.35
Time point 2 milk CRP 119 0.24 0.06 0.18*
3 6weeks plasma CRP 119 2.83 3.16
Time point 3 milk CRP 116 0.05 5.05 0.23*
3 6weeks plasma CRP 116 2.66 3.22
Time point 4 milk CRP 114 0.03 6.32 0.27**
3 6weeks plasma CRP 114 2.97 3.06
Time point 5 milk CRP 182 0.02 6.15 0.19*
36weeks plasma CRP 182 2.83 3.06
*P<0.05, **P<0.005
Sample Description n Mean Standard
deviation
Correlation
Time point 1 milk CRP 85 0.64 0.12 -0.47
6weeks plasma CRP 85 1.28 3.53
Time point 2 milk CRP 114 0.26 0.06 0.28**
6weeks plasma CRP 114 1.38 4.26
Time point 3 milk CRP 113 0.05 5.46 0.48***
6weeks plasma CRP 113 1.27 4.76
Time point 4 milk CRP 115 0.03 6.17 0.63***
6weeks plasma CRP 115 1.36 5.10
Time point 5 milk CRP 165 0.02 6.17 0.50***
6weeks plasma CRP 165 1.55 4.57
**P<0.005, ***P<0.0005
How plasma CRP levels taken at weeks 36 antenatally relate to milk plasma seems difficult to interpret. 
Plasma taken at week 6 postpartum seems to be a useful guide to milk CRP levels from time point 2 
onwards. Further work is needed to see how categorising both milk CRP and plasma CRP affect this data, 
however sample size is insufficient at this stage to allow for further analysis. This is further complicated by 
missing sample data o f those with high levels o f milk CRP that need repeat analysis.
Table 4: Paired sample descriptives comparing milk CRP and plasma CRP (36 weeks antenatally and 6 
weeks postnatally) at same time points as described previously on page 4 (CRP measured in mg/L) of HTV 
status uninfected subjects. Please note that as both plasma and milk CRP values have been logged means 
and standard deviations have been represented geometrically.
Sample Description n Mean Standard
deviation
Correlation
Time point 1 milk CRP 46 0.50 0.11 0.34*
36weeks plasma CRP 46 3.13 2.53
Time point 2 milk CRP 63 0.23 0.05 0.34**
36weeks plasma CRP 63 3.42 2.29
Time point 3 milk CRP 61 0.04 5.27 0.42**
3 6weeks plasma CRP 61 2.77 2.25
Time point 4 milk CRP 61 0.02 5.41 0.50***
3 6weeks plasma CRP 61 2.97 2.27
Time point 5 milk CRP 98 0.01 6.03 0.23*
3 6weeks plasma CRP 98 3.10 2.32
*P<0.05, **P<0.005, ***P<0.0005
Sample Description n Mean Standard
deviation
Correlation
Time point 1 milk CRP 40 0.52 0.09 -0.10
6weeks plasma CRP 40 1.02 3.25
Time point 2 milk CRP 59 0.21 0.06 0.10
6weeks plasma CRP 59 1.24 3.42
Time point 3 milk CRP 56 0.04 5.43 0.35*
6weeks plasma CRP 56 1.16 3.32
Time point 4 milk CRP 57 0.02 5.49 0.50***
6weeks plasma CRP 57 1.16 3.71
Time point 5 milk CRP 82 0.02 6.09 0.30*
6weeks plasma CRP 82 1.34 3.53
*P<0.05, **P<0.005
Plasma CRP levels taken at 36 weeks antenatally correlate well with milk CRP levels at time point 1 (days 
3 and 7) in HTV uninfected and there are correlations at 6 weeks postpartum as seen when analysising 
irrespective o f HTV status. Further work is needed to see how categorising both milk CRP and plasma CRP 
affect this data, however sample size is insufficient at this stage to allow for further analysis.
Table 5: Paired sample descriptives comparing milk CRP (mg/L) data (logged (In) data for time points 3-5 
and square rooted for time points 1 and 2) and plasma CRP (36 weeks antenatally and 6 weeks postnatally) 
at same time points as described previously on page 4 (CRP measured in mg/L) o f HIV infected subjects. 
Please note that as both plasma and milk CRP values have been logged means and standard deviations have 
been represented geometrically.
Sample Description n Mean Standard
deviation
Correlation
Time point 1 milk CRP 46 0.68 0.13 0.10
3 6weeks plasma CRP 46 2.29 4.18
Time point 2 milk CRP 56 0.26 0.07 0.11
3 6weeks plasma CRP 56 2.29 4.06
Time point 3 milk CRP 55 0.07 4.69 0.15
3 6weeks plasma CRP 55 2.53 4.35
Time point 4 milk CRP 53 0.05 6.65 0.15
3 6weeks plasma CRP 53 3.00 4.01
Time point 5 milk CRP 84 0.04 5.21 0.22*
36weeks plasma CRP 84 2.53 3.97
*P<0.05
Sample Description n Mean Standard
deviation
Correlation
Time point 1 milk CRP 45 0.76 0.14 -0.08
6weeks plasma CRP 45 1.58 ' 3.71
Time point 2 milk CRP 55 0.31 0.07 0.39**
6weeks plasma CRP 55 1.54 5.26
Time point 3 milk CRP 57 0.06 5.33 0.58***
6weeks plasma CRP 57 1.40 6.42
Time point 4 milk CRP 58 0.05 6.40 0.72***
6weeks plasma CRP 58 1.58 6.55
Time point 5 milk CRP 83 0.03 5.92 0.64***
6weeks plasma CRP 83 1.80 5.70
**P<0.005, ***P<0.0005
Plasma CRP levels taken at 6 weeks postpartum correlate well with milk CRP levels at time points 2, 3, 4 
and 5 in HTV infected. However there is not the correlations at 36 weeks antenatally as seen when 
analysising irrespective o f HIV status, this may be due to a reduction in sample size. Further work is 
needed to see how categorising both milk CRP and plasma CRP affect this data, however sample size is 
insufficient at this stage to allow for further analysis.
Appendix 3.1.2 
Zambian pilot study
Breast milk biological markers
Table 1 Non-normalised data
Sample Description n Mean , Range (Minimum,
Maximum) Skewness
CRP admission (mg/L) 36 1.77 19.67 (0.00, 19.67) 4.85
CRP discharge (mg/L) 36 1.28 5.98 (0.00, 5.98) 1.96
Na/K admission 37 1.52 9.81 (0.02, 10.01) 2.59
Na/K discharge 37 0.78 8.11 (0.03, 8.14) 5.05
EL-8 admission (pg/mL) 30 3635.87 57871.48 (2.92, 57874.40) 4.35
EL-8 discharge (pg/mL) 30 3711.88 91040.53 (1.97,91042.50) 5.40
Table 2 Data normalisation by natural logging (In). Data presented geometrically
Sample Description n Mean Range (Minimum,
Maximum) Skewness
CRP admission (mg/L) 36 0.77 19.67 (0.00, 19.67) -1.28
CRP discharge (mg/L) 36 0.66 5.98 (0.00, 5.98) -1.07
EL-8 admission (pg/mL) 30 413.10 57871.48 (2.92, 57874.40) -0.29
IL-8 discharge (pg/mL) 30 187.71 91040.53 (1.97,91042.50) 0.24
Na/K data could not be normalised and so is presented categorically in the analysis (data not shown). 
Although breast milk CRP is not + /-1.00 skewness, it is approaching normalisation and so shall be logged 
throughout.
Appendix 3.1.3 
Tanzanian study
Table 1 Non-normalised data
Sample Description n Mean Range (Minimum,
Maximum) Skewness
Plasma CRP 1 month (mg/L) 82 0.82 11.90 (0.02, 11.92) 5.09
Plasma CRP 3 months (mg/L) 78 1.55 62.52 (0.03, 62.55) 8.07
Breast milk CRP 1 month (mg/L) 82 0.06 0.57 (0.00, 0.57) 4.43
Breast milk CRP 3 month (mg/L) 78 0.06 0.44 (0.00, 0.44) 4.69
Table 2 Data normalisation by natural logging (In). Data presented geometrically
Sample Description n Mean Range (Minimum,
Maximum) Skewness
Plasma CRP 1 month (mg/L) 82 0.35 11.90 (0.02, 11.92) 1.95
Plasma CRP 3 months (mg/L) 78 0.27 62.52 (0.03, 62.55) 3.64
Breast milk CRP 1 month (mg/L) 82 0.01 0.57 (0.00, 0.57) 0.30
Breast milk CRP 3 month (mg/L) 78 0.00 0.44 (0.00, 0.44) 1.07
Breast milk CRP could not be normalised so all data is presented non-parametrically.
Appendix 3.1.4 
South Africa study
Biological factors
Non-normalised data
Sample Description n Mean Range (Minimum,
Maximum) Skewness
Breast milk CRP 1 week (mg/L) 232 0.69 7.45 (0.00, 13.68) 6.59
Breast milk CRP 6 weeks (mg/L) 219 0.23 3.67 (0.00, 3.68) 5.10
Breast milk CRP 3 months (mg/L) 162 0.12 1.05 (0.00, 1.06) 2.78
Breast milk IL-8 1 week (pg/mL) 258 2525.95 149725.49 (13.51,
149738.99)
9.99
Breast milk IL-8 6 weeks (pg/mL) 234 1059.22 37806.16 (10.41,
37816.57)
6.45
Breast milk IL-8 3 months (pg/mL) 172 1055.31 31855.6 (19.20,
31874.80)
6.28
Breast milk Na/K 1 week 255 0.92 6.29 (0.14, 6.42) 3.29
Breast milk Na/K 6 weeks 233 0.95 19.14 (0.14, 19.29) 6.53
Breast milk Na/K 3 months 166 1.16 39.37 (0.13,39.49) 8.51
Breast milk RNA viral load 1 week (copies/mL) 187 19204.78 1262780.00 (0.00,
1262780.00)
9.82
Breast milk RNA viral load 6 week (copies/mL) 194 15292.46 1144388.00 (0.00,
1144388.00)
11.03
Breast milk RNA viral load 3 months (copies/mL) 160 6647.63 206959.00 (0.00,
207159.00)
6.12
Plasma CD4 count (mm3) 230 459.33 1210.00 (4.00,
1214.00)
0.502
Plasma CD 8 count (mm3) 230 832.79 3531.00 (26.00,
3557.00)
2.137
CD4/CD8 ratio 230 0.62 2.577 (0.004,
2.581)
2.107
Normalised data
Sample Description n Mean Range (Minimum,
Maximum) Kurtosis*
Breast milk CRP 1 week (mg/L)a 232 0.34 7.45 (0.00, 13.68) -0.28
Breast milk CRP 6 weeks (mg/L)8 219 0.08 3.67 (0.00, 3.68) -0.21
Breast milk CRP 3 months (mg/L)8 162 0.06 1.05 (0.00, 1.06) -0.81
Breast milk IL-8 1 week (pg/mL)8 258 291.75 149725.49 (13.51,
149738.99)
0.70
Breast milk EL-8 6 weeks (pg/mL)8 234 192.37 37806.16 (10.41,
37816.57)
1.93
Breast milk IL-8 3 months (pg/mL)8 172 . 233.71 31855.6 (19.20,
31874.80)
1.73
Breast milk Na/K 1 week 255 n/a 6.29 (0.14, 6.42) n/a
Breast milk Na/K 6 weeks 233 n/a 19.14 (0.14,19.29) n/a
Breast milk Na/K 3 months 166 n/a 39.37 (0.13,39.49) n/a
Breast milk RNA viral load 1 week (copies/mL) b 187 1093.64 1262780.00 (0.00,
1262780.00)
1.31
Breast milk RNA viral load 6 week (copies/mL)b 194 1039.91 1144388.00 (0.00,
1144388.00)
0.55
Breast milk RNA viral load 3 months (copies/mL)b 160 913.87 206959.00 (0.00,
207159.00)
-0.23
Plasma CD4 count (mm3) 230 As non­
normalised
1210.00 (4.00,
1214.00)
0.08
Plasma CD 8 count (mm3) 0 230 777.84 3531.00 (26.00,
3557.00)
2.51
CD4/CD8 ratio0 230 0.55 2.577 (0.004,
2.581)
2.00
♦Kurtosis presented as all values fall within +/-3.00
n/a: Not applicable, Na/K data could not be normalised and was categorised by ROC curve analysis (see 
Appendix 3.2)
8 Normalised by natural log (In) 
b Normalised by log baseio(log)
0 Normalised by square root
Appendix 3.2 
-ROC Curve Analysis
A Receiver Operating Characteristic curve (or ROC curve) is a plot of the true positive 
rate against the false positive rate for the different possible cut points of a diagnostic test.
An ROC curve demonstrates the tradeoff between sensitivity and specificity (any increase 
in sensitivity will be accompanied by a decrease in specificity) with the area under the 
curve being a measure of accuracy.
Eight different cut points were analysed. These cut points were independently entered 
into SPSS as baseline values and the ROC curve then computed the sensitivity and 
specificity using each value of the rating as possible cut points. The values chosen had 
the highest sensitivity without a concomitant drop in specificity (<0.9 or > 0.9).
Na/K ratio 
cut off point
Sensitivity (%) Specificity (%)
<0.4 or> 0.4 68.3 100
<0.5 or> 0.5 72.5 100
<0.6 or > 0.6 74.5 100
<0.7 or > 0 .7 78.7 100
<0.8 or > 0 .8 81.8 100
<0.9 or > 0.9 87.5 100
<1.0 or> 1.0 70.3 100
<1.2 or> 1.2 63.7 100
Appendix 4 
Stage 2 Analysis
Appendix 4.1
Principal components analysis Zambian community study
Principal components factor analysis all variables: Zambian community study
Correlation Matrix
HDENC ELECC FRIDGEC MSTATUSC EMPLOYC HEMPLOYC HHOLDC INCOMEC DECISC GRADEC
Correlation HDENC 1.000 .013 .219 .114 .265 .015 .128 .103 .084 -.116
ELECC .013 1.000 .265 -.078 -.108 .105 .128 -.148 -.281 .244
FRIDGEC .219 .265 1.000 -.009 .074 .038 -.142 -.052 -.019 .175
MSTATUSC .114 -.078 -.009 1.000 .069 .139 -.068 .678 .532 -.215
EMPLOYC .265 -.108 .074 .069 1.000 -.052 -.193 -.027 .008 .080
HEMPLOYC .015 .105 .038 .139 -.052 1.000 .162 .098 .033 .145
HHOLDC .128 .128 -.142 -.068 -.193 .162 1.000 -.084 -.037 .055
INCOMEC .103 -.148 -.052 .678 -.027 .098 -.084 1.000 .539 -.220
DECISC .084 -.281 -.019 .532 .008 .033 -.037 .539 1.000 -.402
GRADEC -.116 .244 .175 -.215 .080 .145 .055 -.220 -.402 1.000
RELIGC -.267 -.038 -.107 -.067 -.117 -.102 .110 -.073 -.046 .116
GRAVC -.027 .117 -.052 -.266 -.042 1 o> CO .036 -.420 -.320 .513
PARC -.076 .074 -.094 -.307 -.027 -.206 .013 -.427 -.346 .491
Correlation Matrix
RELIGC GRAVC PARC
Correlation HDENC -.267 -.027 -.076
ELECC -.038 .117 .074
FRIDGEC -.107 -.052 -.094
MSTATUSC -.067 -.266 -.307
EMPLOYC -.117 -.042 -.027
HEMPLOYC -.102 -.169 -.206
HHOLDC .110 .036 .013
INCOMEC -.073 -.420 -.427
DECISC -.046 -.320 -.346
GRADEC .116 .513 .491
RELIGC 1.000 .171 .115
GRAVC .171 1.000 .893
PARC .115 .893 1.000
Communalities
Initial Extraction
HDENC 1.000 .436
ELECC 1.000 .516
FRIDGEC 1.000 .458
MSTATUSC 1.000 .787
EMPLOYC 1.000 .488
HEMPLOYC 1.000 .472
HHOLDC 1.000 .346
INCOMEC 1.000 .756
DECISC 1.000 .644
GRADEC 1.000 .668
RELIGC 1.000 .361
GRAVC 1.000 .877
PARC 1.000 .867
Extraction Method: Principal Component Analysis.
Total Variance Explained
Initial Eigenvalues Extraction Sums of Squared Loadings Rotation Sums of Squared Loadings
Component Total % of Variance Cumulative % Total % of Variance Cumulative % Total % of Variance Cumulative %
1 3.346 25.741 25.741 3.346 25.741 25.741 2.331 17.930 17.930
2 1.614 12.415 38.156 1.614 12.415 38.156 2.264 17.415 35.345
3 1.440 11.075 49.231 1.440 11.075 49.231 1.619 12.452 47.797
4 1.274 9.804 59.035 1.274 9.804 59.035 1.461 11.238 59.035
5 1.116 8.582 67.616
6 .955 7.343 74.960
7 .870 6.691 81.651
8 .698 5.366 87.017
9 .513 3.944 90.961
10 .507 3.900 94.861
11 .344 2.645 97.507
12 .226 1.738 99.245
13 9.814E-02 .755 100.000
Extraction Method: Principal Component Analysis.
Component Matrix3
Component
1 2 3 4
HDENC -.180 .574 -.259 8.537E-02
ELECC .282 .469 .459 7.712E-02
FRIDGEC 1.686E-02 .676 -.001 4.654E-03
MSTATUSC -.664 2.974E-03 -.049 .586
EMPLOYC -.063 .377 -.584 3.995E-03
HEMPLOYC -.158 .287 .561 .224
HHOLDC 9.681 E-02 -.041 .568 .110
INCOMEC -.742 -.063 5.293E-03 .448
DECISC -.703 -.181 -.134 .313
GRADEC .632 .241 9.250E-02 .450
RELIGC .214 -.510 .170 .164
GRAVC .791 -.097 -.229 .435
PARC .799 -.131 -.271 .372
Extraction Method: Principal Component Analysis, 
a. 4 components extracted.
Rotated Component Matrix3
Component
1 2 3 4
HDENC -.002 .139 .645 -.014
ELECC .154 -.237 .230 .619
FRIDGEC 2.645E-02 -.089 .622 .248
MSTATUSC -.072 .877 9.700E-02 5.440E-02
EMPLOYC 9.845E-02 5.392E-02 .568 -.391
HEMPLOYC -.088 .183 7.859E-02 .652
HHOLDC 1.032E-02 -.035 -.258 .528
INCOMEC -.232 .836 2.811 E-02 4.197E-02
DECISC -.264 .740 -.033 -.156
GRADEC .730 -.153 .103 .316
RELIGC .213 1.464E-02 -.562 1.904E-02
GRAVC .903 -.204 -.113 -.090
PARC .875 -.246 -.129 -.154
Extraction Method: Principal Component Analysis. 
Rotation Method: Varimax with Kaiser Normalization.
a. Rotation converged in 6 iterations.
Component Transformation Matrix
Component 1 2 3 4
1 .711 -.689 -.127 .062
2 .017 -.120 .923 .364
3 -.230 -.090 -.362 .899
4 .664 .709 -.013 .236
Extraction Method: Principal Component Analysis. 
Rotation Method: Varimax with Kaiser Normalization.
^incipal components factor analysis: Maternal Control
Correlation Matrix
GRAVC INCOMEC MSTATUSC DECISC GRADEC RELIGC
Correlation GRAVC 1.000 -.407 -.310 -.325 .500 .172
INCOMEC -.407 1.000 .606 .603 -.287 -.070
MSTATUSC -.310 .606 1.000 .500 -.201 -.075
DECISC -.325 .603 .500 1.000 -.440 -.047
GRADEC .500 -.287 -.201 -.440 1.000 .114
RELIGC .172 -.070 -.075 -.047 .114 1.000
Commuhalities
Initial Extraction
GRAVC 1.000 .605
INCOMEC 1.000 .737
MSTATUSC 1.000 .646
DECISC 1.000 .674
GRADEC 1.000 .555
RELIGC 1.000 .570
Extraction Method: Principal Component Analysis.
Total Variance Explained
Initial Eigenvalues Extraction Sums of Squared Loadings Rotation Sums of Squared Loadings
Component Total % of Variance Cumulative % Total % of Variance Cumulative % • Total % of Variance Cumulative %
1 2.715 45.246 45.246 2.715 45.246 45.246 2.346 39.101 39.101
2 1.074 17.897 63.143 1.074 17.897 63.143 1.443 24.042 63.143
3 .897 14.942 78.085
4 .589 9.819 87.903
5 .409 6.818 94.722
6 .317 5.278 100.000
Extraction Method: Principal Component Analysis.
Component Matrix3
Component
1 2
GRAVC -.679 .380
INCOMEC .811 .283
MSTATUSC .724 .349
DECISC .794 .210
GRADEC -.635 .389
RELIGC -.197 .729
Extraction Method: Principal Component Analysis, 
a. 2 components extracted.
Rotated Component Matrix3
Component
1 2
GRAVC -.418 .656
INCOMEC .848 -.135
MSTATUSC .803 -.036
DECISC .799 -.191
GRADEC -.375 .644
RELIGC .172 .735
Extraction Method: Principal Component Analysis. 
Rotation Method: Varimax with Kaiser Normalization, 
a. Rotation converged in 3 iterations.
Component Transformation Matrix
Component 1 2
1 .881 -.474
2 .474 .881
Extraction Method: Principal Component Analysis. 
Rotation Method: Varimax with Kaiser Normalization.
Principal components factor analysis: Wealth
Correlation Matrix
FRIDGEC ELECC GRADEC HEMPLOYC EMPLOYC MEALS HDENC RELIGC
Correlation FRIDGEC 1.000 .265 .175 .038 .074 .130 .219 -.107
ELECC .265 1.000 .244 .105 -.108 .162 .013 -.038
GRADEC .175 .244 1.000 .145 .080 .212 -.116 .116
HEMPLOYC .038 .105 .145 1.000 -.052 .094 .015 -.102
EMPLOYC .074 -.108 .080 -.052 1.000 -.117 .265 -.117
MEALS .130 .162 .212 .094 -.117 1.000 -.267 . -.014
HDENC .219 .013 -.116 .015 .265 -.267 1.000 -.267
RELIGC -.107 -.038 .116 -.102 -.117 -.014 -.267 1.000
Communalities
Initial Extraction
FRIDGEC 1.000 .500
ELECC 1.000 .460
GRADEC 1.000 .424
HEMPLOYC 1.000 .145
EMPLOYC 1.000 .309
MEALS 1.000 .432
HDENC 1.000 .671
RELIGC 1.000 .332
Extraction Method: Principal Component Analysis.
Total Variance Explained
Initial Eigenvalues Extraction Sums of Squared Loadings Rotation Sums of Squared Loadings
Component Total % of Variance Cumulative % Total % of Variance Cumulative % Total % of Variance Cumulative %
1 1.686 21.081 21.081 1.686 21.081 21.081 1.664 20.805 20.805
2 1.586 19.820 40.901 1.586 19.820 40.901 1.608 20.096 40.901
3 1.054 13.179 54.080
4 .968 12.104 66.184
5 .887 11.083 77.267
6 .704 8.794 86.061
7 .587 7.337 93.398
8 .528 6.602 100.000
Extraction Method: Principal Component Analysis.
Component Matrix3
Component
1 2
FRIDGEC .322 .630
ELECC .581 .350
GRADEC .625 .182
HEMPLOYC .316 .212
EMPLOYC -.319 .455
MEALS .654 -.058
HDENC -.436 .693
RELIGC .187 -.545
Extraction Method: Principal Component Analysis, 
a. 2 components extracted.
Rotated Component Matrix3
Component
1 2
FRIDGEC .579 .406
ELECC .677 3.769E-02
GRADEC .638 -.131
HEMPLOYC .378 3.937E-02
EMPLOYC -.069 .551
MEALS .551 -.358
HDENC -.061 .817
RELIGC -.090 -.569
hxtraction Method: Principal Component Analysis. 
Rotation Method: Varimax with Kaiser Normalization.
a. Rotation converged in 3 iterations.
Component Transformation Matrix
Component 1 2
1 .884 -.468
2 .468 .884
Extraction Method: Principal Component Analysis. 
Rotation Method: Varimax with Kaiser Normalization.
Descriptives of factor analysis output (note only maternal control 2 used in final analysis)
Descriptive Statistics
N Minimum Maximum Mean Std. Skewness Kurtosis
Statistic Statistic Statistic Statistic Statistic Statistic Std. Error Statistic Std. Error
Maternal control 
1 79 -1.85300 1.23882 -.1378678 1.0167348 -.688 .271 -1.072 .535
Maternal control 
2 79 -6.46332 1.54025 -.0805373 1.0781710 -2.999 .271 15.025 .535
Wealth 1 
Wealth 2 
Valid N (listwise)
73
73
73
-3.56092
-1.47395
1.49624
7.05494
.0933631
.0082581
.8321047
1.1152312
-1.562
3.510
.281
.281
4.178
21.634
.555
.555
Descriptives to normalise wealth and maternal control 2
Descriptive Statistics
N Minimum Maximum Mean Std. Skewness Kurtosis
Statistic Statistic Statistic Statistic Statistic Statistic Std. Error Statistic Std. Error
Inverse Wealth 1 
Inverse Wealth 2
73
73
-16.17
-10.60
20.77
44.68
.5457
6.4631
5.4447
14.1228
-.719
1.915
.281
.281
5.483
2.740
.555
.555
Squ rt maternal 
control 2 79 .000 41.775 1.15422 4.75172 8.245 .271 70.868 .535
Valid N (listwise) 73
Appendix 4.2 
Principal components South Africa study
Principal components factor analysis South Africa study: all socio economic variables
Communafities
Initial Extraction
HOUSE 1.000 .730
No of rooms 1.000 .817
NOPEOP 1.000 .806
ELECTR 1.000 .813
FRIGO - 1.000 .555
TELE 1.000 .633
WATERS 1.000 .627
education of mother 1.000 .584
EMPL 1.000 .897
OCCTYP 1.000 .881
FATHPRE 1.000 .622
BIRTHS 1.000 .738
Extraction Method: Principal Component Analysis.
Total Variance Explained
Initial Eigenvalues Extraction Sums of Squared Loadings Rotation Sums of Squared Loadings
Component Total % of Variance Cumulative % Total % of Variance Cumulative % Total % of Variance Cumulative %
1 3.960 32.997 32.997 3.960 32.997 32.997 2.723 22.689 22.689
2 2.195 18.290 51.287 2.195 18.290 51.287 2.370 19.751 42.440
3 1.465 12.210 63.497 1.465 12.210 63.497 1.860 15.501 57.941
4 1.084 9.030 72.526 1.084 9.030 72.526 1.750 14.585 72.526
5 .783 6.522 79.048
6 .594 4.950 83.998
7 .456 3.800 87.798
8 .418 3.484 91.282
9 .398 3.320 94.603
10 .258 2.147 96.750
11 .218 1.815 98.565
12 .172 1.435 100.000
Extraction Method: Principal Component Analysis.
Component Matrix3
Component
1 2 3 4
HOUSE .628 .294 .334 .372
No of rooms .715 -.441 4.396E-02 -.330
NOPEOP -.596 .493 -.042 .453
ELECTR .788 .308 .241 .200
FRIGO .739 8.332E-02 2.449E-02 -.016
TELE .687 -.101 .375 -.101
WATERS .632 .309 2.870E-02 .362
education of mother .591 -.143 -.460 -.058
EMPL 5.487E-03 .858 -.163 -.366
OCCTYP .168 .824 -.215 -.356
FATHPRE -.492 6.815E-02 .611 4.443E-02
BIRTHS .200 -.150 -.702 .428
Extraction Method: Principal Component Analysis, 
a. 4 components extracted.
Rotated Component Matrix3
Component
1 2 3 4
HOUSE .853 4.898E-02 1.657E-02 -.026
No of rooms .207 .850 -.141 .180
NOPEOP -.044 -.880 .128 -.116
ELECTR .853 .241 .152 6.803E-02
FRIGO .556 .426 .128 .219
TELE .539 .571 -.062 -.112
WATERS .746 1.585E-02 .104 .245
education of mother .175 .407 6.526E-02 .619
EMPL 6.612E-02 -.158 .930 -.050
OCCTYP .156 -.057 .922 5.958E-02
FATHPRE -.083 -.288 -.146 -.715
BIRTHS 4.561 E-02 -.170 -.171 .823
Extraction Method: Principal Component Analysis. 
Rotation Method: Varimax with Kaiser Normalization.
a. Rotation converged in 6 iterations.
Component Transformation Matrix
Component 1 2 3 4
1 .711 .608 .077 .345
2 .351 -.443 .816 -.124
3 .362 .115 -.230 -.896
4 .491 -.649 -.525 .250
Extraction Method: Principal Component Analysis. 
Rotation Method: Varimax with Kaiser Normalization.
Principal components factor analysis: Wealth
Communalities
Initial Extraction
HOUSE 1.000 .573
No of rooms 1.000 .374
ELECTR 1.000 .765
FRIGO 1.000 .573
TELE 1.000 .555
WATERS 1.000 .447
Extraction Method: Principal Component Analysis.
Total Variance Explained
Initial Eigenvalues Extraction Sums of Squared Loadings
Component Total % of Variance Cumulative % Total % of Variance Cumulative %
1 3.287 54.782 54.782 3.287 54.782 54.782
2 .996 16.594 71.376
3 .557 9.280 80.656
4 .489 8.148 88.805
5 .423 7.052 95.857
6 .249 4.143 100.000
Extraction Method: Principal Component Analysis.
Component Matrix®
Compone
nt
1
HOUSE .757
No of rooms .612
ELECTR .875
FRIGO .757
TELE .745
WATERS .668
Extraction Method: Principal Component Analysis, 
a. 1 components extracted.
Rotated Component Matrix®
a. Only one component was extracted. The solution cannot be rotated.
Principal components factor analysis: Maternal Control
Communalities
Initial Extraction
NOPEOP 1.000 .834
No of rooms 1.000 .837
EMPL 1.000 .889
OCCTYP 1.000 .893
Extraction Method: Principal Component Analysis.
Total Variance Explained
Initial Eigenvalues Extraction Sums of Squared Loadings Rotation Sums of Squared Loadings
Component Total % of Variance Cumulative % Total % of Variance Cumulative % Total % of Variance Cumulative %
1 1.909 47.731 47.731 1.909 47.731 47.731 1.774 44.342 44.342
2 1.545 38.618 86.349 1.545 38.618 86.349 1.680 42.007 86.349
3 .328 8.202 94.551
4 .218 5.449 100.000
Extraction Method: Principal Component Analysis.
Component Matrix3
Component
1 2
NOPEOP .610 -.680
No of rooms cn "4 .710
EMPL .814 .477
OCCTYP .737 .592
Extraction Method: Principal Component Analysis, 
a. 2 components extracted.
Rotated Component Matrix*
Component
1 2
NOPEOP 6.840E-02 .911
No of rooms -.024 -.915
EMPL .936 .118
OCCTYP .945 -.020
Extraction Method: Principal Component Analysis. 
Rotation Method: Varimax with Kaiser Normalization, 
a. Rotation converged in 3 iterations.
Component Transformation Matrix
Component 1 2
1 .793 .610
2 .610 -.793
Extraction Method: Principal Component Analysis. 
Rotation Method: Varimax with Kaiser Normalization.
Descriptives of factor analysis output
Descriptive Statistics
N Minimum Maximum Mean Std. Skewness Kurtosis
Statistic Statistic Statistic Statistic Statistic Statistic Std. Error Statistic Std. Error
Wealth 198 -1.61552 1.55220 -1.08E-16 1.0000000 -.298 .173 -1.344 .344
Maternal control 1 270 -.69576 2.58616 -8.02E-17 1.0000000 1.200 .148 -.214 .295
Maternal control 2 
Valid N (listwise)
270
196
-3.00483 1.13221 -3.38E-17 1.0000000 -.657 .148 -.439 .295
Appendix 5 
Stage 3 Analysis
Appendix 5.1
Independent t test analysis of breast milk inflammatory factors in the Zambian
community study
102
Breast milk biological variables and HIV status
Table 1: Independent T test to check for differences of milk CRP (mg/L) data (logged (In) data for time
points 3-5 and square rooted for time points 1 and 2, between groups (HIV+ and HTV-), please note that
means, standard deviations and min, max values have been presented geometrically.
Sample Description n Mean Standard
deviation
(Minimum,
maximum)
Skewness Significance
(2-tailed)*
Time point 1 HTV- 104 0.49 0.10 (0.01,2.33) 0.57 0.03
Time point 1 HTV+ 104 0.70 0.12 (0.00, 3.02) 0.43
Time point 2 HTV- 146 0.21 0.05 (0.01, 1.00) 0.62 0.14
Time point 2 HTV+ 130 0.27 0.07 (0.00, 1.34) 0.50
Time point 3 HIV- 133 0.04 5.04 (0.00, 0.84) -0.55 0.43
Time point 3 HTV+ 139 0.05 5.55 (0.00, 1.27) -0.79
Time point 4 HIV- 132 0.02 5.25 (0.00, 0.45) -0.11 0.01
Time point 4 HTV+ 124 0.04 6.38 (0.00, 1.07) -0.60
Time point 5 HTV- 213 0.01 6.18 (0.00,0.70) -0.02 0.001
Time point 5 HTV+ 199 0.03 5.57 (0.00, 0.82) -0.57
*Equal variance assumed.
Table 2: Independent T test to check for differences of milk IL-8 (pg/L), both breasts, data (logged (In) 
data for all time points, between groups (HIV+ and HTV-), please note that means, standard deviations and 
min, max values have been presented geometrically.
Sample
Description
n Mean Standard
deviation
95% Confidence 
Interval
Significance
(2-tailed)*
All HIV- 282 26.84 54.05 . (0.16, 1.62) 0.017
All HIV+ 272 11.02 113.20
Day 14 HIV- 101 3.12 33.12 (-0.54,1.76) 0.305
Day 14 HTV+ 91 17.99 93.69
Week5&9 HTV- 181 24.05 70.11 (0.08, 1.96) 0.033
Week5&9HIV+ 181 8.67 122.73
*Equal variance assumed.
Table 3: Independent T test to check for differences o f milk Na/K data (logged (In) data for all time points, 
data is not meaned, both breasts are included) between groups (HIV+ and HTV-), please note that means, 
standard deviations and min, max values have been presented geometrically.
Sample Description n Mean (Minimum,
maximum)
Significance
(2-tailed)*
Time point 1 HIV- 
Time point 1 HTV+
131
127
0.62 (0.22, 6.32) 0.591
Time point 2 HTV- 
Time point 2 HTV+
160
145
0.55 (0.20, 9.24) 0.729
Time point 3 HTV- 
Time point 3 HIV+
154
142
0.47 (0.17,13.86) 0.013
Time point 4 HTV- 
Time point 4 HTV+
142
157
0.44 (0.15, 16.27) <0.001
Time point 5 HTV- 
Time point 5 HIV+
229
256
0.40 (0.09, 13.69) 0.025
* Equal variance assumed.
Appendix 5.2
Independent t test analysis of morbidity in the Zambian community study
Breast milk biological variables and morbidity 
Morbidity measured over 16 weeks postpartum
Following this preliminary analysis data was further analysed according to the following morbidity 
groupings:
A) Healthy: ‘no morbidity’, ‘seeking advice about morbidity’, ‘treated with panadol and Fe’
Ever sick: ‘antibiotics, antimalarials’, ‘ongoing morbidity’, ‘UTH recovered’, UTH ongoing 
morbidity’. At any time over 16 weeks postpartum.
B) Healthy: ‘no morbidity’
Ever sick: ‘seeking advice about morbidity’, ‘treated with panadol and Fe’, ‘antibiotics, 
antimalarials’, ‘ongoing morbidity’, ‘UTH recovered’, UTH ongoing morbidity’. At any time over 
16 weeks postpartum.
Table 1 A: Independent T test to check for differences o f milk CRP (mg/L) data (logged (In) data for time 
points 3-5 and square rooted for time points 1 and 2, between groups (healthy or ever sick) independent of 
HIV status, please note that means and standard deviations have been presented geometrically.
Sample Description n Mean Standard
deviation
Significance
(2-tailed)*
Time point 1 healthy 65 0.48 0.09 0.001
Time point 1 ever sick 41 0.83 0.13
Time point 2 healthy 85 0.20 0.05 0.016
Time point 2 ever sick 55 0.31 0.07
Time point 3 healthy 90 0.04 5.35 0.040
Time point 3 ever sick 48 0.07 4.99
Time point 4 healthy 80 0.03 6.03 0.395
Time point 4 ever sick 55 0.04 5.75
Time point 5 healthy 123 0.02 6.15 0.003
Time point 5 ever sick 87 0.04 5.20
*Equal variance assumed.
Table IB: Independent T test to check for differences o f milk CRP (mg/L) data (logged (In) data for time 
points 3-5 and square rooted for time points 1 and 2, between groups (healthy or ever sick) independent of 
HIV status, please note that means and standard deviations have been presented geometrically.
Sample Description n Mean Standard
deviation
Significance
(2-tailed)*
Time point 1 healthy 33 0.54 0.10 0.37
Time point 1 ever sick 73 0.64 0.12
Time point 2 healthy 45 0.22 0.06 0.38
Time point 2 ever sick 95 0.25 0.06
Time point 3 healthy 50 0.04 4.58 0.40
Time point 3 ever sick 88 0.05 5.81
Time point 4 healthy 46 0.02 6.53 0.28
Time point 4 ever sick 89 0.03 5.59
Time point 5 healthy 71 0.01 5.81 0.002
Time point 5 ever sick 139 0.03 5.69
*Equal variance assumed.
Table 2A: Independent T test to check for differences of milk CRP (mg/L) between groups (healthy or ever
sick) for HIV uninfected subjects, please note that means and standard deviations have been presented
geometrically.
Sample Description n Mean Standard
deviation
Significance
(2-tailed)*
Time point 1 healthy 39 0.51 0.10 0.99
Time point 1 ever sick 11 0.51 0.09
Time point 2 healthy 50 0.20 0.05 0.27
Time point 2 ever sick 21 0.26 0.07.
Time point 3 healthy 50 0.04 5.38 0.81
Time point 3 ever sick 17 0.04 4.74
Time point 4 healthy 47 0.02 5.36 0.78
Time point 4 ever sick 21 0.02 4.70
Time point 5 healthy 78 0.01 6.24 0.16
Time point 5 ever sick 27 0.02 4.90
*Equal variance assumed.
Table 2B: Independent T test to check for differences o f milk CRP (mg/L) data (logged (In) data for time 
points 3-5 and square rooted for time points 1 and 2, between groups (healthy or ever sick) for HTV 
uninfected subjects, please note that means and standard deviations have been presented geometrically.
Sample Description n Mean Standard
deviation
Significance
(2-tailed)*
Time point 1 healthy 25 0.54 0.10 0.58
Time point 1 ever sick 25 0.47 0.10
Time point 2 healthy 28 0.21 0.05 0.98
Time point 2 ever sick 43 0.21 0.06
Time point 3 healthy 31 0.03 4.63 0.30
Time point 3 ever sick 36 0.05 5.62
Time point 4 healthy 28 0.01 5.03 0.06
Time point 4 ever sick 40 0.03 4.87
Time point 5 healthy 49 0.01 5.77 0.01
Time point 5 ever sick 56 0.02 5.61
*Equal variance assumed.
The decreasing sample sizes makes data difficult to interpret at this stage. Please note these are only
approximate morbidity categories used for mid point analyses only and may not be suitable for final
analyses.
Table 3 A: Independent T test to check for differences of milk CRP (mg/L) between groups (healthy or ever
sick) for HIV infected subjects, please note that means and standard deviations have been presented
geometrically.
Sample Description n Mean Standard
deviation
Significance
(2-tailed)*
Time point 1 healthy 26 0.44 0.07 0.0001
Time point 1 ever sick 30 0.97 0.13
Time point 2 healthy 35 0.21 0.06 0.06
Time point 2 ever sick 34 0.34 0.07
Time point 3 healthy 40 0.03 5.35 0.006
Time point 3 ever sick 31 0.10 4.85
Time point 4 healthy 33 0.04 6.68 0.80
Time point 4 ever sick 34 0.05 6.25
Time point 5 healthy 45 0.02 5.80 0.10
Time point 5 ever sick 60 0.04 5.26
*Equal variance assumed.
Table 3B: Independent T test to check for differences o f milk CRP (mg/L) between groups (healthy or ever 
sick) for HIV infected subjects, please note that means and standard deviations have been presented 
geometrically.
Sample Description n Mean Standard
deviation
Significance
(2-tailed)*
Time point 1 healthy 8 0.52 0.12 0.53
Time point 1 ever sick 48 0.73 0.12
Time point 2 healthy 17 0.22 0.08 0.74
Time point 2 ever sick 52 0.29 0.07
Time point 3 healthy 19 0.06 4.49 0.44
Time point 3 ever sick 52 0.05 6.04
Time point 4 healthy 18 0.06 6.88 0.65
Time point 4 ever sick 49 0.04 6.25
Time point 5 healthy 22 0.03 5.17 0.98
Time point 5 ever sick 83 0.04 5.69
*Equal variance assumed.
The decreasing sample sizes makes data difficult to interpret at this stage. Please note these are only
approximate morbidity categories used for mid point analyses only and may not be suitable for final
analyses.
Table 4A: Independent T test to check for differences o f milk IL-8 data (pg/L) logged (In) data for all time
points, between groups (healthy or ever sick) independent of HIV status, please note that means and
standard deviations have been presented geometrically.
Sample Description n Mean Standard
deviation
95% C l Significance
(2-tailed)*
All samples well 328 18.62 85.03 (-0.50,1.02) 0.501
All samples sick 215 14.37 75.62
Day 14 well 116 22.92 69.46 (-1.23, 1.19) 0.976
Day 14 sick 71 23.35 42.85
Week 5 & 9 well 212 16.62 95.16 (-0.58, 1.35) 0.434
Week 5 & 9 sick 144 11.31 122.73
*Equal variance assumed.
Table 4B: Independent T test to check for differences of milk IL-8 data (pg/L) logged (In) data for all time 
points, between groups (healthy or ever sick) independent o f HIV status, please note that means and 
standard deviations have been presented geometrically.
Sample Description n Mean Standard
deviation
95% Cl Significance
(2-tailed)*
All samples well 182 14.89 ' 84.07 (-0.97, 0.60) 0.649
All samples sick 361 17.87 79.44
Day 14 well 65 16.60 72.81 (-1.73,0.72) 0.419
Day 14 sick 122 27.52 50.93
Week 5 & 9 well 117 14.02 92.45 (-1.03,0.99) 0.967
Week 5 & 9 sick 239 14.32 97.28
*Equal variance assumed.
Table 5A: Independent T test to check for differences o f milk IL-8 data (pg/L) (logged (In)) data for all
time points, between groups (healthy or ever sick) of HIV uninfected subjects, please note that means and
standard deviations have been presented geometrically.
Sample Description n Mean Standard
deviation
95% C l Significance 
(2-tailed) *
All samples well 300 15.77 72.01 (-2.91, -0.78) 0.001
All samples sick 71 ' 99.99 13.79
Day 14 well 71 17.79 45.43 (-3.50, -0.31) 0.020
Day 14 sick 25 119.15 7.90
Week 5 & 9 well 129 14.77 92.16 (-3.23, -0.41) 0.012
Week 5 & 9 sick 46 90.90 18.16
*Equal variance assumed.
Table 5B: Independent T test to check for differences of milk IL-8 data (pg/L) (logged (In)) data for all 
time points, between groups (healthy or ever sick) o f HTV uninfected subjects, please note that means and 
standard deviations have been presented geometrically.
Sample Description n Mean Standard
deviation
95% C l Significance
(2-tailed)*
All samples well 120 9.69 78.44 (-2.68, -0.80) <0.001
All samples sick 151 55.37 32.97
Day 14 well 43 13.61 43.89 (-2.80, 0.04) 0.057
Day 14 sick 53 54.20 25.30
Week 5 & 9 well 77 8.01 106.51 (-3.19, -0.70) 0.002
Week 5 & 9 sick 99 56.02 38.36
*Equal variance assumed.
Table 6 A: Independent T test to check for differences o f milk IL-8 data (pg/L) (logged (In)) data for all
time points, between groups (healthy or ever sick) o f HIV infected subjects, please note that means and
standard deviations have been presented geometrically.
Sample Description n Mean Standard
deviation
95% C l Significance
(2-tailed)*
All samples well 128 24.14 109.51 (0.36, 2.59) 0.010
All samples sick 144 5.52 105.60
Day 14 well 45 34.21 128.36 (-0.62,3.15) 0.185
Day 14 sick 46 9.63 64.89
Week 5 & 9 well 83 19.99 102.17 (0.15, 2.95) 0.031
Week 5 & 9 sick 98 4.25 130.31
*Equal variance assumed.
Table 6B: Independent T test to check for differences o f milk IL-8 data (pg/L) (logged (In)) data for all 
time points, between groups (healthy or ever sick) of HIV infected subjects, please note that means and 
standard deviations have been presented geometrically.
Sample Description n Mean Standard
deviation
95% C l Significance
(2-tailed)*
All samples well 
All samples sick
62
210
34.23
7.92
88.37
116.15
(0.13,2.80) 0.032
Day 14 well 22 24.49 183.94 (-1.82,2.62) 0.719
Day 14 sick 69 16.35 74.03
Week 5 & 9 well 40 41.15 59.34 (0.32, 3.68) 0.020
Week 5 & 9 sick 141 5.55 136.92
*Equal variance assumed.
Table 7A: Independent T test to check for differences o f milk Na/K data (logged (In) data for all time
points, left and right breasts are both presented, between groups (healthy or ever sick) independent of HIV
status, please note that samples analysed non parametrically (Mann-Whitney test).
Sample Description n Mean (Min, Max) Significance
(2-tailed)*
Time point 1 healthy 
Time point 1 ever sick
150
94
0.62 (0.22, 6.32) 0.021
Time point 2 healthy 
Time point 2 ever sick
188
112
0.55 (0.20, 9.24) 0.636
Time point 3 healthy 
Time point 3 ever sick
190
102
0.47 (0.17, 13.86) 0.036
Time point 4 healthy 
Time point 4 ever sick
174
118
0.44 (0.15, 16.27) 0.171
Time point 5 healthy 
Time point 5 ever sick
273
200
0.40 (0.09, 13.69) 0.535
*Equal variance assumed.
Table 7B: Independent T test to check for differences o f milk Na/K data (logged (In) data for all time 
points, left and right breasts are both presented, between groups (healthy or ever sick) independent o f HTV 
status, please note that samples analysed non parametrically (Mann-Whitney test).
Sample Description n Median (Min, Max) Significance
(2-tailed)*
Time point 1 healthy 
Time point 1 ever sick
81
163
0.62 (0.22, 6.32) 0.900
Time point 2 healthy 
Time point 2 ever sick
103
197
0.55 (0.20, 9.24) 0.515
Time point 3 healthy 
Time point 3 ever sick
111
181
0.47 (0.17, 13.86) 0.075
Time point 4 healthy 
Time point 4 ever sick
96
196
0.44 (0.15,16.27) 0.097
Time point 5 healthy 
Time point 5 ever sick
157
316
0.40 (0.09, 13.69) 0.056
*Equal variance assumed.
Table 8 A: Independent T test to check for differences o f milk Na/K data (logged (In) data for all time
points, left and right breasts are both presented, between groups (healthy or ever sick) for HIV uninfected,
please note that samples analysed non parametrically (Mann-Whitney test).
Sample Description n Median (Min, Max) Significance
(2-tailed)*
Time point 1 healthy 
Time point 1 ever sick
92
25
0.62 (0.24,2.53) 0.157
Time point 2 healthy 
Time point 2 ever sick
114
41
0.57 (0.20, 7.12) 0.125
Time point 3 healthy 
Time point 3 ever sick
117
33
0.43 (0.18, 13.86) 0.162
Time point 4 healthy 
Time point 4 ever sick
99
40
0.40 (0.15,2.50) 0.201
Time point 5 healthy 
Time point 5 ever sick
160
59
0.39 (0.13, 11.79) 0.583
*Equal variance assumed.
Table 8B: Independent T test to check for differences o f milk Na/K data (logged (In) data for all time 
points, left and right breasts are both presented, between groups (healthy or ever sick) for HIV uninfected 
subjects, please note that samples analysed non parametrically (Mann-Whitney test).
Sample Description n Median (Min, Max) Significance
(2-tailed)*
Time point 1 healthy 67 0.62 (0.24, 2.53) 0.961
Time point 1 ever sick 60
Time point 2 healthy 66 0.57 (0.20,7.12) 0.703
Time point 2 ever sick 89
Time point 3 healthy 73 0.43 (0.18, 13.86) 0.600
Time point 3 ever sick 77
Time point 4 healthy 60 0.40 (0.15, 2.50) 0.818
Time point 4 ever sick 79
Time point 5 healthy 102 0.39 (0.13, 11.79) 0.464
Time point 5 ever sick 117
*Equal variance assumed.
Table 9A: Independent T test to check for differences of milk Na/K data (logged (In) data for all time
points, left and right breasts are both presented, between groups (healthy or ever sick) for HIV infected
subjects, please note that samples analysed non parametrically (Mann-Whitney test).
Sample Description n Median (Min, Max) Significance
(2-tailed)*
Time point 1 healthy 58 0.63 (0.22, 6.32) 0.028
Time point 1 ever sick 69
Time point 2 healthy 74 0.54 (0.21, 9.24) 0.588
Time point 2 ever sick 71
Time point 3 healthy 73 0.49 (0.17, 7.98) 0.472
Time point 3 ever sick 69
Time point 4 healthy 75 0.50 (0.17, 16.27) 0.560
Time point 4 ever sick 78
Time point 5 healthy 113 0.43 (0.09, 13.69) 0.741
Time point 5 ever sick 114
*Equal variance assumed.
Table 9B: Independent T test to check for differences o f milk Na/K data (logged (In) data for all time 
points, left and right breasts are both presented, between groups (healthy or ever sick) for HIV infected 
subjects, please note that samples analysed non parametrically (Mann-Whitney test).
Sample Description n Median (Min, Max) Significance
(2-tailed)*
Time point 1 healthy 
Time point 1 ever sick
24
103
0.63 (0.22, 6.32) 0.635
Time point 2 healthy 
Time point 2 ever sick
37
108
0.54 (0.21,9.24) 0.060
Time point 3 healthy 
Time point 3 ever sick
38
104
0.49 (0.17,7.98) 0.024
Time point 4 healthy 
Time point 4 ever sick
36
117
0.50 (0.17, 16.27) 0.267
Time point 5 healthy 
Time point 5 ever sick
55
199
0.43 (0.09, 13.69) 0.008
*Equal variance assumed.
The decreasing sample sizes makes data difficult to interpret at this stage. Please note these are only
approximate morbidity categories used for mid point analyses only and may not be suitable for final
analyses.
Time point specific morbidity
Healthy: ‘no morbidity’
Ever sick: ‘seeking advice about morbidity’, ‘treated with panadol and Fe’, ‘antibiotics, antimalarials’, 
‘ongoing morbidity’, ‘UTH recovered’, UTH ongoing morbidity’.
Table 1: Independent T test to check for differences o f milk CRP (mg/L) data (logged (In) data for time 
points 3-5 and square rooted for time points 1 and 2, between groups (healthy or ever sick) independent of 
HIV status, left and right breast presented. Please note that means and standard deviations have been 
presented geometrically.
Sample Description n Mean Standard
deviation
Significance
(2-tailed)*
Time point 1 healthy 91 0.47 0.09 0.61
Time point 1 ever sick 50 0.71 0.10
Time point 2 healthy 208 0.23 0.06 0.24
Time point 2 ever sick 41 0.25 0.09
Time point 3 healthy 192 0.05 5.58 0.91
Time point 3 ever sick 63 0.04 5.72
Time point 4 healthy 200 0.03 6.08 0.97
Time point 4 ever sick 38 0.02 6.83
Time point 5 healthy 335 0.02 6.18 0.15
Time point 5 ever sick 48 0.03 8.13
♦Equal variance assumed.
Table 2: Independent T test to check for differences o f milk IL-8 data (pg/L) (logged (In)) data for all time 
points, between groups (healthy or ever sick) independent o f HTV status, please note that means and 
standard deviations have been presented geometrically.
Sample Description n Mean Standard
deviation
Significance
(2-tailed)*
Day 14 well 137 19.15 76.62 0.16
Day 14 sick 30 22.34 39.30
Week 5 well 133 15.18 105.93 0.13
Week 5 sick 29 35.75 47.95
Week 9 well 151 12.77 86.41 0.02
Week 9 sick 24 3.95 287.01
♦Equal variance assumed.
Table 3: Independent T test to check for differences of milk Na/K data (logged (In) data for all time points,
left and right breasts are both presented, between groups (healthy or ever sick) independent of HIV status,
please note that samples analysed non parametrically (Mann-Whitney test).
Sample Description n Median (Min, Max) Significance
(2-tailed)*
Time point 1 healthy 
Time point 1 ever sick
104
71
0.62 (0.22, 6.32) 0.30
Time point 2 healthy 
Time point 2 ever sick
238
44
0.55 (0.20, 9.24) 0.01
Time point 3 healthy 
Time point 3 ever sick
217
61
0.47 (0.17,13.86) 0.69
Time point 4 healthy 
Time point 4 ever sick
230
42
0.44 (0.15, 16.27) 0.61
Time point 5 healthy 
Time point 5 ever sick
407
55
0.40 (0.09, 13.69) 0.09
♦Equal variance assumed.
Table 4: Independent T test to check for differences of milk CRP (mg/L) data (logged (In) data for time 
points 3-5 and square rooted for time points 1 and 2, between groups (healthy or ever sick) in HIV 
uninfected women, left and right breast presented. Please note that means and standard deviations have 
been presented geometrically.
Sample Description n Mean Standard
deviation
Significance
(2-tailed)*
Time point 1 healthy 38 0.36 0.06 0.23
Time point 1 ever sick 31 0.61 0.10
Time point 2 healthy 104 0.21 0.05 0.84
Time point 2 ever sick 23 0.17 0.05
Time point 3 healthy 98 0.05 5.19 0.40
Time point 3 ever sick 29 0.03 5.06
Time point 4 healthy 102 0.02 5.65 0.66
Time point 4 ever sick 18 0.01 5.14
Time point 5 healthy 181 0.01 6.19 0.61
Time point 5 ever sick 20 0.02 6.21
♦Equal variance assumed.
Table 5: Independent T test to check for differences o f milk IL-8 data (pg/L) (logged (In)) data for all time 
points, between groups (healthy or ever sick) in HTV uninfected women, please note that means and 
standard deviations have been presented geometrically.
Sample Description n Mean Standard
deviation
Significance
(2-tailed)*
Day 14 well 64 28.96 42.48 0.55
Day 14 sick 20 16.14 31.50
Week 5 well 64 30.17 61.51 0.22
Week 5 sick 16 74.90 23.40
Week 9 well 76 10.03 118.72 0.03
Week 9 sick 8 172.53 4.34
♦Equal variance assumed.
Table 6: Independent T test to check for differences o f milk Na/K data (logged (In) data for all time points,
left and right breasts are both presented, between groups (healthy or ever sick) in HIV uninfected women,
please note that samples analysed non parametrically (Mann-Whitney test).
Sample Description n Median (Min, Max) Significance
(2-tailed)*
Time point 1 healthy 
Time point 1 ever sick
.42
40
0.62 (0.24, 2.53) 0.93
Time point 2 healthy 
Time point 2 ever sick
117
26
0.57 (0.20, 7.12) 0.08
Time point 3 healthy 
Time point 3 ever sick
117
29
0.43 (0.18, 13.86) 0.88
Time point 4 healthy 
Time point 4 ever sick
111
17
0.40 (0.15,2.50) 0.66
Time point 5 healthy 
Time point 5 ever sick
204
17
0.39 (0.13, 11.79) 0.93
*Equal variance assumed.
Table 7: Independent T test to check for differences o f milk CRP (mg/L) data (logged (In) data for time 
points 3-5 and square rooted for time points 1 and 2, between groups (healthy or ever sick) in HIV infected 
women, left and right breast presented. Please note that means and standard deviations have been presented 
geometrically.
Sample Description n Mean Standard
deviation
Significance
(2-tailed)*
Time point 1 healthy 53 0.56 0.11 0.84
Time point 1 ever sick 19 0.89 0.10
Time point 2 healthy 104 0.25 0.06 0.17
Time point 2 ever sick 18 0.37 0.12
Time point 3 healthy 94 0.05 6.06 0.91
Time point 3 ever sick 34 0.06 6.16
Time point 4 healthy 98 0.04 6.21 0.89
Time point 4 ever sick 20 0.05 6.56
Time point 5 healthy 154 0.03 5.63 0.04
Time point 5 ever sick 28 0.04 16.76
*Equal variance assumed.
Table 8: Independent T test to check for differences o f milk IL-8 data (pg/L) (logged (In)) data for all time 
points, between groups (healthy or ever sick) in HIV infected women, please note that means and standard 
deviations have been presented geometrically.
Sample Description n Mean Standard
deviation
Significance
(2-tailed)*
Day 14 well 73 13.32 120.70 0.35
Day 14 sick 10 42.81 66.30
Week 5 well 69 8.02 157.97 0.23
Week 5 sick 13 14.39 96.66
Week 9 well 75 16.32 62.19 0.001
Week 9 sick 16 0.60 422.19
*Equal variance assumed.
Table 9: Independent T test to check for differences o f milk Na/K data (logged (In) data for all time points,
left and right breasts are both presented, between groups (healthy or ever sick) in HIV infected women,
please note that samples analysed non parametrically (Mann-Whitney test).
Sample Description n Median (Min, Max) Significance
(2-tailed)*
Time point 1 healthy 
Time point 1 ever sick
62
31
0.63 (0.22,6.32) 0.13
Time point 2 healthy 
Time point 2 ever sick
121
18
0.54 (0.21,9.24) 0.07
Time point 3 healthy 
Time point 3 ever sick
100
32
0.49 (0.17, 7.98) 0.57
Time point 4 healthy 
Time point 4 ever sick
119
25
0.50 (0.17, 16.27) 0.82
Time point 5 healthy 
Time point 5 ever sick
203
38
0.43 (0.09, 13.69) 0.08
*Equal variance assumed.
Appendix 5.3 
Forward conditional stepwise regression analysis 
Zambian community study
Stepwise forward regressional logistic regression: non biological variables
Case Processing Summary
Unweighted Cases3 N Percent
Selected Cases Included in Analysis 1680 87.5
Missing Cases 240 12.5
Total 1920 100.0
Unselected Cases 0 .0
Total 1920 100.0
a. If weight is in effect, see classification table for the total number of cases.
Dependent Variable Encoding
Oriqinal Value Internal Value
0 0
1 1
Categorical Variables Codings
Parameter
Frequency (1)
infant sex (1=f, 0 784 1.000
1=m) 1 896 .000
Block 0: Beginning Block
Classification Tablea,b
Observed
Predicted
HIV Percentage
Correct0 1
Step 0 HIV 0 848 0 100.0
1 832 0 .0
Overall Percentage 50.5
a. Constant is included in the model.
b. The cut value is .500
Variables in the Equation
S.E. Wald df Sig. Exp(B)
Step 0 Constant -.019 .049 .152 .696 .981
Variables not in the Equation
Step
0
Variables maternal age 
infant sex 
(ref=female) 
maternal weight 
an
maternal height 
an
blood pressure 
sys an
blood pressure 
dys an
maternal control 
wealth 1 
wealth 2
Overall Statistics
Score
71.434
80.508
61.372
2.939
21.392
7.658
.004
12.047
17.552
309.870
df Sig.
.000
.000
.000
.086
.000
.006
.947
.001
.000
.000
Block 1: Method = Forward Stepwise (Conditional)
Omnibus Tests of Model Coefficients
Chi-square df Sig.
Step 1 Step 81,160 1 .000
Block 81.160 1 .000
Model 81.160 1 .000
Step 2 Step 77.434 1 .000
Block 158.594 2 .000
Model 158.594 2 .000
Step 3 Step 102.656 1 .000
Block 261.250 3 .000
Model 261.250 3 .000
Step 4 Step 39.954 1 .000
Block 301.203 4 .000
Model 301.203 4 .000
Step 5 Step 17.685 1 .000
Block 318.888 5 .000
Model 318.888 5 .000
Step 6 Step 20.289 1 .000
Block 339.177 6 .000
Model 339.177 6 .000
Step 7 Step 4.709 1 .030
Block . 343.886 7 .000
Model 343.886 7 .000
Model Summary
Step
-2 Log 
likelihood
Cox & Snell 
R Square
Nagelkerke R 
Square
1 2247.662 .047 .063
2 2170.228 .090 .120
3 2067.573 .144 .192
4 2027.619 .164 .219
5 2009.934 .173 .231
6 1989.645 .183 .244
7 1984.936 .185 .247
Classification Table3
Observed
Predicted
HIV Percentage
Correct0 1
Step 1 HIV 0 544 304 64.2
1 352 480 57.7
Overall Percentage 61.0
Step 2 HIV 0 480 368 56.6
1 384 448 53.8
Overall Percentage 55.2
Step 3 HIV 0 592 256 69.8
1 320 512 61.5
Overall Percentage 65.7
Step 4 HIV 0 592 256 69.8
1 272 560 67.3
Overall Percentage 68.6
Step 5 HIV 0 608 240 71.7
1 320 512 61.5
Overall Percentage 66.7
Step 6 HIV 0 592 256 69.8
1 304 528 63.5
Overall Percentage 66.7
Step 7 HIV 0 592 256 69.8
1 288 544 65.4
Overall Percentage 67.6
a. The cut value is .500
Variables in the Equation
B S.E. Wald df Sig. Exp(B)
Sjep SEX1(1) .892 .100 79.169 1 .000 2.440
1 Constant -.435 .068 40.499 1 .000 .647
^ e p
2
MATERAGE .096 .011 72.779 1 .000 1.100
SEX1(1) .938 .103 82.946 1 .000 2.554
Constant -2.739 .280 95.791 1 .000 .065
Variables in the Equation
B S.E. Wald df Sig. Exp(B)
S^ep
3
MATERAGE .125 .012 101.486 1 .000 1.133
SEX1(1) .988 .107 85.554 1 .000 2.685
WTAN -.063 .007 86.351 1 .000 .939
Constant .590 .446 1.750 1 .186 1.804
SJep
4
MATERAGE .138 .013 115.160 1 .000 1.147
SEX1(1) .949 .108 77.024 1 .000 2.582
WTAN -.072 .007 97.762 1 .000 .931
INVWTH2 .025 .004 37.409 1 .000 1.025
Constant .764 .460 2.755 1 .097 2.147
SJep
5
MATERAGE .155 .014 128.694 .000 1.168
SEX1(1) .957 .109 77.498 1 .000 2.605
WTAN -.073 .007 100.360 1 .000 .929
MATCON1 -.250 .060 17.548 1 .000 .779
INVWTH2 .027 .004 44.749 1 .000 1.027
Constant .452 .470 .925 1 .336 1.571
Sjtep
6
MATERAGE .161 .014 136.031 1 .000 1.175
SEX1(1) .978 .110 79.340 1 .000 2.658
WTAN -.069 .007 85.984 1 .000 .934
BPSYSAN -.030 .007 20.042 1 .000 .971
MATCON1 -.274 .060 20.664 1 .000 .760
INVWTH2 .027 .004 43.671 1 .000 1.027
Constant 3.255 .792 16.882 1 .000 25.928
SJep MATERAGE .162 .014 135.353 1 .000 1.176
SEX1(1) .960 .110 75.974 .000 2.611
WTAN -.077 .008 82.633 1 .000 .926
HTAN .021 .010 4.727 1 .030 1.021
BPSYSAN -.030 .007 20.042 1 .000 .971
MATCON1 -.261 .061 18.601 1 .000 .770
INVWTH2 .029 .004 48.414 1 .000 1.029
Constant .415 1.523 .074 1 .785 1.514
a. Variable(s) entered on step 1: SEX1.
b. Variable(s) entered on step 2: MATERAGE.
c. Variable(s) entered on step 3: WTAN.
Variables in the Equation
d. Variable(s) entered on step 4: INVWTH2.
e. Variable(s) entered on step 5: MATCON1.
f. Variable(s) entered on step 6: BPSYSAN.
g. Variable(s) entered on step 7: HTAN.
Model if Term Removed3
Variable
Model Log 
Likelihood
Change in 
-2 Log 
Likelihood df
Sig. of the 
Change
Step 1 SEX1 -1164.411 81.161 1 .000
Step 2 MATERAGE -1123.876 77.523 1 .000
SEX1 -1127.943 85.657 1 .000
Step 3 MATERAGE -1091.159 114.745 1 .000
SEX1 -1078.312 89.051 1 .000
WTAN -1085.395 103.216 1 .000
Step 4 MATERAGE -1080.161 132.704 1 .000
SEX1 -1053.679 79.740 1 .000
WTAN -1074.802 121.986 1 .000
INVWTH2 -1033.803 39.987 1 .000
Step 5 MATERAGE -1080.176 150.419 1 .000
SEX1 -1045.126 80.317 1 .000
WTAN -1067.801 125.667 1 .000
MATCON1 -1013.819 17.703 1 .000
INVWTH2 -1028.821 47.707 1 .000
Step 6 MATERAGE -1074.731 159.817 1 .000
SEX1 -1036.090 82.534 1 .000
WTAN -1047.405 105.164 1 .000
BPSYSAN -1004.994 20.342' 1 .000
MATCON1 -1005.279 20.912 1 .000
INVWTH2 -1018.287 46.928 .000
Step 7 MATERAGE -1072.247 159.558 1 .000
SEX1 -1031.871 78.805 1 .000
WTAN -1044.553 104.170 1 .000
HTAN -994.825 4.714 1 .030
BPSYSAN -1002.642 20.347 1 .000
MATCON1 -1001.869 18.802 1 .000
INVWTH2 -1018.121 51.307 1 .000
a. Based on conditiona parameter estimates
Variables not in the Equation
Score df Sig.
Step Variables MATERAGE 76.668 1 .000
1 WTAN 64.947 1 .000
HTAN 4.213 1 .040
BPSYSAN 24.083 1 .000
BPDYSAN 5.152 1 .023
MATCON1 .014 .904
INVWTH1 13.863 1 .000
INVWTH2 13.399 1 .000
Overall Statistics 241.003 .000
Step Variables WTAN 97.017 1 .000
2 HTAN 8.660 1 .003
BPSYSAN 36.533 1 .000
BPDYSAN 10.827 1 .001
MATCON1 9.177 1 .002
INVWTH1 11.579 1 .001
INVWTH2 21.138 1 .000
Overall Statistics 171.359 .000
Step Variables HTAN .979 .322
3 BPSYSAN 18.329 1 .000
BPDYSAN 6.202 1 .013
MATCON1 9.996 1 .002
1NVWTH1 8.229 1 .004
INVWTH2 39.671 1 .000
Overall Statistics 83.292 .000
Step Variables HTAN 6.856 1 .009
4 BPSYSAN 17.076 .000
BPDYSAN 6.213 1 .013
MATCON1 17.705 1 .000
INVWTH1 4.527 1 .033
Overall Statistics 43.490 .000
Step Variables HTAN 4.738 1 .029
5 BPSYSAN 20.328 1 .000
BPDYSAN 8.203 1 .004
INVWTH1 3.471 1 .062
Overall Statistics 25.761 4 .000
Variables not in the Equation
Score df Sig.
Step . Variables HTAN 4.747 1 .029
6 BPDYSAN .064 1 .801
INVWTHi .915 1 .339
Overall Statistics 5.441 3 .142
Step Variables BPDYSAN .091 1 .763
7 INVWTH1 .501 1 .479
Overall Statistics .694 2 .707
Stepwise forward regressional logistic regression: antenatal variables
Case Processing Summary
Unweighted C ases3 N Percent
Selected Cases Included in Analysis 1360 70.8
Missing Cases 560 29.2
Total 1920 100.0
Unselected Cases 0 .0
Total 1920 100.0
a. If weight is in effect, see  classification table for the total number of cases.
Dependent Variable Encoding
Original Value Internal Value
0 0
1 1
Categorical Variables Codings
Parameter
Frequency . (D
DELPROB 0 992 1.000
1 368 .000
Block 0: Beginning Block
Observed
Predicted
HIV Percentage
Correct0 1
StepO HIV 0 704 0 100.0
1 656 0 .0
Overall Percentage 51.8
a. Constant is included in the model.
b. The cut value is .500
Variables in the Equation
B S.E. Wald df Sig. Exp(B)
Step 0 Constant -.071 .054 1.693 1 .193 .932
Variables not in the Equation
Score df Sig.
Step Variables delivery problems 
0 4.572 1 .032
haemoglobin an 35.522 1 .000
plasma CRP an 4.185 1 .041
plasma AGP an 7.688 1 .006
Overall Statistics 51.488 4 .000
3lock 1: Method = Forward Stepwise (Conditional)
vinniD us rests ot iwoaei coefficients
Chi-square . df Sig.
Step 1 Step 35.979 1 .000
Block 35.979 1 .000
Model 35.979 1 .000
Step 2 Step 10.823 . 1 .001
Block 46.802 2 .000
Model 46.802 2 .000
Step 3 Step 4.065 1 .044
Block 50.867 3 .000
Model 50.867 3 .000
Model Summary
Step
-2 Log 
likelihood
Cox & Snell 
R Square
Nagelkerke R 
Square
1 1847.687 .026 .035
2 1836.864 .034 .045
3 1832.798 .037 .049
Classification Table3
Observed
Predicted
HIV Percentage
Correct0 1
Step 1 HIV 0 480 224 68.2
1 320 336 51.2
Overall Percentage 60.0
Step 2 HIV 0 464 240 65.9
1 288 368 56.1
Overall Percentage 61.2
Step 3 HIV 0 480 224 68.2
1 304 352 53.7
Overall Percentage 61.2
a. The cut value is .500
Variables in the Equation
B S.E. Wald df Sig. Exp(B)
S|ep HBAN -.213 .036 34.676 1 .000 .808
1 Constant 2.219 .392 32.008 .000 9.199
S£ep HBAN -.224 .037 37.587 1 .000 .799
2 LNAGAPNC -.502 .154 10.606 1 .001 .605
Constant 2.074 .395 27.602 1 .000 7.959
S«teP DELPROB(1) .258 .128 4.050 1 .044 1.295
3 HBAN -.216 .037 34.537 1 .000 .805
LNAGAPNC -.562 .157 12.750 1 .000 .570
Constant 1.772 .422 17.637 1 .000 5.882
a. Variable(s) entered on step 1: HBAN.
b. Variable(s) entered on step 2: LNAGAPNC.
c. Variable(s) entered on step 3: DELPROB.
Model if Term Removed3
Variable
Model Log 
Likelihood
Change in 
-2 Log 
Likelihood df
Sig. of the 
Change
Step 1 HBAN -941.834 35.981 .000
Step 2 HBAN -937.972 39.080 .000
LNAGAPNC -923.846 10.828 1 .001
Step 3 DELPROB -918.432 4.066 .044
HBAN -934.283 35.767 1 .000
LNAGAPNC -922.922 13.046 1 .000
a. Based on conditional parameter estimates
Variables not in the Equation
Score df Sig.
Step 1 Variables DELPROB(1) 1.849 1 .174
LNCRPAN 5.757 1 .016
LNAGAPNC 10.751 1 .001
Overall Statistics 16.547 .001
Step 2 Variables DELPROB(1) 4.059 1 .044
LNCRPAN 3267 1 .071
Overall Statistics 5.831 .054
Step 3 Variables LNCRPAN 1.771 1 .183
Overall Statistics 1.771 1 .183
Stepwise forward regressional logistic regression: early postnatal variables
Case Processing Summary
Unweighted C ases3 N Percent
Selected Cases Included in Analysis 292 15.2
Missing Cases 1628 84.8
Total 1920 100.0
Unselected Cases 0 .0
Total 1920 100.0
a. If weight is in effect, see classification table for the total number of cases.
Dependent Variable Encoding
Original Value Internal Value
0 0
1 1
Categorical Variables Codings
Parameter
Frequency (1)
0= morbidity grouping 
0 , 1=morbidity
0
1
89 1.000
groupings 1-6 203 .000
NAK3CAT 0 214 1.000
1 78 .000
Block 0: Beginning Block
Classification Tab!ea*b
Observed
Predicted
HIV Percentage
Correct0 1
StepO HIV 0 154 0 100.0
1 138 0 .0
Overall Percentage 52.7
a. Constant is included in the model.
b. The cut value is .500
Variables in the Equation
B S.E. Wald df Sig. Exp(B)
Step 0 Constant -.110 .1-17 .876 1 .349 .896
Variables not in the Equation
Score df Sig.
Step
0
Variables feeding 
technique 
ebf or mixed 
feeding 
breast, 
inflammation 
maternal temp 
breast milk CRP 
<d14
2.095
.859
1.762
2.933
14.412
1
1
1
1
1
,148
.354
.184
.087
.000
breast milk Na/K .244 .622categorical <d14 1
morbidity 26.097 1 .000
Overall Statistics 48.718 7 .000
Block 1: Method = Forward Stepwise (Conditional)
Omnibus Tests of Model Coefficients
Chi-square df . Sig.
Step 1 Step 27.118 1 .000
Block 27.118 1 .000
Model 27.118 1 .000
Step 2 Step 12.857 1 .000
Block 39.975 2 .000
Model 39.975 2 .000
Step 3 Step 5.665 1 .017
Block 45.639 3 .000
Model 45.639 3 .000
Model Summary
Step
-2 Log 
likelihood
Cox & Snell 
R Square
Nagelkerke R 
Square
1 376.803 .089 .118
2 363.946 .128 .171
3 358.281 .145 .193
Classification Table8
Observed
Predicted
H V Percentage
Correct0 1
Step 1 HIV 0 67 87 43.5
1 22 116 84.1
Overall Percentage 62.7
Step 2 HIV 0 102 52 66.2
1 43 95 68.8
Overall Percentage 67.5
Step 3 HIV 0 103 51 66.9
1 41 97 70.3
Overall Percentage 68.5
a. The cut value is .500
Variables in the Equation
B S.E. Wald df Sig. Exp(B)
SJep M0RBB(1) -1.4G1 .284 24.396 1 .000 .246
1 Constant .288 • .142 4.114 .043 1.333
SfieP SQRTCRP3 1.366 .395 11.947 1 .001 3.921
2 MORBB(1) -1.383 .290 22.802 .000 .251
Constant -.664 .306 4.718 1 .030 .515
S<tep BREAST3 -.380 .161 5.550 1 .018 .684
3 SQRTCRP3 1.520 .403 14.185 .000 4.570
MORBB(1) -1.455 .295 24.252 .000 .234
Constant -.593 .308 3.702 1 .054 .553
a. Variable(s) entered on step 1: MORBB.
b. Variable(s) entered on step 2: SQRTCRP3.
c. Variable(s) entered on step 3: BREAST3.
Model if Term Removed3
Variable
Model Log 
Likelihood
Change in 
-2 Log 
Likelihood df
Sig. of the 
Change
Step 1 MORBB -202.042 27.280 1 .000
Step 2 SQRTCRP3 -188.424 12.901 1 .000
MORBB -194.691 25.435 1 .000
Step 3 BREAST3 -181.979 5.677 1 .017
SQRTCRP3 -186.867 15.452 1 .000
MORBB -192.808 27.334 .000
a. Based on conditional parameter estimates
Variables not in the Equation
Score df Sig.
Step Variables CORRCTF3 1.818 .178
1 FEED3 1.640 .200
BREAST3 3.127 1 .077
TEMPD3 3.137 1 .077
SQRTCRP3 12.569 1 .000
NAK3CAT(1) .586 1 .444
Overall Statistics 24.527 .000
Step Variables CORRCTF3 3.555 1 .059
2 FEED3 1.728 1 .189
BREAST3 5.760 1 .016
TEMPD3 2.391 1 .122
NAK3CAT(1) 2.097 1 .148
Overall Statistics 12.746 .026
Step Variables CORRCTF3 1.634 1 .201
3 FEED3 1.086 1 .297
TEMPD3 2.201 1 .138
, NAK3CAT(1) -1.536 1 .215
Overall Statistics 6.921 4 .140
Logistic Regression
Case Processing Summary
Unweighted Cases3 N Percent
Selected Cases Included in Analysis 723 37.7
Missing C ases 1197 62.3
Total 1920 100.0
Unselected Cases 0 .0
Total 1920 100.0
a. If weight is in effect, see classification table for the total number of cases.
Dependent Variable Encoding
Original Value Internal Value
0 0
1 1
Categorical Variables Codings
Parameter
Frequency (1)
NAK14CAT 0 626 1.000
1 97 .000
Block 0: Beginning Block
Classification Tablea>b
Observed
Predicted
HIV Percentage
Correct0 1
Step 0 HIV 0 369 0 100.0
1 354 0 .0
Overall Percentage 51.0
a. Constant is included in.the model.
b. The cut value is .500
Variables in the Equation
B S.E. Wald df Sig. Exp(B)
Step 0 Constant -.041 .074 .311 1 .577 .959
Variables not in the Equation
Score df Sig.
Step Variables CRRCTF14 1.393 1 .238
0 FEED14 6.978 1 .008
BREAST14 15.276 .000
TEMPD14 .390 1 .532
LNCRPPN .619 1 .431
LNAGPPNC 50.689 1 .000
LNCRPD14 6.804 1 .009
NAK14CAT(1) 7.452 1 .006
Overall Statistics 94.704 8 .000
Block 1: Method = Forward Stepwise (Conditional)
Omnibus Tests of Model Coefficients
Chi-square df Sig.
Step 1 Step 52.337 1 .000
Block 52.337 1 .000
Model 52.337 1 .000
Step 2 Step 16.398 1 .000
Block 68.735 2 .000
Model 68.735 2 .000
Step 3 Step 9,655 1 .002
Block 78.390 3 .000
Model . 78.390 3 .000
Step 4 Step 10.685 1 .001
Block 89.074 4 .000
Model 89.074 4 .000
Step 5 Step 9.398 1 .002
Block 98.472 5 .000
Model 98.472 5 .000
Model Summary
Step
-2 Log 
likelihood
Cox & Snell 
R Square
Nagelkerke R 
Square
1 949.642 .070 .093
2 933.245 .091 .121
3 923.590 .103 .137
4 . 912.905 .116 .155
5 903.508 .127 .170
Classification Table3
Observed
Predicted
HIV Percentage
Correct0 1
Step 1 HfV 0 240 129 65.0
1 135 219 61.9
Overall Percentage 63.5
Step 2 HIV 0 241 128 65.3
1 . 160 194 54.8
Overall Percentage 60.2
Step 3 HIV 0 247 122 66.9
1 134 220 62.1
Overall Percentage 64.6
Step. 4 HIV 0 237 132 64.2
1 140 214 60.5
Overall Percentage 62.4
Step 5 HIV 0 246 123 66.7
1 130 224 63.3
Overall Percentage 65.0
a. The cut value is .500
Variables in the Equation
B S.E. Wald df Sig. Exp(B)
SJep LNAGPPNC 1.641 .238 47.461 1 .000 5.160
1 Constant .137 .082 2.816 1 .093 1.147
Sgep BREAST14 -.641 .168 14.625 1 .000 .527
2 LNAGPPNC 1655 .239 48.089 1 .000 5.233
Constant .258 .088 8.681 1 .003 1.294
SJep BREAST14 -.584 .167 12.232 1 .000 .558
3 LNCRPPN -.189 .062 9.205 1 .002 .828
LNAGPPNC 2.107 .286 54.389 1 .000 8.220
Constant .360 .095 14.413 1 .000 1.434
Sjep FEED14 1.143 .375 9.301 1 .002 3.136
4 BREAST14 -.571 .169 11.444 1 .001 .565
LNCRPPN -.237 .066 12.949 1 .000 .789
LNAGPPNC 2.208 .290 57.821 1 .000 9.101
Constant .330 .096 11.815 1 .001 1.391
SJep FEED14 1.189 .379 9.824 1 .002 .999
5 BREAST14 -.675 .177 14.471 1 .000 .509
LNCRPPN -.234 .066 12.390 1 .000 .792
LNAGPPNC 2.173 .293 54.942 1 .000 8.785
NAK14CAT(1) -.737 .245 9.086 .003 .479
Constant .979 .239 16.848 .000 2.663
a. Variable(s) entered on step 1: LNAGPPNC.
b. Variabie(s) entered on step 2: BREAST14.
c. Variable(s) entered on step 3: LNCRPPN.
d. Variable(s) entered on step 4: FEED14.
e. Variable(s) entered on step 5: NAK14CAT.
moaei irierm Removed3
Variable
Model Log 
Likelihood
Change in 
-2 Log 
Likelihood df
Sig. of the 
Change
Step 1 LNAGPPNC -500.991 52.339 .000
Step 2 BREAST14 -474.843 16.441 1 .000
LNAGPPNC -493.067 52.889 .000
Step 3 BREAST14 -468.585 13.579 1 .000
LNCRPPN -466.625 9.661 .002
LNAGPPNC -492.390 61.190 1 .000
Step 4 FEED14 -461.804 10.703 1 .001
BREAST14 -462.809 12.712 1 .000
LNCRPPN -463.442 13.978 1 .000
LNAGPPNC -489.338 65.771 1 .000
Step 5 FEED14 -457.438 11.369 1 .001
BREAST14 -459.998 16.489 1 .000
LNCRPPN -458.431 13.355 1 .000
LNAGPPNC -482.953 62.398 1 .000
NAK14CAT -456.461 9.414 1 .002
a. Based on conditional parameter estimates
Variables not in the Equation
Score df Sig. _
Step Variables CRRCTF14 .757 1 .384
1 FEED14 6.238 1 .013
BREAST14 15.628 1 .000
TEMPD14 .051 1 .822
LNCRPPN 12.384 1 .000
LNCRPD14 .095 1 .758
NAK14CAT(1) 5.339 1 .021
Overall Statistics 46.224 .000
Step Variables CRRCTF14 .957 1 .328
2 FEED14 6.365 1 .012
TEMPD14 .034 1 .854
LNCRPPN 9.541 1 .002
LNCRPD14 .050 1 .823
NAK14CAT(1) 9.375 1 .002
Overall Statistics 31.563 .000
Step Variables CRRCTF14 .878 .349
3 FEED14 10.851 1 .001
TEMPD14 .037 1 .847
LNCRPD14 1.400 .237
NAK14CAT(1) 8.647 1 .003
Overall Statistics 22.432 .000
Step Variables CRRCTF14 1.470 1 .225
4 TEMPD14 .250 1 .617
LNCRPD14 1.484 1 .223
NAK14CAT(1) 9.312 1 .002
Overall Statistics 11.825 .019
Step Variables CRRCTF14 1.735 1 .188
5 TEMPD14 .274 1 .601
LNCRPD14 .453 1 .501
Overall Statistics 2.552 3 .466
Stepwise forward regressional logistic regression: final model (all variables entered: p<0.05, OR>1.0)
Case Processing Summary
Unweighted Cases3 N Percent
Selected Cases Included in Analysis 237 12.3
Missing Cases 1683 87.7
Total 1920 100.0
Unselected Cases 0 .0
Total 1920 100.0
a. If weight is in effect, see classification table for the total number of cases.
Dependent Variable Encoding
Original Value. Internal Value
0 0
1 1
Categorical Variables Codings
Frequency
Parameter
(1)
SEX1 0 101 1.000
1 136 .000
DELPROB 0 163 1.000
1 74 .000
Block 0: Beginning Block
Classification Tablea,b
Observed
Predicted
HIV Percentage
Correct0 1
Step 0 HIV . 0 0 113 .0
1 0 124 100.0
Overall Percentage 52.3
a. Constant is included in the model.
b. The outvalue is .500
Variables in the Equation
B S.E. Wald df Sig. Exp(B)
Step 0 Constant .093 .130 .510 1 .475 1.097
Variables not in the Equation
• Score df Sig.
Step
0
Variables blood pressure 
Sys an .496 1 .481
maternal wealth! 20.610 1 .000
maternal wealth 
2 .819 1 .365
delivery problems 9.047 1 .003
maternal age 12.193 1 .000
infant sex 8.608 1 .003
plasma AGP pn 12.614 1 .000
breast milk CRP 
<d14 10.621 1 .001
Overall Statistics 57.651 8 .000
Block 1: Method = Forward Stepwise (Conditional)
Omnibus Tests of Model Coefficients
Chi-square df Sig.
Step 1 Step 22.480 1 .000
Block 22.480 1 .000
Model 22.480 1 .000
Step 2 Step 10.864 1 .001
Block 33.344 2 .000
Model 33.344 2 .000
Step 3 Step 8.190 1 .004
Block 41.534 3 .000
Model 41.534 3 .000
Step 4 Step 10.326 1 .001
Block 51.860 4 .000
Model 51.860 4 .000
Step 5 Step 8.220 1 .004
Block 60.080 5 .000
Model 60.080 5 .000
Model Summary
Step
-2 Log 
likelihood
Cox & Snell 
R Square
Nagelkerke R 
Square
1 305.561 .090 .121
2 294.697 .131 .175
3 286.507 .161 .214
4 276,181 .197 .262
5 267.961 .224 .299
Classification Table3
Observed
Predicted
H V Percentage
Correct0 1
Step 1 HIV 0 34 79 30.1
1 28 96 77.4
Overall Percentage 54.9
Step 2 HIV 0 67 46 59.3
1 31 93 75.0
Overall Percentage 67.5
Step 3 HIV 0 53 60 46.9
1 37 87 70.2
Overall Percentage 59.1
Step 4 HIV 0 73 40 64.6
1 34 90 72.6
Overall Percentage 68.8
Step 5 HIV 0 76 37 67.3
1 37 87 70.2
Overall Percentage 68.8
a. The cut value is .500
Variables in the Equation
B S.E. Wald df . Sig. Exp(B)
SJteP 1NVWTH1 .134 .033 16.177 1 .000 1.1431 Constant .180 .136 1.736 ' .188 1.197
S$ep INVWTH1 .136 .035 15.249 1 .000 • 1.145
2 MATERAGE .086 .027 10.307 1 .001 1.090
Constant -1.862 .647 8.273 .004 .155
S^ep INVWTH1 .136 .035 14.737 1 .000 1.145
3 MATERAGE .089 ,028 10.497 .001 1.093
SEX1(1) .815 .289 7.973 1 .005 2.259
Constant -2.285 .685 11.126 .001 .102
Sjep INVWJH1. .136 .036 14.651 1 .000 1.146
4 DELPROB(1) 1.010 .320 9.932 1 .002 2.745
MATERAGE .093 .028 10.952 1 .001 1.097
SEX1(1) .975 .304 10.255 1 .001 2.650
Constant -3.125 .760 16.896 1 .000 .044
SJep INVWTH1 ,112 .034 11.071 1 .001 1.119
5 DELPROB(1) 1.117 .331 11.371 1 .001 3.055
MATERAGE .091 .029 10.291 1 .001 1.096
SEX1(1) .930 .309 9.058 1 .003 2.534
SQRTCRP3 1.364 .488 7.816 1 .005 3.911
Constant -4.119 .859 22.976 1 .000 .016
a. Variable(s) entered on step 1: INVWTH1,
b. Variable(s) entered on step 2: MATERAGE.
c. Variable(s) entered on step 3: SEX1.
d. Variable(s) entered on step 4: DELPROB.
e. Variable(s) entered on step 5: SQRTCRP3.
Model If Term Removed*
Variable
Model Log 
Likelihood
Change in 
-2 Log 
Likelihood df
Sig. of the 
Change
Step 1 INVWTH1 -164.128 22.694 .000
Step 2 INVWTH1 -157.934 21.171 1 .000
MATERAGE -152.820 10.943 1 .001
Step 3 INVWTH1 -153.536 20.566 1 .000
MATERAGE -148.826 11.145 1 .001
SEX1 -147.363 8^219 1 .004
Step 4 INVWTH1 -148.066 19.950 1 .000
DELPROB -143.285 10.390 .001
MATERAGE -143.875 11.569 1 .001
SEX1 -143.529 10.876 1 .001
Step 5 INVWTH1 -141.088 14.214 .000
DELPROB -140.020 12.080 1 .001
MATERAGE -139.370 10.780 .001
SEX1 -138.742 9.524 1 .002
SQRTCRP3 -138.144 8.327 1 .004
a. Based on conditional parameter estimates
Variables not in the Equation
Score df Sig.
Step Variables BPSYSAN .010 .920
1 INVWTH2 .001 1 .975
DELPROB(1) 7.892 1 .005
MATERAGE 10.773 1 .001
SEX1(1) 7.955 1 .005
LNAGPPNC 7.206 .007
SQRTCRP3 7.385 1 .007
Overall Statistics 39.664 .000
Step Variables BPSYSAN 1.035 1 ..309
2 INVWTH2 .451 1 .502
DELPROB(1) 7.725 1 .005
SEX1(1) 8.115 1 .004
LNAGPPNC 8.104 1 .004
SQRTCRP3 7.569 1 .006
Overall Statistics 29,677 .000
Step Variables BPSYSAN .970 1 .325
3 INVWTH2 .752 1 .386
DELPROB(1) 10.258 1 .001
LNAGPPNC 5.088 .024
SQRTCRP3 6.502 1 .011
Overall Statistics 22.229 .000
Step Variables BPSYSAN 1.306 1 .253
4 INVWTH2 .644 1 .422
LNAGPPNC 4.650 1 .031
SQRTCRP3 8.089 1 .004
Overall Statistics 12.657 .013
Step Variables BPSYSAN 1.281 1 .258
5 INVWTH2 .405 1 .525
LNAGPPNC 3.092 1 .079
Overall Statistics 5.065 3 .167
Appendix 5.4 
Forward conditional stepwise regression analysis 
South Africa study
Appendix 5.4.1 
Breast milk RNA viral load: 
Detectable vs. undetectable
Case Processing Summary
Unweighted Cases3 N Percent
Selected Cases Included in Analysis 50 17.2
Missing Cases 240. 82.8
Total 290 100.0
Unselected Cases 0 .0
Total 290 100.0
a. If weight is in effect, see classification table for the total number of cases.
Dependent Variable Encoding
Original Value Internal Value
<=200 0
>200 1
Block 0: Beginning Block
Classification Tablea,b
Observed
Predicted
viral load detectable 1w Percentage
Correct<=200 >200
Step 0 viral load detectable <=200 0 10 .0
1w >200 0 40 100.0
Overall Percentage 80.0
a. Constant is included in the model.
b. The cut value is .500
Variables in the Equation
B S.E. Wald df Sig. Exp(B)
Step 0 Constant , 1.386 .354 15.374 1 .000 4.000
/  r ' A n r l l t i A r i A  l \
Classification Table8
Observed
Predicted
viral load detectable 1w Percentage
Correct<=200 >200
Step 1 viral load detectable <=200 0 10 .0
1w >200 2 38 95.0
Overall Percentage 76.0
Step 2 viral load detectable <=200 3 7 30.0
1w >200 1 39 97.5
Overall Percentage 84.0
Step 3 viral load detectable <=200 6 4 60.0
1w >200 1 39 97.5
Overall Percentage 90.0.
Step 4 viral load detectable <=200 6 4 60.0
1w >200 1 39 97.5
Overall Percentage 90.0
a. The cut value is .500
Variables in the Equation
B S.E. Wald df Sig. Exp(B)
S|ep WEIGHT1W -1.857 .779 5.680 .017 .156
1 Constant 8.489 3.118 7.415 1 .006 4860.837
3Jep WEIGHT1W -2.927 1.165 6.312 .012 .054
2 MATCON2 -1.313 .503 6.804 .009 .269
Constant 12.587 4.664 7.282 1 .007 292745.41
S«tep MODEL(1) 2.992 1.530 3.826 1 .050 19.932
3 WEIGHT1W -3.192 1.204 7.028 1 .008 .041
MATCON2 -1.905 .697 7.460 .006 .149
Constant 11.311 4.588 6.078 1 .014 81753.927
Sjep MODEL(1) 6.105 3.525 3.000 1 .083 448.231
4 WEIGHT1W -7.335 3.662 4.012 1 .045 .001
WTGAIN1W -.077 .044 3.089 .079 .925
MATCON2 -4.603 2.287 4.051 1 .044 .010
Constant 28.055 14.216 3.895 1 .048 1.53E+12
a. Variable(s) entered on step 1: WEIGHT1W.
b. Variable(s) entered on step 2: MATCON2.
c. Variable(s) entered on step 3: MODEL.
d. Variab!e(s) entered on step 4: WTGAIN1W.
---«-----  j egi cssiun: jyetectaDIe breast milk viral load 6 weeks postpartum
Case Processing Summary
Unweighted Cases3 N Percent
Selected Cases Included in Analysis 41 14.1
Missing Cases 249 85.9
Total 290 100.0
Unselected Cases 0 .0
Total 290 100.0
a. If weight is in effect, see classification table for the total number of cases.
Dependent Variable Encoding
Original Value Internal Value
<=200 0
>200 1
►lock 0: Beginning Block
Classification Tablea,b
Observed
Predicted
viral load detectable 1 w Percentage
Correct<=200 >200
Step 0 viral load detectable <=200 0 8 .0
1w >200 0 33 100.0
Overall Percentage 80.5
a. Constant is included in the modej.
b. The cut value is .500
Variables in the Equation
B S.E. Wald df Sig. Exp(B)
StepO Constant 1.417 .394 12.930 1 .000 4.125
vctnaoies not in the Equation
Step
0
Variables infant sex 
mode of delivery 
maternal age 
maternal plasma 
CD4 at delivery 
maternal temp 6 
weeks
maternal wealth 
maternal control 
1
maternal control 
2
exclusive type of 
feeding 6 weeks 
infant weight at 6 
weeks
infant weight gain 
6 weeks 
breast milk CRP 
6 weeks
breast milk IL-8 6 
weeks
breast milk Na/K 
6 weeks
Overall Statistics
Score
2.064 
1.403
.507
.103
.654
2.106
.019
4.780
.785
6.827
.010
1.359
2.065
.001
24.228
df Sig.
14
.151
.236
.476
.748
.419
.147
.892
.029
.376
.009
.920
.244
.151
.977
.043
Block 1: Method = Forward Stepwise (Conditional)
w iaasiiibtinon i ao iea
Observed
Predicted
viral load detectable 1w Percentage
Correct<=200 >200
Step 1 viral load detectable <=200 2 6 25.0
1w >200 1 32 97.0
Overall Percentage 82.9
Step 2 viral load detectable <=200 6 2 75.0
1w >200 1 32 97.0
Overall Percentage 92.7
a. The cut value is .500
Variables in the Equation
B S.E. Wald df Sig. Exp(B)
SJep WEIGHT6W -1.559 .658 5.617 1 .018 .210
1 Constant 9.749 3.663 7.085 1 .008 17141.579
^ e p WEIGHT6W -3.594 1.258 8.158 1 .004 .027
2 WTGAIN6W .177 .076 5.463 1 .019 1.194
Constant 13.681 4.929 7.705 1 .006 874320.97
a. Variable(s) entered on step 1: WEIGHT6W.
b. Variable(s) entered on step 2: WTGAIN6W.
Model if Term Removed3
Variable
Model Log 
Likelihood
Change in 
-2 Log 
Likelihood df
Sig; of the 
Change
Step 1 WEIGHT6W -20.516 7.934 1 .005
Step 2 WE1GHT6W -21.110 15.993 1 .000
WTGAIN6W -16.843 7.460 . 1 .006
a. Based on conditiona parameter estimates
 0----- * wjwii. ucieciHDie Dreast milk viral load 3 months postpartum
Case Processing Summary
Unweighted Cases® N Percent
Selected Cases Included in Analysis 44 15.2
Missing Cases 246 84.8
Total 290 100.0
Unselected Cases 0 .0
Total 290 100.0
a. If weight is in effect, see classification table for the total number of cases.
Dependent Variable Encoding
Original Value Internal Value
<=200 0
>200 1
Block 0: Beginning Block
Classification Tablea,b
Observed
Predicted
viral load detectable 1w Percentage
Correct<=200 >200
Step 0 viral load detectable <=200 0 13 .0
1w >200 0 31 100.0
Overall Percentage 70.5
a. Constant is included in the model.
b. The cut value is .500
Variables in the Equation
B S.E. Wald df Sig. Exp(B)
i  Step 0 Constant .869 .330 6.917 1 .009 2.385
Variables not in the Equation
Step
0
Variables
Overall Statistics
Score df Sig.
infant sex .983 1 .322
mode of delivery .004 1 .951
maternal age 2.284 1 .131
maternal plasma 
CD4 at delivery .931 1 ,335
WEALTH 4.778 1 .029
maternal control 
1 .069 1 .793
maternal control 
2 7.816 1 .005
feeding typ 3 
months 1.845 1 ,174
infant weight 3 
months 1.470 1 .225
infant weight gain 
3months .161 1 .689
maternla temp 3 
months 4.634 1 .031
breast milk CRP 
3 months .365 1
.546
breast milk Na/K 
3 months 2.366 1 .124
breast milk IL-8 3 
months 2.644 1
.104
25.510 14 .030
Block 1: Method = Forward Stepwise (Conditional)
Classification Table3
Observed
Predicted
viral load detectable 1w Percentage
Correct<=200 >200
Step 1 viral load detectable <=200 7 6 53.8
1w >200 4 27 87.1
Overall Percentage 77.3
Step 2 viral load detectable <=200 7 6 53.8
1w >200 2 29 93.5
Overall Percentage 81.8
a. The cut value is .500
Variables in the Equation
B S.E. Wald df Sig. Exp(B)
% p MATCON2 -1.155 .447 6.674 1 .010 .315
1 Constant .649 .367 3.130 1 .077 1.914
MATCON2 -1.242 .497 6.257 1 .012 .289
2 MTEMP3M -1.340 .665 4.065 1 .044 .262
Constant 49.915 24.475 4.159 1 .041 4.76E+21
a. Variable(s) entered on step 1: MATCON2.
b. Variable(s) entered on step 2: MTEMP3M.
Appendix 5.4.2 
Maternal plasma CD4 count taken at delivery 
<200 vs. >200mm3
* «i rraiu sicpwise logistic regression: Maternal plasma CD4 count at delivery (<=200, >200)
antenatal variables
Case Processing Summary
Unweighted Cases3 N Percent
Selected Cases Included in Analysis 152 52.4
Missing Cases 138 47.6
Total 290 100.D
Unselected Cases 0 .0
Total 290 100,0.
a. If weight is in effect, see classification table for the total number of cases.
Block 0: Beginning Block
Classification Tabiea,b
Observed
Predicted
CD4200 Percentage
Correct.00 1.00
Step 0 CD4200 .00 0 24 .0
1.00 0 128 100.0
Overall Percentage 84.2
a. Constant is included in the model.
b. The cut value is .500
Variables in the Equation
B S.E. Wald df Sig. Exp(B)
Step 0 Constant 1.674 .222 56.634 1 .000 5.333
Variables not in the Equation
Score df Sig.
Step Variables infant sex .020 1 .888
0 mode delivery 2.808 1 .094
maternal age .044 1 .834
WEALTH 2.951 1 .086
maternal control .381 1 .537
maternal control .956 1 .328
Overall Statistics 8.675 6 .193
  ..vvuutai ucuvery
-«'>■*« piasiua LU4 count at delivery (<=200, >200) 1 week postpartum
Case Processing Summary
Unweighted Cases3 N Percent
Selected Cases Included in Analysis 91 31.4
Missing Cases 199 68.6
Total 290 100.0
Unselected Cases 0 .0
Total 290 100.0
a. If weight is in effect, see classification table for the total number of cases.
Dependent Variable Encoding
Original Value Internal Value
.00 0
1.00 1
Categorical Variables Codings
I Parameter
Frequency (1)
NAK1WCAT 0 69 1.000
1 22 .000
lock 0: Beginning Block
v iu o o i i i v a u u i l  I aD I6M,l/
Observed
Predicted
CD4200 Percentage
Correct.00 1.00
StepO CD4200 .00 0 21 .0
1.00 0 70 100.0
Overall Percentage 76.9
a. Constant is included in the model.
b. The cut value is .500
Variables in the Equation
> B S.E. Wald df Sig. Exp(B)
StepO Constant 1.204 .249 23.416 1 .000 3.333
Variables not in the Equation
Score df Sig.
Step
0
Variables type of
breastfeeding 1 
week
3,469 1 .063
infant weight 1 
week 1.024 1 .311
infant weight gain 
1 week 1.487 1 .223
matemla temp 1 
week 3.470 1 .062
breast milk CRP 
1 week .079 1 .778
breast milk Na/K 
1 week .288 1 .592
breast milk IL8 1 
Week .616 1 .433
breast milk viral 
load 1 week 5.882 1 .015
Overall Statistics 13.051 8 .110
ock 1: Method = Forward Stepwise (Conditional)
Variables in the Equation
B S.E. Wald df Sig. Exp(B)
S|ep LNVLW1 -.309 .133 5.408 1 .020 .734
1 Constant 3.390 1.001 11.465 1 .001 29.652
a. Variable(s) entered on step 1: LNVLW1.
— .— ...yiaoum count at delivery (<=200, >200)
o weeks postpartum
Case Processing Summary
Unweighted Cases3 N Percent
Selected Gases Included in Analysis 120 41.4
Missing Cases 170 58.6
Total 290 100.0
Unselected Cases 0 .0
Total 290 100.0
a. If weight is in effect, see  classification table for the total number of cases.
Dependent Variable Encoding
Original Value Internal Value .
.00 0
1.00 1
Categorical Variables Codings
Parameter
Frequency (1)
NAK6WCAT 0 99 1.000
1 21 .000
Block 0: Beginning Block
^idssmcation Table3*0
Observed
Predicted
CD4200 Percentage
Correct.00 1.00
StepO CD4200 .00 0 20 .0
1.00 0 . 100 100.0
Overall Percentage 83.3
a. Constant is included in the model.
b. The cut value is .500
Variables in the Equation
B S.E. Wald df Sig. Exp(B)
' Step 0 Constant 1.609 .245 43.172 1 .000 5.000
Variables not in the Equation
Score df Sig.
Step
0
Variables type of infant 
feed 6 week 
infant weight 6 
weeks
infant weight gain . 
6 weeks 
maternal temp 6 
weeks
breast milk Na/K 
6 weeks
.471
.079
.217
3.459
.935
1
1
1
.493
.778
.642
.063
.334
Overall Statistics 5.926 5 .314
Forward stepwise logistic regression: Maternal plasma CD4 count at delivery (<=200, >200) 
3 months postpartum
Case Processing Summary
Unweighted Cases3 N Percent
Selected Cases Included in Analysis 86 29.7
Missing Cases 204 70.3
Total 290 100.0
Unselected Cases 0 .0
Total 290 100.0
a. If weight is in effect, see classification table for the total number of cases.
Dependent Variable Encoding
Original Value Internal Value
.00 0
1.00 1
Categorical Variables Codings
Parameter
Frequency (1)
NAK3MCAT 0 70 1.000
1 16 .000
Block 0: Beginning Block
uiassmcation Table3’0
Observed
Predicted
CD4200 Percentage
Correct.00 1.00
Step 0 CD4200 .00 0 20 .0
1.00 0 66 100.0
Overall Percentage 76.7
a. Constant is included in the model.
b. The cut value is .500
Variables in the Equation
B S.E. Wald df Sig. Exp(B)
Step 0 Constant 1.194 .255 21.879 1 .000 3.300
Variables not in the Equation
Score df Sig.
Variables type of feeding 3 
months .014 1 .907
infant weight 3 
months • .267 1 .605
infant weight gain 
3 months 1.174 1 .279
maternal temp 3 
months .633 .426
breast milk CRP 
3months 1.543 1 .214
breast milk Na/K 
3 months 5.957 1 .015
breast milk IL8 3 
months .240 1 .624
breast milk Viral 
load 3 months 3.248 1 .072
Overall Statistics 16.289 8 .038
lock 1: Method = Forward Stepwise (Conditional)
Omnibus Tests of Model Coefficients
Chi-square df Sig.
Step 1 Step 9.526 1 .002
Block . 9.526 1 .002
Model 9.526 1 .002
Step 2 Step 6.484 1 -011
Block 16.010 2 .000
Model 16.010 2 .000
Model Summary
-2 log Cox & Snell Nagelkerke R
Step likelihood R Square Square
1 83.758 .105 .158
2 77.274 .170 .257
Classification Table3
Observed
Predicted
CD4200 Percentage
Correct.00 1.00
Step 1 CD4200 .00 0 20 .0
1.00 0 66 100.0
Overall Percentage 76.7
Step 2 CD4200 .00 5 15 25.0
1.00 3 63 95.5
Overall Percentage 79.1
a. The cut value is .500
Variables in the Equation
B S.E. Wald df Sig. Exp(B)
SJep NAK3MCAT{1) -20.287 10048.244 .000 1 .998 .000
1 Constant 21.203 10048.244 .000 1 .998 1.62E+09
S&ep NAK3MCAT(1) -20.840 9653.843 .000 1 .998 .000
2 LNVLM3 -.390 .160 5.970 .015 .677
Constant 24.297 9653.844 .000 1 .998 3.57E+10
a. Variable(s) entered on step 1: NAK3MCAT.
b. Variable(s) entered on step 2: LNVLM3.
Appendix 5.4.3 
Maternal plasma CD4 count taken at delivery 
<500 vs. >500mm3
trwara stepwise logistic regression: Maternal plasma CD4 count at delivery (<=200, >200) 
tial model only
Case Processing Summary
Jnweighted Cases3 N Percent
Selected Cases Included in Analysis 102 35.2
Missing Cases 188 64.8
Total 290 100.0
Jnselected Cases 0 .0
"otal 290 100.0
a. If weight is in effect, see classification table for the total number of cases.
»pendent Variable Encoding
)riginal Value Internal Value
0
1
Categorical Variables Codings
Parameter
Frequency (1)
xclusive breastfeeding EBF 82 1.000
t6w mixed 20 .000
>ck 0: Beginning Block
Classification Tablea,b
Predicted
CD4INVCA Percentage
CorrectObserved 0 1
Step 0 CD4INVCA 0 0 40 .0
1 0 62 100.0
Overall Percentage 60.8
a. Constant is included in the model.
b. The cut value is .500
Variables in the Equation
B S.E. Wald df Sig. Exp(B)
Step 0 Constant .438 .203 4.670 1 .031 1.550
Variables not in the Equation
Score df Sig.
Step. Variables EBF6W(1) 4.509 1 .034
0 WEALTH 3.849 1 .050
LNCRP6W 21.671 1 .000
LNVLW6 5.673 1 .017
Overall Statistics 26.576 4 .000
Sock 1: Method = Forward Stepwise (Conditional)
Omnibus Tests of Model Coefficients
Chi-square df Sig.
Step 1 Step 24.760 1 .000
Block 24.760 1 .000
Model 24.760 1 .000
Step 2 Step 4.110 1 .043
Block 28.871 2 .000
Model 28.871 2 .000
Model Summary
I -2 Log Cox & Snell Nagelkerke R
Step 1 likelihood R Square Square
1 I 111.859 .216 .292
2 | 107.749 .247 .334
Classification Table3
Observed
Predicted
CD4INVCA Percentage
Correct0 1
Step 1 CD4INVCA 0 22 18 55.0
1 9 53 85.5
Overall Percentage 73.5
Step 2 CD4INVCA 0 22 18 55.0
1 12 50 80.6
Overall Percentage 70.6
a. The cut value is .500
Variables in the Equation
B S.E. Wald df Sig. _ Exp(B) _
S ep LNCRP6W .924 .218 17.912 1 .000 2.519
1 Constant 2.804 .628 19.915 1 . .000 16.508
LNCRP6W .913 .224 16.553 1 . .000 2.491
2 LNVLW6 .245 ,125 3.820 .051 1.278
Constant 1.067 1.050 1.034 1 .309 2.907
a. Variable(s) entered on step 1: LNCRP6W.
b. Variable(s) entered on step 2: LNVLW6.
Model if Term Removeda
'
Variable
Model Log 
Likelihood
Change in 
-2 Log 
Likelihood df
Sig. of the 
Change
Step 1 LNCRP6W -68.454 25.049 1 .000
Step 2 LNCRP6W -65.505 23.262 1 .000
LNVLW6 -55.947 4.144 1 .042
a. Based on conditional parameter estimates
Variables not in the Equation
Score df Sig.
Step Variables EBF6W(1) 2.381 1 .123
1 WEALTH .946 1 .331
LNVLW6 4.106 1 .043
Overall Statistics 6.600 3 .086
Step Variables EBF6W(1) 1.601 1 .206
2 WEALTH .888 1 .346
Overall Statistics 2.744 2 .254
